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ABSTRACT 
 
More than half of the world population is infected with Helicobacter pylori (H. pylori), a 
Gram-negative, spiral-shaped bacterium that, after persistent colonization of gastric mucosa, is 
responsible for the development of several gastric diseases, including gastric adenocarcinoma. 
Although different treatment regimens have been applied, the eradication is still unsuccessful in 
approximately 20% of the patients, mainly due to bacteria resistance to available antibiotics.  
Docosahexaenoic acid (DHA) is an omega-3 polyunsaturated fatty acid with bactericidal 
activity against H. pylori, inhibiting their growth in vitro and decreasing their gastric colonization 
in 50% of infected mice. The low DHA efficacy in vivo could be explained by its high 
susceptibility to oxidation or by its degradation in the gastric environment. For this reason, the 
main goal of this work was the development of an antibiotic-free engineered system for the 
treatment of H. pylori gastric infection. DHA was encapsulated into lipid nanoparticles, namely 
nanostructured lipid carriers (NLC), to protect DHA against the gastric environment and improve 
its efficacy against H. pylori. This system was developed for oral administration and NLC should 
be able to penetrate through the gastric mucosa and to reach H. pylori at infection site.  
NLC were synthesized by hot homogenization and ultrasonication using a blend of 
lipids: a solid lipid (Precirol
®
ATO5) and a liquid lipid (Miglyol
®
812), and a surfactant (Tween
®
60). 
Homogenous and spherical NLC were successfully optimized and produced with the size of 211 
± 8 nm for unloaded-NLC and 302 ± 14 nm for DHA-loaded NLC. Both NLC have a negative 
surface charge (-28 ±3 mV). A good entrapment efficiency was obtained (66 ± 7%), with DHA 
incorporated in the matrix of NLC decreasing NLC crystallinity. NLC were stable in simulated 
gastric fluid, but were able to release DHA in bacteria medium over 3h (40%). Bactericidal 
enhancement of DHA activity was proved with DHA nanoencapsulation, since DHA-loaded 
NLC, even at low DHA concentration (10 µM) are bactericidal against H. pylori in opposite to 
free DHA which was only bactericidal at concentrations higher than 100 µM. Unexpectedly, 
unloaded-NLC were also bactericidal against H. pylori in all concentrations tested. 
Nevertheless, DHA-loaded NLC (2.5% v/v [containing 50 µM of DHA]) had a faster bactericidal 
activity (30 min) than unloaded- NLC (> 9h).  
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NLC mechanism of action towards H. pylori was explored using bioimaging and 
biochemical studies, which demonstrated that NLC were able to adhere to H. pylori, cross their 
outer and inner membrane, promoting an increase of periplasmic space and, subsequently, 
disruption of bacterial membrane, leakage of cytoplasmic content and bacteria death. 
Moreover, all observed H. pylori were in bacillary shape which is also an indicator of the fast 
bactericidal effect of NLC, meaning that bacteria did not have time to change their morphology 
from bacillary to a coccoid shape. Furthermore, the NLC developed are not cytotoxic to human 
gastric adenocarcinoma cells at bactericidal concentrations (up to 2.5% v/v).  
In vivo studies suggested a reduction of H. pylori colonization in 82.5% and 92.6% for 
unloaded and DHA-loaded NLC treatment, respectively. This reduced infection was verified 
without causing gastric or hepatic toxicity. However, 1/3 of untreated infected mice did not 
present infection after 14 days of treatment, which indicates the need for further assays.  
To evaluate if the unexpected bactericidal effect of unloaded-NLC was selective to H. 
pylori, these NLC were tested against other bacteria. Unloaded-NLC at bactericidal 
concentrations for H. pylori, did not affect the other bacteria tested, namely Lactobacillus casei 
and Escherichia coli, from gut microbiota.   
These promising findings suggest that NLC should be envisaged an antibiotic-free 
alternative H. pylori infection treatment.  
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RESUMO 
Mais de metade da população mundial está infetada pela bactéria Helicobacter pylori 
(H. pylori), uma bactéria Gram-negativa com forma de espiral, que após persistente 
colonização da mucosa gástrica é responsável pelo desenvolvimento de várias doenças 
gástricas, nomeadamente o adenocarcinoma gástrico. Embora tenham sido aplicados 
diferentes regimes de tratamento, a erradicação desta bactéria é ainda ineficaz em 
aproximadamente 20% dos pacientes, principalmente devido à resistência bacteriana aos 
antibióticos disponíveis.  
O ácido docosahexaenóico (docosahexaenoic acid, DHA) é um ómega-3, ácido gordo 
polinsaturado, com anti-bacteriana contra H. pylori, inibindo o seu crescimento in vitro e 
diminuindo cerca de 50% a sua colonização na mucosa gástrica. A reduzida eficácia do DHA in 
vivo poderá ser explicada pela elevada suscetibilidade do DHA oxidar ou pela sua degradação 
em ambiente gástrico. Por essa razão, o principal objetivo deste trabalho foi o desenvolvimento 
de um sistema livre do uso de antibióticos para o tratamento da infeção gástrica por H. pylori. 
O DHA foi encapsulado em nanopartículas lipídicas, nomeadamente nanostructurated lipid 
carriers (NLC), para proteger o DHA contra o ambiente gástrico e melhorar a sua eficácia 
contra a H. pylori. Este sistema foi desenvolvido para a administração oral, e as NLC deverão 
ser capazes de penetrar através da mucosa gástrica e alcançar H. pylori no local de infeção. 
As NLC foram sintetizadas por homogeneização a quente e ultra-sonicação, usando 
uma mistura de lípidos: um lípido sólido (Precirol
®
ATO5) e um lípido líquido (Miglyol
®
812),e um 
surfactante (Tween
®
60). 
Foram otimizadas NLC homogéneas e esféricas, e produziram-se NLC com tamanho 
de 211 ± 8 nm para unloaded-NLC e 302 ± 14 nm para DHA-loaded NLC, estas NLC possuem 
uma superfície carregada negativamente (-28 ±3 mV). Após a produção obteve-se uma boa 
eficiência de encapsulação (66 ± 7%), verificando-se que o DHA foi incorporado na matriz 
lipídica da NLC, o que resultou numa diminuição da sua cristalinidade.  
Estas NLC são estáveis em fluido gástrico, mas também permitem a libertação do DHA 
em meio de bactéria após 3h (40%). Provou-se que a nanoencapsulação melhorou a atividade 
bactericida do DHA, uma vez que DHA-loaded NLC apresentou efeito bactericida com as 
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concentrações mais baixas de DHA (10 µM), contrariamente ao DHA-livre que só revelou um 
efeito bactericida com concentrações maiores do que 100 µM. Inesperadamente, unloaded-
NLC também revelaram uma atividade bactericida contra H. pylori, em todas as concentrações 
testadas. Além do mais, DHA-loaded NLC (2.5% v/v [50 µM of DHA]) manifestou uma atividade 
bactericida mais rápida (30 min) do que unloaded- NLC (> 9h). 
O mecanismo de ação das NLC contra H. pylori foi explorado utilizando bioimagem e 
estudos bioquímicos que demonstraram que as NLC são capazes de aderir à membrana de H. 
pylori, atravessar a sua membrana externa e interna, promovendo um aumento do espaço 
periplásmatico e subsequentemente a rutura da membrana da bactéria, libertando o seu 
conteúdo citoplasmático e promovendo a morte da bactéria. Além disso, observou-se que 
todas as bactérias exibiam uma morfologia bacilar, que é um indicador do rápido efeito 
bactericida das NLC, o que significa que as bactérias não tiveram tempo para alterar a sua 
morfologia de forma bacilar para forma coccoide. Adicionalmente, verificou-se que as NLC 
desenvolvidas não são citotóxicas para as células de adenocarcinoma gástrico humano, nas 
concentrações bactericidas (até 2.5% v/v). 
Estudos in vivo sugeriram uma redução de 82.5% e 92.6% da colonização de H. pylori 
quando tratadas, respetivamente com unloaded e DHA-loaded NLC. Verificou-se que esta 
redução da infeção não causou toxicidade gástrica ou hepática. Contudo, 1/3 dos ratinhos 
infetados não tratados não manifestaram infeção após 14 dias de tratamento, o que indica a 
necessidade da repetição destes ensaios.  
Para avaliar se o inesperado efeito bactericida das unloaded-NLC foi seletivo para H. 
pylori, estas NLC foram testadas contra outras bactérias, demonstrando que estas unloaded-
NLC não têm efeito contra as bactérias testadas, nomeadamente Lactobacillus casei e 
Escherichia coli, bactérias do macrobiota intestinal.  
Estas promissoras descobertas propõem que as NLC devem ser consideradas como 
um tratamento da infeção de H. pylori sem recurso a antibióticos.  
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CHAPTER I 
 
AIMS AND THESIS ORGANIZATION 
1.1 - Motivation and aims 
 
Helicobacter pylori (H. pylori) is a Gram-negative and spiral-shaped bacterium that 
colonizes the stomach of half of the world population [1,2]. Persistent infection with this 
bacterium has been associated with several gastric diseases including gastritis, peptic ulcers, 
and gastric adenocarcinoma. It is estimated that approximately 78% of global gastric cancers 
are attributed to H. pylori infection [1,3,4], being this bacterium classified as a type I carcinogen 
for humans by the International Agency for Research on Cancer (IARC). Therefore, H. pylori 
infection eradication is a promising strategy for gastric cancer prevention [1,3-5]. Although 
infection has been decreasing worldwide, as a consequence of changes in dietary habits and 
improvement of socioeconomic conditions, in Portugal, H. pylori infection still remains in high 
values (80%) [6-8]. Recommended treatment is based on the combination of at least two 
antibiotics and a proton pump inhibitor [5,9]. However, this therapy fails in about 20% of the 
patients, which could be related to several reasons, but principally, with poor patient compliance 
to therapy and with the increased number of H. pylori strains resistant to conventional antibiotics 
[9,10]. Strategies to overcome these issues, such as the development of an H. pylori vaccine, 
have been attempted. However, progress has been very slow and no alternative treatments are 
available.  
Natural compounds such as polyunsaturated fatty acids (PUFA) have been suggested as 
alternatives or as co-adjuvants of available antibiotic therapies. Docosahexaenoic acid (DHA) 
was able to inhibit H. pylori growth in vitro in a dose-dependent way and to decrease gastric 
colonization in vivo. Additionally, it was able to attenuate the host inflammatory response 
[11,12]. Nevertheless, DHA efficiency in the eradication of H. pylori from mice gastric mucosa 
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was significantly lower than the conventional antibiotherapy, failing in 50% of mice [11]. The 
failure of the orally administered DHA could be related to its poor solubility in water, low 
penetration through the mucus layer, low residence time in the stomach, and low stability in 
vivo. The low stability in vivo may result from oxidation, carboxylic protonation, esterification and 
lipid-protein complexation in the gastric environment [13,14].  
Taking the above-mentioned facts into consideration, the major goal of this thesis was the 
development of an antibiotic-free strategy for the treatment of H. pylori gastric infection. The 
developed strategy was based on the encapsulation of DHA using lipid nanoparticles, namely 
nanostructured lipid carriers (NLC), aiming to improve DHA stability and efficacy against H. 
pylori. The proposed system was designed for oral administration, and should be able to 
penetrate through the gastric mucus layer, reach the surface of gastric epithelial cells and 
release DHA in a concentration capable of treating H. pylori infection in situ. As such, 
encapsulation would overcome problems associated with degradation and oxidation of DHA in 
gastric environment. NLC are employed in this study since lipids are known to promote oral 
absorption of compounds, while also showing good physical stability, controlled release and 
biocompatibility features. The proposed formulations provide an opportunity to exploit antibiotic-
free therapies using NLC, either loaded or unloaded, attending that they are safe and well-
tolerated both by the gastric mucosa and by other bacteria from gut microbiota.  
 
1.2 - Structure 
 
This thesis is organized in 8 chapters. 
Chapter I includes the work motivation, the general objectives and a description of the 
thesis organization and structure.  
An overview of the main features and virulence factors of Helicobacter pylori, their 
relationship with gastric cancer, the current treatments and the new strategies that have been 
investigated for bacterium eradication are presented in chapter II.  This chapter also provides a 
description of polyunsaturated fatty acids (PUFA), namely its general features, health benefits 
and its activity against H. pylori and other microorganisms. Lipid nanoparticles are also 
reviewed, with a brief description of solid lipid nanoparticles, nanostructured lipid carriers (NLC) 
and liposomes, as well as the molecules and methods that can be used for their production. 
Chapter III comprises a brief introduction to the methodology behind the characterization 
techniques used to validate the developed nanoparticles. 
The production of lipid nanoparticles, namely solid lipid nanoparticles (SLN) and 
nanostructured lipid carriers (NLC) was optimized as described in appendix 1 and 2. Firstly, 
SLN were optimized using different lipids, surfactants and parameters of production. Cetyl 
palmitate, Precirol
®
ATO5 and Tween
®
60 were identified as the most promising compounds for 
lipid nanoparticles production. However, due to the lack of reproducibility after DHA loading into 
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SLN, a second generation of lipid nanoparticles was pursued. NLC were then optimized using 
the same solid lipids (cetyl palmitate and Precirol
®
ATO5). However, Precirol
®
ATO5 was 
selected due to its FDA approval for oral administration. As such, the studies described in the 
following chapters of this thesis used Precirol
®
ATO5 as solid lipid for NLC production.  
The optimization of DHA loading into NLC is described in Chapter IV. The goal of this work 
was to evaluate if DHA encapsulation was able to improve DHA activity towards H. pylori and 
human gastric cells (cytotoxicity) in vitro.  
Due to the unexpected bactericidal activity of unloaded-NLC observed in chapter IV, the 
goal of chapter V was to clarify the NLC selectivity towards H. pylori and to understand their 
mode of action. To assess selectivity, other bacteria with different features, namely 
morphological (rod vs spherical) and structural (Gram-positive vs Gram negative), were 
exposed to unloaded-NLC. This approach also aimed to evaluate if unloaded-NLC were safe to 
gut microbiota, namely gastrointestinal Lactobacillus and Escherichia coli.   
In chapter VI, additional characterization was performed, evaluating the physical state 
of the lipid core in the produced NLC and correlating with the DHA loading and DHA release 
profile. Due to the fast and high affinity of NLC to adhere to H. pylori membrane observed in 
previous chapters, permeability assays were performed for an additional understanding of how 
NLC may disrupt the bacterial membrane. Attending to the in vitro efficiency of NLC, the in vivo 
therapeutic potential of DHA-loaded and unloaded lipid nanoparticles was evaluated. The in 
vivo trial used an infected mice model that was treated with NLC in a non-cytotoxic 
concentration to a human gastric cell line. The toxicity profile was also evaluated through 
histological analysis of mouse stomach and liver.  
Results described in chapters IV to VI are integrated and discussed in chapter VII, 
highlighting the major findings of this thesis. Future perspectives regarding the contribution of 
the present study for development of new alternatives to the conventional H. pylori infection 
treatment are also discussed.  
As mentioned before, appendixes 1 and 2 include the optimization of lipid nanoparticles 
production, while appendix 3 comprises a national patent submitted during the PhD and 
appendix 4 contains a review that has been published (co-author). 
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CHAPTER II 
 
GENERAL INTRODUCTION 
2.1- Helicobacter pylori 
Infection with H. pylori is very prevalent, being present in at least 50% of adults 
worldwide. Infection is typically acquired in early infancy remaining present for life if not treated 
[1,2]. This bacterium inhabits in the stomach and is responsible for several gastrointestinal 
diseases, including gastritis, peptic ulcer, duodenal ulcer and gastric adenocarcinoma [3-6].  
2.1.1- Morphology and structure 
 
H. pylori is a microaerophilic, Gram-negative, spiral-shaped bacterium with 2.5-4.0 μm 
long and 0.5-1.0 μm wide, four to six unipolar flagella (Figure 1), that persistently inhabits the 
human stomach [7]. Each flagellum is ~ 30 µm long and approximately 2.5 nm thick. Flagella 
display a characteristic terminal bulb, which is an extension of the flagellar sheath that exhibits 
the typical bilayer structure of a membrane [8].  
 
 
Figure 1-Scanning electron micrograph of H. pylori. Adapted from Seabra et al [144] 
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H. pylori has a hydrophilic and negative surface charge in vitro. The typical cell wall of 
this bacterium consists of outer and inner membranes separated by the periplasm of 
approximately 30 nm thickness. The outer membrane composition is unique in its protein 
content and lipopolysaccharide structure. The dense cytoplasm contains nucleoid material and 
ribosomes. H. pylori peptidoglycan revealed a unique muropeptide composition, less complex 
structurally than that observed in other Gram-negative bacteria [9-12].  
H. pylori has an unusual fatty acid membrane profile, with the most abundant being the 
myristic acid (31 to 45%) and the 19-carbon cyclopropane fatty acid (20 to 24%). The H. pylori 
total lipid content (by weight) is 6% neutral lipids, 20.6% glycolipids and 73.4% phospholipids, 
and cholesterol glucosides that are very rare in animals [12].  
A key component of the outer membrane of H. pylori is the lipopolysaccharide (LPS), 
which consists of a lipid A, a core oligosaccharide, and an O-specific chain.  The surface 
exposed O-specific chain of H. pylori LPS mimics Lewis blood group antigens in structure. 
Molecular mimicry between H. pylori LPS and the host, based on Lewis antigens, may 
contribute to pathogenesis, since the expression of Lewis antigens on their surface may help to 
camouflage the bacteria and thus, allowing H. pylori survival [8,10,12].   
A large number of proteins such as porins and adhesins are present in the outer 
membrane of H. pylori and are involved in the bacteria adhesion, colonization, and the immune 
response. Some outer membrane proteins perform transport functions essential for bacterial 
metabolism while maintaining the selective permeability of the outer membrane to substances 
like antibiotics [12].  
The presence urease, a cytoplasmic protein that can be also found on H. pylori surface, 
allows H. pylori to survive and colonize the gastroenteric tract since urease is able to hydrolyze 
urea into ammonia and carbon dioxide, elevating the acidic gastric pH to neutral pH. However, 
urea is toxic to the bacterium at neutral pH since an unfavorable alkaline environment is 
generated. Thus, the urea channel is regulated positively by protons, opening at acid pH to 
allow more urea into the buffer cytosolic and closing at neutral pH to avoid over-alkalinization 
[13].  
 
2.1.2- Colonization and virulence factors  
 
It is known that the stomach performs numerous functions: temporary storage of ingested 
nutrients; mechanical breakdown of solid food; chemical digestion of proteins; regulation of the 
passage of chime into the duodenum; secretion of intrinsic factor for vitamin B12 absorption; 
secretion of gut hormones; and secretion of acid to aid digestion and microbial defense. The 
stomach can be divided into four parts: (1) cardia, which surrounds the opening of the 
esophagus into the stomach; (2) fundus, which is the area above the level of the cardial orifice; 
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(3) body, which is the largest region of the stomach; and (4) pyloric part, which is divided into 
the pyloric antrum and pyloric canal and is the distal end of the stomach (Figure 2) [14-16]. 
Most intestinal type and diffuse gastric adenocarcinoma associated with H. pylori occur in the 
gastric antrum, body or fundus (less likely), and normally, H. pylori infects the gastric antrum 
part [17]. 
 
Figure 2- Parts of the stomach and its anatomy [17]. 
 
The stomach wall and the proximal 3.0 cm of the duodenum are composed of four layers: 
serosa, muscularis, submucosa, and mucosa, together with vessels and nerves (Figure 3) [18].  
 
Figure 3-Structures of human gastric mucosa. Serosa is an extension of the visceral peritoneum and is a thin serous 
membrane made of a simple squamous epithelial tissue and areolar connective tissue. Muscularis is a thin layer of 
smooth muscle fibers lying external to the layer of glands, arranged with its fibers running in three different directions: 
longitudinal external, circular media and oblique internal. The submucosa is composed of various connective tissues, 
and contains thick bundles of collagen, numerous elastin fibers, blood vessels, and nerves, and surrounds the mucosa, 
the innermost layer of the stomach. Mucosa maintains structural integrity and resists auto-digestion by substances such 
as hydrochloric acid and pepsin. The gastric mucosa is a thick layer with a soft, smooth surface that is mostly reddish 
brown in life but pink in the pyloric region. It contains a layer of loose connective tissue of lamina propria, a thin layer of 
smooth muscle, the muscularis mucosae, and a simple columnar epithelium tissue. Adapted from [14,15,18,19]. 
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The epithelial tissue of gastric mucosa is a layer of simple columnar cells that covers the 
entire luminal surface of the mucosa tubular invagination, gastric pits or foveolae. There are 60 
to 100 gastric pits per square millimeter of gastric mucosa, with diameters of approximately 70 
μm and depths around 0.2 mm. The base of each gastric pit receives several long, tubular 
gastric glands that extend deep into the lamina propria as far as the muscularis mucosae 
[14,15,18]. Simple columnar mucus-secreting epithelium covers the entire luminal surface, 
including the gastric pits and is composed of a continuous layer of surface mucous cells that 
release gastric mucus from their apical surfaces to form a thick, protective lubricant layer over 
the gastric lining  (Figure 4) [14].  
 
Figure 4- Gastric mucosa and submucosa protected from chemical injury by a mucus-bicarbonate surface barrier that 
neutralizes gastric H
+
 and by epithelial “tight junctions” that prevent H
+
 access to subepithelial tissue. Thick mucus from 
the surface epithelial cells traps the secreted bicarbonate on the surface of the gastric mucosa. The bicarbonate-
containing mucus layer protects the cells from the caustic acid (pH ~1.5), keeping the pH at the surface ~7.0. Adapted 
from Mulroney& Myers (2009) [20].  
 
The mucosal surface is highly hydrated (>95%) and covered by a viscous mucus gel with 
a thickness of approximately 300 µm. The mucus serves both as a lubricant and as a physical 
barrier protecting the mucosal epithelium against gastric acid and maintaining their neutral pH 
despite the highly acidic intragastric lumen. The main components of the mucus barrier are 
mucin glycoproteins. Mucins are highly O-glycosylated proteins located at the interface between 
the epithelial cell layers and the external environment [21]. The main mucins in the stomach are 
the membrane-associated MUC1 and the secreted gel-forming MUC5AC and MUC6, which 
have been shown to protect the epithelium against H. pylori adhesion, in vitro [21].   
H. pylori road to colonization is summarized in the four steps described in Figure 5: 
survival, motility, adhesion and damaging.  
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Figure 5- Schematic diagram of the H. pylori infection and pathogenesis. The urease activity and flagella-mediated 
motility of H. pylori facilitate its survival and movement towards the lower mucus gel, above the epithelium, and is 
followed by the interaction several adhesins, including blood-antigen binding protein A, sialic acid-binding adhesin, and 
other outer membrane proteins with receptors on the host epithelium cells. After successful colonization, toxins 
including CagA, and VacA, are involved in damaging the host tissue and intracellular replication. Adapted from Kao et 
al. [6].  
 
H. pylori enter the gastric lumen where its urease activity is used to neutralize the acidic 
environment and the surface layer around the bacterium. The flagella and the helicoidal shape 
of H. pylori facilitate their entrance and travel through the mucus layer allowing them to reach 
the apical domain of gastric epithelial cells. This is followed by specific interactions between 
bacterial adhesins with host cell receptors, which lead to successful colonization and persistent 
infection [6,13]. H. pylori adhesion to gastric mucosa is a crucial step in the establishment of a 
successful infection since it protects the bacteria from displacement by forces such as those 
generated by peristalsis movements, shedding of the mucous layer and gastric emptying. Some 
of the adhesins include blood-antigen binding protein A (BabA), which binds to fucosylated 
Lewis B blood group antigen, and the sialic acid-binding adhesin (SabA), which binds to 
inflammation-associated sialyl-Lewis x antigen. This close proximity to the gastric epithelium 
enables the bacteria to scavenge nutrients from host cells, which are released when bacterial 
toxins like cytotoxin-associated gene A (CagA) type IV damage the host tissues, causing 
alteration of the cytoskeleton [22-24]. Then, vacuolating cytotoxin (VacA) induces alterations of 
tight junctions and the formation of large vacuoles increasing transcellular permeability, 
cytoskeleton changes and apoptosis [23,25,26]. Toxic factors such as the H. pylori neutrophil-
activating protein crosses the epithelial lining and recruit neutrophils and monocytes that cause 
tissue damage by releasing reactive oxygen intermediates (ROIs) and nitrogen reactive 
species. The combined toxic activity of VacA and of ROIs leads to tissue damage that is 
enhanced by loosening of the protective mucus layer and acid permeation [13]. The damage 
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inflicted by such toxins may ultimately lead to the development of gastrointestinal symptoms. 
The complement of toxin genes that a particular strain of H. pylori possesses strongly affects its 
virulence [6,27].  H. pylori virulence factors and their potential role in pathogenesis are 
summarized in Table 1. 
 
Table 1-H. pylori virulence factors. Adapted from Monack et al.(2004) [28]. 
Virulence factors Description /potential role in pathogenesis 
Flagella Involved in motility 
Essential for colonization 
Urease Resists acidic conditions in the stomach 
Activates innate immune responses during early 
steps of infection 
BabA Outer membrane protein 
Binds to fucosylated Lewis B blood group antigen 
Mediates adhesion to epithelial cells and possibly 
stomach epithelium 
SabA Outer membrane protein 
Mediates the adhesion of H. pylori to inflamed 
gastric mucosa by binding the sialylated 
carbohydrate structure 
CagA Translocated into host cell by type IV secretion 
apparatus encoded on Cag-PAI 
Disrupts tight junctions 
Epidemiologic link to cancer 
VacA Vacuolating toxin 
Induces apoptosis 
Involved in the immunomodulation and colonization 
of the mouse stomach 
 
2.1.3- Routes of transmission  
 
The routes for H. pylori transmission are not completely understood, but it is known that 
the reservoir of H. pylori is the human stomach. This bacterium appears to have a narrow host 
range. New infections are thought to occur as consequence of direct human-to-human 
transmission or environmental contamination [29,30].  
The possible routes for H. pylori transmission are summarized in Figure 6. 
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Figure 6-Transmission routes for H. pylori: direct person-to-person transmission, i.e. oral-oral, breastfeeding, gastro-
oral, fecal-oral and iatrogenic via; and possible reservoirs outside the human host, namely water, vegetables, and 
animal contamination. Adapted from Azevedo et al.(2007) [31]. 
 
Most H. pylori infections are thought to be acquired in childhood via person-to-person. 
The close personal contact is important for the spread of H. pylori and its prevalence increases 
in family members with infected children [29,30,32]. The presence of H. pylori in the gastric 
juice, in up to 58% of patients infected with the bacterium, raised the possibility that the refluxed 
gastric juice may also represent a vehicle of transmission. The vomiting and regurgitation of 
gastric material into the mouth are fairly common in childhood and may represent an important 
route of transmission [30,31]. Saliva is another possible source of H. pylori transmission since 
the gastric flora can reach and colonize the mouth after regurgitation or vomiting. Still, the oral-
oral transmission is not common for H. pylori, at least in adults [29].  
Environmental or animal reservoirs, such as water, food, and animals, may be 
considered sources of H. pylori infection. Indeed, water is considered a vehicle in the 
transmission of H. pylori, in situation where poor hygienic practices during childhood are 
observed, in case of absence of a household bath, in non-hygienic drinking water situations and 
in the absence of a sewage disposal facility, which may lead to contamination or 
recontamination of drinking water [29,31,33]. Food products may also be contaminated while 
handling, under poor hygienic conditions. The food products most likely to transmit H. pylori are 
milk, meat, and vegetables. Vegetables are suspected to be vulnerable to H. pylori colonization 
when contaminated water is used for washing or irrigation [29,30]. 
The low socioeconomic status was reported as one of the most important factor in the 
spreading of H. pylori [30,33]. The high age-specific prevalence of H. pylori infection in 
developing countries has been attributed to low socioeconomic levels. Obviously, 
socioeconomic status is not restricted to income and social class but takes into consideration 
other factors such as levels of hygiene, the density of living, sanitation, urbanization and 
educational opportunities [30,33]. Educational level has been used as a marker of 
socioeconomic status and has been considered as one of the important determinants of H. 
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pylori prevalence in both developed and developing countries. Household crowding, sharing a 
bed and increasing household contact have also been identified as risks for H. pylori infection, 
because during childhood, crowded living conditions affect current bacterium status, and the 
number of children in the present household increases the risk of infection for the adult family 
members [30,33]. Another factor influencing the transmission of H. pylori is the genetic 
predisposition [30,33].  
 
2.2. Outcomes of H. pylori infection 
2.2.1- Gastric cancer in the World 
Gastric cancer still ranks fifth for cancer incidence and third of cancer deaths worldwide 
(723 000 deaths, estimated in 2013) [34-36]. The majority of gastric cancer-related deaths 
occurred in East Asia, nearly half in China (Figure 7) [2,36,37].  
 
Figure 7- Estimated age-standardized death rates, for both sexes, caused by gastric cancer worldwide in 2012 [37].  
 
Around 78% of all gastric cancer cases are estimated to be attributed to chronic H. pylori 
infection, considered to be the strongest identified risk factor for gastric cancer, with more than 
60% of new gastric cancer cases worldwide being attributed to this bacterium [32]. In most 
individuals, H. pylori colonization is asymptomatic, but long-term carriage of the pathogen 
significantly increases the risk of developing site-specific diseases, suggested a sequential 
model of intestinal type-gastric carcinogenesis. Beside with outer environmental and host 
factors, trigger a precancerous cascade is initiated with chronic gastritis, evolving to atrophic 
gastritis, to intestinal metaplasia, followed by dysplasia, being the ultimate stage of this cascade 
invasive carcinoma (Figure 8) [7,32].  
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In 1994, H. pylori were classified by the International Agency for Research on Cancer as 
a Group 1 carcinogen, based on its association with gastric adenocarcinoma and mucosa-
associated lymphoid tissue (MALT) lymphoma [1,2,34].  
 
 
Figure 8- Multifactorial pathway leading to gastric carcinoma. Hosts, bacterial and environmental factors act in 
combination to contribute to the precancerous cascade that leads to the development of gastric cancer. Adapted from 
Wroblewski et al. [32].  
 
2.2.2-  Gastric cancer in Portugal  
In Portugal, gastric cancer incidence (27.8%) and mortality (21.7%) rates are among the 
highest in Europe (19,5%) in 2013, especially in the North of the country (Figure 9), predicting 
an incidence of 40.1% in 2020 [4,38,39]. Regarding the number of deaths, stomach cancer 
accounts for 10.2% of all malignant cancer deaths [38].  
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Figure 9-Stomach cancer standardized (A) incidence and (B) mortality rates per 100 000  population in 2013 [40]. 
 
In the last half century, Portugal went through several important economic and social 
changes, resulting in an improvement of the living standards, even though unequally across the 
different socioeconomic groups [4]. Some studies reported that the Northern Portugal has a 
higher gastric cancer risk factor than the Southern Portugal, due to the North of Portugal dietary 
habits, such as the preference for salty/cured foods, which favor the onset of gastric cancer 
[38,41].  
 
2.3. Treatment of H. pylori 
2.3.1- Current therapy 
 
H. pylori eradication is the most promising strategy to reduce the incidence of gastric 
cancer. This treatment is recommended in infected patients with duodenal or gastric ulcers, 
early gastric cancer and gastric MALT lymphomas [7,42]. Treatment is also indicated for gastric 
cancer prevention in high-risk individuals and in patients with functional dyspepsia [42]. 
Recommended indications for treatment are summarized in Table 2.  
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Table 2- Indications for H. pylori infection eradication therapy. Adapted from Mitchell et al.(2016) [43]. 
Indication Benefits of treatment 
Past or present peptic ulcer disease Heals ulcers and reduces relapse 
Functional dyspepsia May reduce symptoms and long-term risk of ulcer 
disease and gastric cancer 
Use of NSAIDs, including aspirin, in some patients Reduces risk of ulcers and bleeding 
Gastric mucosal atrophy and intestinal metaplasia Reduces risk of gastric cancer 
Patients requiring long-term acid suppression with 
proton pump inhibitors 
Reduces progression of intestinal metaplasia 
Family history of gastric cancer Reduces long-term risk of gastric cancer 
Prior early gastric cancer Reduces risk of further gastric cancer 
Low-grade gastric MALT lymphoma Induces regression of lymphoma 
Patient choice, after risks and benefits, are 
discussed 
Fulfills patient’s desire to reduce risk of infection 
  
Consensus conferences have recommended therapeutic regimens to achieve H. pylori 
cure rates higher than 80% on an intention-to-treat basis; for instance, the most efficient 
therapies available should be used first to avoid the cost inconvenience and risks associated 
with treatment failure [42,44,45].  
Current initial treatments for H. pylori infection are summarized at Table 3. 
   
Table 3- Current initial therapy regimens to treat H. pylori infection. Adapted from Costa et al. (2010) [46], Malfertheiner 
et al (2012, 2016) [47,48]  and Thung et al. (2016)[3]. 
 Regimen Time of 
treatment 
Recommendations & 
comments 
Triple therapy Proton-pump inhibitor(PPI) 
Clarithromycin (500 mg) 
Amoxicillin (1g) or  
Metronidazole (500 mg) 
7-14 
days 
Twice 
daily 
Consider in areas of low 
clarithromycin resistance 
Quadruple 
therapy 
Proton-pump inhibitor (PPI) 
Levofloxacin (500 mg) 
Amoxicillin (1g)  
Metronidazole (500 mg) 
10 
days 
Consider in areas of high 
clarithromycin resistance  
Proton-pump inhibitor (PPI) 
(morning and evening) 
Bismuth (525 mg) 
Metronidazole (250 mg) 
Tetracycline (500 mg) 
14 
days 
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Currently, the most widely used treatment for H. pylori infection is the triple therapy, 
which includes the combination of two antibiotics, such as clarithromycin and amoxicillin or 
metronidazole, and a proton pump inhibitor (PPI) such as omeprazole [7,22,49,50]. However, 
the initial 90% cure rates obtained with this triple therapy have decreased to 75% or less, in 
some regions [7], which can be related to the increasing number of H. pylori strains that are 
resistant to the antibiotics used (Table 4), especially clarithromycin [46].  
 
Table 4- Percentage of antibiotic resistance in some countries. 
Antibiotic  Percentage of resistance  Reference 
Clarithromycin <18% in southern Europe [46] 
Metronidazole 20 to 40% in Europe and the USA 
9 to 12% in Japan 
[3] 
Amoxicillin <2% in Europe 
>38% Asia and South America 
[3,51] 
 
Levofloxacin-based triple therapy represents an alternative therapy in patients with 
persistent infection despite the use of multiple standard treatments [46,50]. Alternatively, a 
quadruple therapy containing bismuth, metronidazole, and tetracycline plus PPI, is quite 
effective even in the presence of clarithromycin and metronidazole resistance, with an 
eradication rate of up to 85%. However, compliance and side effects such as diarrhea, 
vomiting, and metallic taste remain as limitations of this regimen [3,46]. 
Another alternative treatment is the sequential therapy that consists of 5 days treatment 
with PPI and amoxicillin, followed by a further 5 days of PPI with two other antibiotics, 
clarithromycin and metronidazole [3,50,52]. The eradication rates for 10 days of sequential 
therapy were 87.2%, instead of 85.7% for 14 days of triple therapy, with no difference in 
compliance or adverse effects [3,50]. The drawback of this therapy is its complex regimen 
which may decrease patient compliance to the therapy and, thus, induce the development of 
multidrug-resistant bacteria [3].  
Summing up, the choice of therapy is based on local antibiotic usage, documented 
antibiotic resistance, outcome data and also the world region [43,46]. It also depends whether it 
is a first-line therapy, a second course, or a rescue therapy for persistent infection [45,46] Other 
major determinants for a successful therapy are patient compliance, mucosal drug 
concentration and the individual primary or secondary bacterial resistance to the antibiotics 
employed [46].  
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2.3.2-  Factors affecting H. pylori treatment failure  
 
The successful eradication of H. pylori infection depends on various factors. These 
factors are associated with nature of the organism itself, the intragastric environment where the 
organism resides, the regimens used to eradicate it, and the behavior and reaction of the host 
[53]. 
The roles that the organism, gastric environment, hosts and drug regimens play in 
treatment failures are often inter-related. The key factors that increase the risk of H. pylori 
eradication therapy failure are described in Table 5.  
 
Table 5- Factors that cause H. pylori treatment failure. 
Factors Major reason & comments  References 
Antimicrobial 
resistance 
 Resistant strains prior to treatment (primary) or be 
developed after a failed treatment (secondary) 
[54-56] 
Patient compliance 
to therapy 
 Multiple different medications 
 Dose frequency (usually daily) 
 Duration of therapy (generally 10-14 days) 
 High frequency of side-effects 
 Limited information to patient about side-effect 
[55-58] 
Gastric environment  Insufficient gastric acid inhibition 
 Easily degradation of antibiotics when the intragastric pH 
is less than 4.0 
[53,59] 
Smoking  Decrease gastric blood flow and mucus secretion 
 Reduce the delivery of antibiotics to the gastric mucosa.  
 Stimulate acid secretion 
 Low efficacy of antibiotics  
[54,57,59,60] 
 
2.4. Alternatives to conventional therapy  
The increased failure of the conventional therapies in the eradication of H. pylori infection 
in clinical practice demonstrates the urgent need for alternative therapeutic approaches. This 
includes the use of new drugs against H. pylori or new adjuvants that can reduce side-effects of 
available treatments and help in patient compliance. 
The most exploited alternative approaches to fight H. pylori infections are the 
development of i) vaccines, ii) photodynamic inactivation, iii) phage therapy, iv) probiotics, v) 
antimicrobial peptides, vi) natural compounds such as plants and spices, phenolic compounds 
and lipophilic compounds, and vii) bioengineered micro/nanoparticles as drug delivery systems 
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or as binding agents [7,22,61,62]. Some examples of the described approaches are 
summarized in Table 6. However, although most of these alternative treatments have been very 
successful in vitro, their efficiency in vivo were not sufficient to be translated for clinical 
applications.  
This is related with the fact that, in vivo, the molecules must achieve a bactericidal 
concentration at site of infection, and for that, they must be able to cross the protective mucus 
layer maintaining its biological activity at the large range of acidic pH [62]. 
 
Animal models can help elucidate the pathogenic mechanisms of H. pylori and aid in the 
development of improved strategies for the treatment of gastric disease [63]. 
The type of animal models developed to study H. pylori pathogenicity can go from 
primate- to rodent- based models. Several animals, including monkeys, pigs, cats, and dogs, 
have been successfully colonized by several H. pylori species. Their major advantage is their 
similar physiology with humans. However, several limiting factors, such as availability and high 
costs, may restrict their use. Other disadvantages of these animal models are related to the 
presence of natural Helicobacter infections such as H. heilmannii in primates and H. suis in 
pigs, and constraints regarding the examination of the long-term effects of colonization [63,64]. 
Because of that, most animal models used are rodents which allow host variables to be 
carefully monitored. Most mouse strains do not develop cancer but only mild inflammation 
following H. pylori infection. A rodent alternative is Mongolian gerbils that are an efficient, robust 
and cost-effective rodent model that can develop cancer when colonized with certain strains of 
H. pylori [64,65]. Table 7 summarizes some of the features of rodent animal models that can be 
used to study H. pylori infection.  
 
 CHAPTER II 
19 
Table 6- Alternative therapies against H. pylori  
Therapy Description Agents References 
Vaccines The key requirements to develop an effective vaccine are appropriate bacterial 
antigens, safe and effective adjuvants and a delivery route. Many vaccine 
formulations and strategies have been tested against H. pylori resulting in significant 
reduction in bacterial load, and production of regulatory T cells that many limit the 
eradicate H. pylori [66,67].  
Antigens 
 UreB (most used)  
 HspC 
 VacA 
 CagA 
 NAP 
In vitro: [68-71] 
Animal model: [72-76] 
Clinical trials: [77-81] 
Photodynamic Photodynamic therapy involves the use of non-toxic photosensitive molecules 
(photosensitizers) that will be activated by a specific wavelength of visible light. After 
activation in presence of oxygen, photosensitizers trigger a destructive action in 
biological systems, leading to bacterial death, due to the production of reactive 
oxygen species, such as singlet oxygen and hydroxyl radical [82-84]. 
Photosensitizer: 
 Ruthenium (II) complex 
covalently bound to 
micrometric glass beads 
(150-200µm) 
 Chorin e6 (ce6) in 
combination with red light 
 Aluminum sulfonated 
phthalocyanine  
In vitro: [83-86] 
Animal model: [87] 
Clinical trials: [88,89] 
Phage therapy 
Bacteriophage therapy consists in the use of lytic bacteriophages (a virus that 
infects bacteria), or their lytic proteins to induce the lysis of H. pylori. The phages 
are engineered in a way that a particular antibody is fused to a protein on the 
phage’s coat. Despite the possibility of using phage therapy to treat antibiotic 
multiresistant bacteria strains, H. pylori phage screening is a rare topic in the 
literature [61,90-93].  
H. pylori phages 
 KHP30 
 KHP40 
 M13 
 BAPOUI 
 JP1/95 
 1603/05 
 Mex228 
In vitro: [94-96] 
Animal model: [95] 
(to be continued) 
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Therapy Description Agents References 
Probiotics Probiotics are live microorganisms that are orally administered to promote a health 
benefit on the host. Probiotics can be used to prevent or decrease H. pylori 
colonization. Moreover, when included in H. pylori eradication therapy, they can 
improve eradication rates, by preventing antibiotic side effects, such as diarrhea. 
Also, probiotics can be produced in large scale at low cost [90-93]. 
Microorganisms 
 L. acidophilus 
 L. casei subsq 
rhammosus 
 L. casei 925 
 L. casei DN-114001 
 L. Shirota 
 L. salivarius WB1004 
 L. gasseri 
 L. johnsoniis La1 
 L. plantarum 8 RA-3 
 L. fermentum BL-96 
 L. fermentum L90265 
 Bifidobacterium infantis 
2036 
 Saccharomyces 
boulardii 
 Bacillus subtilis 
 Weissella confuse 
In vitro: [97-102] 
Animal model: 
[98,100,103,104] 
Clinical trials: [105-110] 
(to be continued) 
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Therapy Description Agents References 
Antimicrobial 
peptides (AMP) 
AMPs are a class of a broad spectrum antibiotic that are part of the innate immune 
system of several organisms such as animals, plants, fungi, bacteria and viruses. 
They are usually small (10-50 aminoacids in length), highly cationic and have 
tendency to form amphipathic structures.  Most AMPs can act by the disruption of 
bacterial membranes due to electrostatic interactions between cationic AMP and 
anionic bacterial membranes, and low tendency to induce bacterial resistance 
[7,61].   
Peptides 
 Magainin 2 
 Odorranain-HP 
 Pexiganan 
 Defensins 
 Cathelicidins 
 RpL1 
 TP4 
 OAK 
 Epi-1 
 
In vitro: [111-119] 
Animal model: 
[115,116,118,120,121] 
Natural 
compounds 
The use of natural food products such as fruits, vegetables, and fish could be used 
as adjuvant therapies or as potential sources for new effective agents against 
bacteria and associated inflammation. There are some molecules known by their 
capacity to inhibit essential bacterial enzymes (such as urease) or to disrupt 
bacterial membranes [7,61,90,92].  
Phenolic compounds 
 Wine polyphenol 
 Apple peel polyphenols 
extracts 
 Olive oil polyphenols 
 Green tea 
 Garlic 
 Broccoli 
 Curcumin 
Lipophilic compounds 
 Terpenes 
 Terpenoids 
 Fatty acids 
In vitro: [122-130] 
Animal model: 
[123,127,130-135] 
Clinical trials: [130,136-
139] 
(to be continued) 
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Therapy Description Agents References 
Bioengineering Bioengineering has become a powerful tool by combining innovative bioengineering 
strategies with bioactive compounds. The encapsulation of antimicrobial compounds 
using gastric retentive polymers enhances their bioavailability, by protecting and 
increasing their retention time in the gastric environment.  
Binding systems that, after oral administration, are able to attract/bind bacteria and 
remove them from the host stomach through the intestinal tract, after gastric mucus 
turnover, were recently proposed as an alternative strategy [7,22]. 
Bioengineering strategies 
 Microspheres 
 Nanoparticles 
 Liposomes 
 NLC 
 
In vitro: [128,129,140-154] 
Animal model:  
[135,140,148,150,155] 
Abbreviations: UreB- urease B; HspC- heat shock proteins complex; NAP- neutrophil-activating protein; L. –Lactobacillus; TP4-Tilapia Piscidin 4; OAK- oligo-acyl-lysyl; Epi-1-Epinecidin-1 
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Table 7. Different features of rodents animal models used to study H. pylori infection. Adapted from Houghton (2012) [156] and Ivanov (2016)[157]. 
Animal model 
H. pylori 
Features/comments 
References 
Strain Infection conditions 
Mice (C57BL/6) SS1 
 Helicobacter-free  
 Oral gavage 
 0.1 mL (10
6
 CFU) of 
bacteria 
 3 doses, 1 per day and 
each separated by 24-48h 
[158] 
 Extensively studied for investigating H. pylori role in gastric 
carcinogenesis 
 Only show a marked influx of mononuclear cells while in 
humans gastritis there are an accumulation of neutrophils and 
mononuclear cells in the mucosa. 
[127,134,135,140,159,160] 
Mice (BALB/c) SS1  Widely used in cancer and immunology studies 
 Characterized by higher bacterial colonization levels but fewer 
epithelial lesion 
 Used as a model of H. pylori-induced MALT lymphoma. 
[159-164] 
Mice (C3H) SS1 
26695 
 Easy to colonize with H. pylori including with strain 26695 or by 
isogenic mutants deficient in Lewis x or y expression. 
[116,118,160,165] 
Mongolian Gerbils NCTC 
11637 
B128 
G1.1 
TN2 
7.13 
 Helicobacter-free  
 Oral gavage: 0.5 mL (10
9
 
CFU) of bacteria 
 2 doses (wait 24–48h 
before the second 
challenge)[65] 
 Model for study the pathogenesis of H. pylori infection, 
especially gastritis, intestinal metaplasia, gastric ulcers and 
gastric carcinoma.  
[166-172] 
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2.4.1- Polyunsaturated fatty acids (PUFA) 
The antibacterial proprieties of PUFA have been investigated in various organisms 
including H. pylori, due to their high potency and lower susceptibility to induce H. pylori 
resistance compared to conventional antibiotics.  
 
2.4.1.1- General features and health benefits 
 
Fatty acids can be classified by their carbon chain length and by their number of double 
bonds [173]. Long-chain fatty acids contain more than twelve carbon atoms. They are formed of 
hydrocarbon chains with a carboxyl group at one end (n end) and a methyl group at the 
opposite end (ω end). Unsaturated fatty acids (Table 8) hold in their chain one 
(monounsaturated) or more (polyunsaturated) carbon-carbon double bonds not saturated with 
hydrogen [174].  PUFA are defined as fatty acids that possess more than two double bonds, 
and their classification as n-3 or n-6  (omega-3 and omega-6, respectively) indicates the 
position of the first double-bond on the hydrocarbon chain, i.e. at the third or sixth carbons from 
the methyl end, respectively [174-176]. 
The n-3 and n-6 PUFA are present in vegetables and in animal tissues. Fish and other 
seafood are the major sources of the long-chain n-3 PUFA, such as eicosapentaenoic acid 
(EPA, C20:5 n-3) and docosahexaenoic acid (DHA, C22:6 n-3), whereas n-6 PUFA are mainly 
found in vegetable oils, nuts and seeds, especially linoleic acid (LA, C18:2 n-6) [174,176] (Table 
9).  
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Table 8-Long-chain fatty acids classification in terms of number of carbon atoms and their double bonds. Adapted from Bazinet & Laye (2014) [173]. 
Name Type 
Number of carbon 
atoms 
Number of double 
bonds 
Symbol Chemical structure 
Oleic acid (OA) Monounsaturated 18 1 18:1n-9 
 
Linoleic acid (LA) n-6 polyunsaturated 18 2 18:2n-6 
 
α-linolenic acid (ALA) n-3 polyunsaturated 18 3 18:3n-3 
 
Arachidonic acid (ARA) n-6 polyunsaturated 20 4 20:4n-6 
 
Eicosapentaenoic acid (EPA) n-3 polyunsaturated 20 5 20:5n-3 
 
Docosapentaenoic acid (DPA) 
n-6 
n-6 polyunsaturated 22 5 22:5n-6 
 
Docosapentaenoic acid (DPA) 
n-3 
n-3 polyunsaturated 22 5 22:5n-3 
 
Docosahexaenoic acid 
(DHA) 
n-3 polyunsaturated 22 6 22:6n-3 
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Table 9-Sources of PUFA high in n-3 and n-6 fatty acids [177]. 
n-3 oils n-6 oils 
Fish oil 
Chia oil 
Perilla oil 
Flaxseed oil 
Canola oil 
Walnut oil 
Soybean oil 
Corn oil 
Safflower 
Sunflower seed oil 
Cottonseed oil 
Soybean oil 
Peanut oil 
Sesame oil 
Grapeseed oil 
Borage oil 
Primrose oil 
  
 
LA can be endogenously converted to longer-chain n-6 PUFA, such as gamma-linolenic 
acid (GLA, C18:3 n-6) and arachidonic acid (ARA, C20:4 n-6) (Figure 10), whereas the n-3 
PUFA, such as EPA and DHA, are converted from the progenitor alpha-linoleic acid (ALA, 
C18:3 n-3) by progressive desaturation and elongation (Figure 10) [176,178]. 
ALA is found in triglycerides, in cholesterol esters and in fewer amounts in phospholipids. 
EPA and DHA are found in the oils of fish (Table 10). EPA is found in triglycerides, cholesterol 
esters and phospholipids, or can be directly obtained from fish oils through diet. It is the 
precursor of eicosanoids comparable to those originating from ARA but with a lesser degree of 
bioactivity [175,177]. EPA may be converted to DHA, and also to eicosanoids, such as 
prostaglandins, thromboxanes, and leukotrienes. DHA is converted also to eicosanoids and to 
anti-inflammatory mediators such as resolvins and protectins [177]. DHA is found mostly in 
phospholipids, and its accumulation in the human body depends mainly on dietary intake 
[175,177,178].    
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Figure 10- n3 and n-6 PUFA and their respective sources and metabolic derivatives. After consumption, the n-3 
PUFA α-linolenic acid (ALA; 18:3n-3) and the n-6 PUFA linolenic acid (LA; 18:2n-6) can be desaturated, a process that 
involves the addition of a double bond, and elongated to become longer chain PUFA. The Δ6 desaturase enzyme is 
considered to be the rate-limiting step for the synthesis of docosahexaenoic acid (DHA; 22:6n-3). Adapted from Bazinet 
& Laye (2014) [173] and Mehta et al.(2009) [175].  
 
Table 10-Content of n-3 PUFA in selected fish (grams per 100g edible portion, raw) Adapted from Simopoulos(2005) 
[177]. 
Fish Total fat 
Total 
PUFA 
ALA 
(18:3n-3) 
EPA 
(20:5n-3) 
DHA 
(22:6n-3) 
Cholesterol 
(mg/100g) 
Anchovy, European 4.8 1.6 - 0.5 0.9 - 
Bluefish 6.5 1.6 - 0.4 0.8 59 
Carp 5.6 1.4 0.3 0.2 0.1 67 
Catfish, channel 4.3 1.0 Tr 0.1 0.2 58 
Cod, Atlantic 0.7 0.3 Tr 0.1 0.2 58 
Croaker, Atlantic 3.2 0.5 Tr 0.1 0.1 61 
Flounder 1.0 0.3 Tr 0.1 0.1 46 
Grouper, red 0.8 0.2 - Tr 0.2 - 
Halibut, Greenland 13.8 1.4 Tr 0.5 0.4 46 
(to be continued) 
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Fish Total fat 
Total 
PUFA 
ALA 
(18:3n-3) 
EPA 
(20:5n-3) 
DHA 
(22:6n-3) 
Cholesterol 
(mg/100g) 
Halibut, Pacific 2.3 0.7 0.1 0.1 0.3 32 
Mackerel, king 13.0 3.2 - 1.0 1.2 53 
Mullet, striped 3.7 1.1 0.1 0.3 0.2 49 
Plaice, European 1.5 0.4 Tr 0.1 0.1 70 
Pollock 1.0 0.5 - 0.1 0.4 71 
Salmon, Chinook 10.4 2.1 0.1 0.8 0.6 - 
Salmon, pink 3.4 1.4 Tr 0.4 0.6 - 
Sole, European 1.2 0.2 Tr Tr 0.1 50 
Swordfish 2.1 0.2 - 0.1 0.1 39 
Tuna, albacore 4.9 1.8 0.2 0.3 1.0 54 
Note: Tr, trace (<0.05g/100g food). 
 
Different types of fish contain different amounts of fatty acids (Table 10) and may present 
different ratios of EPA:DHA. Populations such as the Japanese, who oily fish consumption is 
greater and regular than populations in Europe, North America, and Australian, have higher 
intakes of very long-chain n-3 PUFA, such as DHA that comprises ~30% of the fatty acids 
present [179].  
Several clinical and epidemiologic studies have been developed to determine the effect of 
PUFA on the various physiologic index and their health or clinical benefits. PUFA confers 
various health benefits, including in rheumatoid arthritis [180], protection against the onset of 
diabetes [181,182], efficient immune response modifications [183], coronary heart disease 
[184], bronchial asthma [185], thyrotoxicosis [186], multiple sclerosis [175], depression [187], 
Alzheimer’s disease [188,189] and cancer [190,191]. PUFA have roles in gastrointestinal 
diseases, such as gastric cancer and colonic cancer, as Wang et al. (2012) reported in a 
randomized clinical trial in which n-3 PUFA enriched emulsions displayed an anti-inflammatory 
effect in patients with gastrointestinal diseases [192]. PUFA have also an effect against 
pathogenic and opportunist microorganisms, inhibiting or killing bacteria [193].  
 
2.4.1.2- PUFA activity against H. pylori 
In 1987, a dietary intake of PUFA was reported as responsible for the decline of H. pylori 
infection in duodenal ulcer incidence [194]. After that, some studies were developed and 
demonstrated that concentrations of 2.5×10
-4 
M of LA could inhibit H. pylori growth in vitro. 
Further studies described that this inhibitory effect increased with the degree of PUFA 
unsaturation (number of double bonds): [oleic  (C18:1) <  linoleic (C18:2) < arachidonic (C20:4) 
< n-3 linolenic (C18:3) =n-6 linolenic (C18:3) = eicosapentaenoic (C20:5) acid] [195]. 
Concentrations of 1×10
-3 
M are able to kill bacteria by cell lysis as observed by Scanning 
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Electron Microscopy (SEM) [195,196]. PUFA can be incorporated into H. pylori phospholipids 
membrane, changing their morphology and inducing the disruption of the cell membrane [196].  
Correia et al. (2012) demonstrated that DHA is also able to inhibit H. pylori growth in vitro in 
a concentration-dependent manner. At concentrations  250 µM, DHA was bactericidal to all H. 
pylori strains studied (26695, B128 and SS1 strains), whereas at concentration ~100 µM DHA 
was only able to inhibit their growth. Also, DHA induced the conversion of H. pylori from bacillus 
to coccoid form, being the coccoid form of H. pylori associated with low cell viability [127]. 
Moreover, DHA reduced ATP production by H. pylori, decreased H. pylori adhesion to AGS 
cells, inhibited their gastric colonization in vivo, and decreased gastric inflammation in a mouse 
model [127,134]. However, DHA efficiency in eradicating H. pylori infection in mice was 
significantly lower than the conventional antibiotherapy, failing in 50% of mice. Nevertheless, 
DHA used as co-adjuvant to conventional antibiotherapies yielded better results than those 
obtained with single conventional therapies.  
Effectively, PUFA may contribute to a protective action against chronic inflammation, having 
an anti-inflammatory effect on H. pylori-infected gastric mucosa, in addition to its bactericidal 
effect [197]. According to Correia et al. (2012, 2013), DHA reduced inflammatory responses 
and the production of prostaglandin E2, associated with inflammation and tissue injury in the 
mouse gastric mucosa. In addition, this PUFA reduced the metabolic activity of H. pylori as well 
as the production of interleukin-8 (IL-8), cyclooxygenase 2 (COX-2) and induced nitric oxide 
synthase from gastric epithelial cells [127,134,198].  
Clinical trials, using a daily administration of 2g EPA and DHA for 12 weeks in patients 
infected with H. pylori, had no significant effects on the eradication of H. pylori, and on the level 
of IL-6 (expecting high levels during H. pylori infection, but a gradual reduction after a 
successful treatment) [138].  
 Correia et al. (2014) also demonstrated that DHA is also incorporated into epithelial cells 
and is able to decrease cell membrane cholesterol levels, as well as cholesterol de novo 
synthesis. In addition, they showed that DHA decreases cholesterol uptake by H. pylori from 
epithelial cells and that H. pylori sensitivity to DHA may be influenced by a previous exposure to 
cholesterol [199]. It was also observed that H. pylori growth in a cholesterol-depleted medium is 
up to thousand-fold more resistant to antibiotics therapy [200,201]. 
The observed PUFA ineffectiveness in vivo can be related to their poor solubility in water 
(which difficult its administration), possible low penetration through the mucus layer and the low 
residence time in the stomach. Moreover, PUFA can suffer easy oxidation, carboxylic 
protonation, esterification, and lipid-protein complexation in gastric environment [193,202]. The 
exposition of EPA and DHA to light, peroxidants or high temperature may induce their rapid 
oxidation. Their autoxidation results in the formation of fatty acid based hydroperoxides and 
their degradation into secondary oxidation products [203].  
One strategy to overcome and preventing PUFA oxidation is their encapsulation into 
nanodelivery systems, such as liposomes. These systems can stabilize and protect PUFA 
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against changes in environmental conditions and improve their bioavailability and activity at 
infection local.  
LA incorporated into liposomes (LipoLLA), with sizes around 100 nm, were able to fuse with 
H. pylori membranes, allowing the free LA to be incorporated into the bacterium membrane, 
disrupting their integrity and killing bacteria in 5 min [128,129]. These LipoLLA were more 
efficient against H. pylori than other liposomal containing other PUFA such as oleic acid 
(LipoOA) and stearic acid (LipoSA). The minimal bactericidal concentration (MBC) for LipoLLA 
was 200 µg/mL, while 1 mg/mL of LipoOA was required to kill 90% of H. pylori and no 
antibacterial effect was observed for LipoSA for concentrations up to 1 mg/mL [128]. LipoLLA 
retention and distribution, as well as its efficiency in the treatment of H. pylori infection were 
evaluated using mice animal models. LipoLLA treatment was able to reduce the number of H. 
pylori in infected mice in a similar way as the currently used triple antibiotic therapy (99 %) and 
without promoting alterations in the histology or increased rates of apoptosis in the mice 
stomach. This effect was not observed when free LA treatment was used, that did not reduce H. 
pylori number in comparison to the triple therapy. Moreover, treatment with LipoLLA reduced 
the mRNA expression of proinflammatory cytokines known to be upregulated by H. pylori 
infection [135].  
2.4.1.3- PUFA activity against other microorganisms 
The effect of PUFA against other microorganisms have been also investigated since PUFA 
are well-suited for the: 1) treatment of superficial skin infections and acne [204-208], where the 
anti-inflammatory proprieties of certain PUFA may provide additional benefits [209,210]; 2) 
treatment and spread prevention of sexually-transmitted diseases [211,212], especially those 
caused by Neisseria gonorrhoeae or herpes simplex virus; 3) prevention of periodontal 
diseases and dental caries [213,214], and 4) reduction of infant gastrointestinal infections 
[215,216].  
Table 11 summarizes some of the PUFA with antimicrobial activity. 
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Table 11- PUFA with antimicrobial activity. 
Fatty acid Microorganism Reference 
EPA 
DHA 
 
Bacillus subtilis 
Listeria monocytogenes 
Staphylococcus aureus 
Enterobacter aerogenes 
Escherichia coli 
Pseudomonas aeruginosa 
Salmonella enteritidis 
Salmonella typhimurium 
Burkholderia cenocepacia 
[217,218] 
LA Staphylococcus aureus 
Bacillus cercus 
Streptococcus mutans 
Pseudomonas aeruginosa 
Salmonella typhimurium 
Vibro parahemolyticus 
Klebsiella pneumoniae 
Proteus mirabillis 
[219,220] 
DHA 
-LA 
EPA 
Staphylococcus aureus 
Propionibacterium acnes 
[205] 
EPA Phaeodactylum tricornutum 
Staphylococcus aureus 
Bacillus cereus 
Staphylococcus epidermidis 
Bacillus weihenstephanensis 
Planococcus citreus 
[221] 
 
 
2.4.1.4- Antibacterial Mechanism of Action 
PUFA antibacterial mechanism of action is unclear but can have inhibitory or cidal effects. It 
depends on many factors, such concentration, targeted microorganism,  the microorganism 
physiological state and the environment conditions such as pH and temperature [209]. When a 
bactericidal interaction takes place, death is induced instantly or it may take longer periods of 
time. Often, the prime target is the bacterial membrane, which can be followed by the changes 
of a cascade of processes that are essential for bacteria survival. These processes are  
schematized at Figure 11 [193].  
PUFA can disrupt the normal function of bacteria membrane and thus, the production of 
energy, by interfering with the electron transport chain and disrupting the oxidative 
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phosphorylation. Other processes that may contribute to bacterial growth inhibition or death 
include cell lysis, inhibition of enzyme activity, impairment of nutrient uptake and the generation 
of toxic peroxidation and auto-oxidation products (Table 12). Free fatty acids can exert a 
protonophore effect, whereby the pH of the cytoplasm is reduced to such an extent that the cell 
ceases to function normally [193,209,222]. Considering that fatty acids act on multiple cellular 
targets, bacteria resistance to fatty acids is expected to be rare [209,216,223].  
 
 
 
Figure 11- Schematic representation of the fatty acids antibacterial mechanism of action. Adapted from Desbois and 
Smith (2010) [193]. 
 
Leakage of cell 
membrane 
Disruption of 
electron transport 
chain  
Interference with 
oxidative 
hosphorylation  
Enzyme 
inhibition 
Inhibition of 
nutrient uptake 
Cell lysis or 
induction of 
autolysis 
Inhibition of fatty 
acid biosynthesis 
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Table 12- Description of principal mechanisms of antibacterial of action of free PUFA. Adapted from Desbois and Smith (2010) [193]. 
Process Description References 
Cell lysis The insertion of free  PUFA into the bacterial inner membrane causes it to become more fluid and permeable, allowing the 
leakage of the internal cell contents, causing growth inhibition or even death. When there is an excessive enhance of 
membrane fluidity, the membrane can become unstable and the cell will ultimately lyse. Notwithstanding, the detergent 
effect of fatty acids, which, at high concentrations, may solubilize large sections of the cell membrane, could further 
account for complete cell lysis. 
[224-226] 
Disruption of electron 
transport chain 
The inner membrane of bacteria is an important site for energy production and it is where the electron transport chain is 
located. The ability of the electron transport chain to transfer electrons is impaired so that the proton gradient and 
membrane potential are reduced; resulting in a decrease in ATP production and the bacterium becomes deprived of an 
essential source of energy. Free PUFA could bind the electron carriers directly, but complete displacement from the 
membrane is likely achieved due to its increase membrane fluidity and instability. 
[222,225,227-
230] 
Oxidative 
phosphorylation 
Free PUFA can reduce ATP synthesis by increasing membrane permeability to protons, which could happen anywhere on 
the inner membrane or at specific proton pores. Thus, the proton gradient and membrane potential are able to be 
decreased by PUFA that after entered into cytosol, can release protons from its carboxyl groups and then returning across 
the membrane to the exterior, leading to an increase in the cytosolic concentration of protons. 
[222,227,231,232] 
Inhibition of  nutrient 
uptake 
Free PUFA are able to inhibit the bacteria ability to take up nutrients, such as amino acids. This reduction of nutrients 
uptake may be related to the disruption of the membrane-located transporter proteins or result from the reduced proton 
motive force required for the active transport. 
 
[233-235] 
Inhibition of enzyme 
activity 
Free PUFA can interact with various intracellular and membrane targets, such enzymes. Inhibition of enzymes in the 
membrane or cytosol is crucial for bacterial survival and its growth. Their antibacterial effect are also due to the inhibition of 
fatty acids biosynthesis.  
 
[236-238] 
Peroxidation and 
auto-oxidation 
PUFA high degree of unsaturation facilitates its degradation and the production of peroxides and reactive oxygen species, 
or its auto-oxidation creating oxylipins and short-chain aldehydes, which are antibacterial.  
[216,227,239,240] 
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2.4.1.5-PUFA encapsulation 
The bioavailability and absorption of PUFA is a complex process, depending on several 
factors, such as physicochemical properties, the presence or absence of other substances that 
enhance or inhibit absorption, metabolization after absorption, the state of health, and other 
individual factors [241-243]. After oral intake, PUFA enter the stomach where they are 
dispersed as fine droplets, due to the mechanical influence of stomach peristalsis movements, 
and travel until the upper small intestine. Besides the type of chemical bond, the concomitant 
intake of food, and the presence of other components also affect the uptake of PUFA. Calcium 
ions can also form a complex with PUFA and thus reduce their availability [243].  
PUFA, like EPA and DHA, have a high degree of unsaturation, making them highly 
susceptible to oxidation, a process that involves the formation of toxic products (i.e. peroxides), 
unpleasantly smelling and tasting aldehydes and ketones [241,242,244,245]. There are a 
variety of materials that can be used for encapsulation of PUFA, to protect them against 
environmental effects (oxygen, light, humidity, pH) and, simultaneously, to improve their 
stability, handling conditions and bioavailability and may minimize the odor and taste problems 
[245,246]. There are some commercial capsules that use gelatin to encapsulate fish oil. 
However, these capsules tend to disintegrate in the stomach releasing the fish oil and 
consequently a fishy odor in the breath combined with undesired regurgitation which diminishes 
patient compliance [246]. Taking this into consideration, a novel lipid-based colloidal formulation 
has been developed. It consists of a highly concentrated lipid nanoparticle dispersion, which 
can be mixed in soft drinks or water, avoiding swallowing problems with solid dosage forms 
[246].  
2.4.1.5.1- Lipid-based colloidal carriers 
 
The application of nanotechnology, particularly the use of engineered small particles like 
microparticles (1-999 µm) and nanoparticles (1-999 nm) for drug delivery, has generated 
significant impact in medicine, revolutionizing the diagnosis and treatment of many diseases 
[49,247]. Why can nanoparticles offer improved properties to a classical organic antibacterial 
agent? One reason lies in their high surface area to volume ratio, resulting in the appearance of 
new mechanical, chemical, electrical, optical, magnetic, electro-optical and magneto-optical 
properties that are different from their bulk properties [248]. Small particles are recognized as 
allowing a sustained therapy since they can achieve higher retention time in the human body 
compared to free small molecules of antibiotics. Some authors defend that size plays a central 
role in the diffusion of the particles through the gastric mucosa to reach H. pylori since 
nanoparticles superior to 200 nm have a decreased diffusion [49,249,250].  
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 Nanoparticles delivery systems possess some advantages: are quasi-monodisperse, are 
thermodynamically stable and show long-term kinetic stability. They improve drug controlled 
release, increase of pharmacokinetic proprieties of the drug, namely lipophilicity and reduce of 
side-effects leading to the increase of therapeutic compliance [49,251,252]. The use of 
nanoparticles in the treatment of H. pylori can also overcome the limitations associated with 
antimicrobial drugs degradation by the acidic pH of the stomach [49].  Moreover, it is 
improbable that bacteria might develop resistance to nanoparticles because numerous and 
complex gene mutation would be necessary to overcome either the multiple mechanisms of 
action of antimicrobial nanoparticles as well as the possibility to combine different antimicrobial 
drugs in the same carrier [253].   
There are various nanoparticles delivery systems, especially, 1) lipid-based colloidal 
carriers such as liposomes or lipid nanoparticles, 2) polymeric nanoparticles, 3) dendrimers and 
4) inorganic nanoparticles (Figure 12), that have been used in the release of antibiotics or novel 
non-antibiotic compounds [254,255]. 
Lipid-based colloidal carriers can overcome problems associated with polymeric 
nanoparticles, namely residues from the organic solvents used in the production process, 
polymer toxicity and the scaling up of the production process to industrial levels [251]. Lipid-
based colloidal carriers have several application routes, namely topical [256,257] for cosmetics 
and dermatological applications, ophthalmic [258,259], nasal [260], parenteral [261] 
(intravenously, intramuscularly or subcutaneously), oral [262] and rectal [263-265]. These 
nanoparticles have shown excellent outcomes in treating and detecting bacterial pathogens by 
enabling targeted, responsive, combinatorial delivery of antimicrobial compounds, effective 
antibacterial vaccination and rapid detection of bacteria.  
 
Figure 12- Schematic illustration of major nanoparticle-based delivery systems for the treatment of bacterial infections: 
(a) liposome, (b) polymeric nanoparticles, (c) dendrimer, and (d) inorganic nanoparticle [254]. 
 
 In addition, multifunctional nanoparticles can respond to several stimuli that are 
characteristic of the pathological site, which is achieved through the inclusion of components 
that react to alterations in pH, temperature, redox conditions and to the overexpression of 
certain biological molecules. These nanoparticles can also respond to stimuli from outside the 
body, for instance, magnetic nanoparticles can be a tool for imaging contrast moiety to enable 
their biodistribution, target accumulation or to monitor the efficacy of a therapy (Figure 13) 
[266].  
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Figure 13- Schematic representation of a drug-loaded multifunctional, stimuli-sensitive nanoparticle. One or more drugs 
can be loaded into the nanoparticle. These can be functionalized with different targets, depending on the purpose of the 
nanoparticle, increasing cell penetration, to enable imaging or to release the drugs in response to a given stimuli [266].  
 
Liposomes and lipid nanoparticles, namely solid lipid nanoparticles (SLN) and 
nanostructured lipid carriers (NLC),  are colloidal nanoparticles that are suitable for the 
entrapping of lipophilic drugs [267], such PUFA.  
2.4.1.5.2-  Liposomes 
Currently, liposomes are the most widely used antimicrobial drug delivery system. 
Liposomes are spherical lipid vesicles composed of self-assembled amphiphilic phospholipids, 
sphingolipids, and cholesterol that are self-assembled in the form of a bilayer membrane with 
an internal aqueous core. Once liposomes have both aqueous and lipid phases, they are able 
to carry both hydrophilic and hydrophobic drugs within the aqueous core or bilayer, respectively 
[254,268,269]. Liposomes are mainly composed of natural or synthetic lipids that are 
considered to be relatively biocompatible and biodegradable [252,270]. One of the most 
commonly used lipid is the phosphatidylcholine, which is an electrically neutral phospholipid 
that contains fatty acyl chains with varying degrees of saturation and length. Cholesterol is 
normally incorporated into the formulation to adjust membrane rigidity and stability [269]. 
 One of the features of liposomes is its lipid bilayer structure, which mimics cell 
membranes and can readily fuse with infectious microorganisms and easily released the drugs 
to the cell membranes or inside the bacteria, consequently, a low drug resistance is induced 
[49,129,269]. 
Liposomes used in drug delivery typically range from 20 nm and a few hundred 
micrometers and are usually dispersed in an aqueous medium [252,268]. Drug release, in vivo 
stability, and biodistribution are determined by the size of the vesicles, their surface charge, 
surface hydrophobicity and membrane fluidity[252]. 
 There are various methods for preparing liposomes. Still, all of them take into 
consideration parameters such as the physiochemical characteristics of the liposomal 
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ingredients, materials to be contained within the liposomes, particle size, polydispersity, surface 
zeta potential, shelf-time, batch-to-batch reproducibility, and the possibility of large-scale 
production [269]. Table 13 summarizes the methods that have been used for liposome 
production.  
Table 14 presents some of the examples of liposomes that have been used for 
antimicrobial delivery.  
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Table 13- Methods of liposome preparation and their advantages and disadvantages for scale-up procedures. Adapted from Kraft et al.(2014)[271]. 
Method Basic technique Advantages for 
scaling 
Disadvantages for 
scaling 
Scalability potential 
Solvent injection Injection of lipids dissolved in a water-miscible solvent 
(generally ethanol) into aqueous phase 
Single-step process 
Continuous processing 
Presence of solvent 
without post-removal 
Not all lipids/drugs 
dissolve in ethanol 
Very good 
Thin film hydration Production of a lipid film followed by solvent evaporation 
and rehydration in aqueous phase 
Simple Requires size reduction 
Equipment size is volume 
dependent 
Suitable for small to mid-size 
batches 
Reverse-phase 
evaporation 
Preparation of an emulsion be mixing lipids dissolved in a 
water-immiscible solvent with aqueous phase followed by 
solvent evaporation  
Simple Multistep process Suitable for small to mid-size 
batches 
Detergent 
depletion (dialysis) 
Lipid-micelle formation with detergent followed by 
detergent dilution or removal 
Gentle Presence of detergent Good for sensitive proteins 
and oligonucleotides 
Supercritical fluid Solvation of lipids in supercritical carbon dioxide followed 
by injection into low-pressure aqueous phase 
No organic solvent 
Sterility 
Multistep process 
Expensive equipment 
Good potential 
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Table 14- Liposomes for antimicrobial drug delivery against H. pylori and other bacteria. 
Formulation Drug combination Targeted 
bacteria 
Main Findings References 
PAA, PAH, PC, and 
cholesterol 
Amoxicillin and 
metronidazole 
H. pylori  Effective in H. pylori eradication 
 Efficient to localize the drugs in the gastric environment  
 Rigid and tough for protecting the drug against the environment 
condition in vivo 
[272] 
EggPC and cholesterol Linolenic acid H. pylori  Effective in killing both spiral and coccoid forms of bacteria via 
disrupting bacterial membrane  in vitro 
 Penetrate on mucus layer of mouse stomach 
 Kill H. pylori and reduce bacterial load in the mouse stomach 
 Reduce the levels of pro-inflammatory cytokines 
 Biocompatible for mouse stomach 
[128,129,135] 
DPPC and cholesterol Metronidazole 
Ampicillin 
H. pylori  Liposome interact with bacteria due to synthetic glycolipid-containing 
fucose 
 Interaction with coccoid forms of H. pylori namely strains with BabA2 
 Efficient to kill bacteria 
[273] 
PC, SA, and cholesterol Amoxicillin 
Bismuth citrate 
H. pylori  Enhance percent bacteria growth inhibition (in vitro) 
 Enhance anti-secretory and ulcer-protective activity (in vivo) 
[274] 
PEGylated liposome Daptomycin and 
clarithromycin 
MRSA  Enhance anti-MRSA activity in vitro 
 Reduce MRSA bacterial load 
 Increase host survival in vivo 
[275] 
(to be continued) 
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Formulation Drug combination Targeted bacteria Main Findings References 
PC, SA, and cholesterol Ciprofloxacin and 
vancomycin 
MRSA  Enhance antibacterial activity 
 More effective in liposomal form than free form in vivo 
 Reduce drug toxicity 
 Reduce incidence of side-effect (severe diarrhea) 
[276] 
DPPC and cholesterol Polymyxin B Pseudomonas 
aeruginosa 
 Decrease bacteria count in lung 
 Increase bioavailability 
 Decrease lung injury caused by bacteria 
[277] 
DSPC and cholesterol Bismuth tobramycin Pseudomonas 
aeruginosa 
 Decrease number of bacteria 
 Reduce the production of quorum-sensing molecules and 
virulence  factors 
 High therapeutic efficacy in vivo 
[278] 
PHEPC and PEGDSPE Gentamicin Klebsiella pneunoniae  Increase survival rate of animal model 
 Increase therapeutic efficacy 
[279] 
DPPC, DCP, and 
cholesterol 
Pyrazinamide Mycobacterium 
tuberculosis 
 Reduce the number of intracellularly located bacteria 
 High therapeutic efficacy in vivo 
[280] 
Abbreviations: DCP, dicetylphosphate; DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine;; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; PAA, poly(acrylic acid); PAH, poly(allylamine hydrochloride); PC, 
phosphatidylcholine; PEGDSPE, 1,2-distearoylsn-glycero-3-phosphoethanolamine-N-(polyethylene glycol-2000); PHEPC, partially hydrogenated egg phosphatidylcholine; SA, stearylamine. 
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2.4.1.5.3-  Lipid nanoparticles  
Lipid nanoparticles are a relatively new class of drug nanocarriers that are able to 
incorporate hydrophobic drugs. These nanoparticles present very low cytotoxicity since are 
prepared using biodegradable and biocompatible lipids without using of organic solvents.. 
Moreover, they can be easily and economically prepared for large-scale production [281-283]. 
Lipid nanoparticles can be produced from oil-in-water nanoemulsions, where the liquid lipid of 
the oil droplets is replaced by a lipid that is solid at body temperature. Because of this, lipid 
nanoparticles remain solid after administration. At the same time, the matrix can be chemically 
protected against degradation. There are two generations of lipid nanoparticles, being the first 
generation  are the solid lipid nanoparticles (SLN) and the second generation, the 
nanostructured lipid carriers (NLC) [282]. Figure 14 illustrates the differences between SLN and 
NLC.  
 
Figure 14- Differences between SLN and NLC. Adapted from Müller et al. (2011) [282]. 
 
2.4.1.5.3.1- Solid Lipid Nanoparticles (SLN)  
By definition, SLN have sizes between 50 to 999 nm and the smaller the particle size the 
more likely will be their stability, their targeted responses and their capacity to encapsulate 
large amounts of the drug. SLN are colloidal particles derived from the oil-water emulsion by 
replacing liquid lipids with a lipid matrix that is solid at body temperature and a surfactant for 
particle stabilization [284-286]. Solid lipids used in SLN formulations include 1) fatty acids such 
as palmitic acid, decanoic acid, and behenic acid; 2) triglycerides such as trilaurin, trimyristin 
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and tripalmitin; 3) steroids such as cholesterol; 4) partial glycerides such as glyceryl 
monostearate and glyceryl behenate; and 5) waxes such as cetyl palmitate. Several types of 
surfactants are commonly used as emulsifiers to stabilize lipid dispersion, including soybean 
lecithin, phosphatidylcholine, poloxamer 188, sodium cholate and sodium glycocholate. The 
typical methods of preparing SLN include spray drying, high shear mixing, ultra-sonication and 
high-pressure homogenization [269,287]. 
SLN can be administrated by various routes such as oral, parental as well as 
transdermal/topical. Oral/intraduodenal administration of SLN are believed to enhance 
bioavailability of drugs by improving its transport through the intestinal epithelial layer and by 
protecting it from the hostile environment of the gastrointestinal tract [287].  
 SLN have several potential advantages [284]: 
 Biocompatible and biodegradable; 
 Prevent drug degradation in body fluids; 
 Increase drug payload; 
 Improve drug half-life; 
 Control drug release; 
 Enhance drug bioavailability; 
 Drug targeting; 
 Large scale manufacturing; 
 Feasibility of sterilization. 
 
However, common deficiencies of SLN include low drug loading capacity and a burst 
release after polymorphic transition during storage. This is related with the increased in the 
perfection of the crystal leaves, resulting in less space to accommodate drug molecules. In 
addition to polymorphic transition, the formation of drug-enriched shell leads to burst release. 
These disadvantages make SLN improper for some of applications as delivery system 
[252,285,287].  
SLN have three different morphologies, based on the location of the incorporated drug 
molecules: (Table 15) 1) drug-enriched shell model; 2) drug-enriched core model, and 3) 
homogeneous matrix model [263,284]. 
Several unique proprieties of SLN make them promising antimicrobial drug delivery 
platforms, with possible applications in cosmetic and pharmaceutical products for skin care. 
One application of SLN is delivering azole antifungal drugs to superficial fungal infection 
patients. The occlusive effect of SLN, together with its small particle size, can extend drug 
residence time on the epidermis and enhance drug penetration through the skin [269]. SLN can 
also be used for oral administration, when included in tablets, capsules, and pellets. SLN can 
transport antibacterial compounds and penetrate the intestinal linings through endocytosis 
rather than passive diffusion. SLN have shown great therapeutic potentials against different 
microorganisms, as it is summarized in Table 16. 
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Table 15- Brief description of the structure of solid lipid nanoparticles (SLN). Adapted from Üner & Yener (2007) [263] and  Shah et al. (2015) [284]. 
SLN structure Description 
Schematic 
illustration 
Drug-enriched shell 
model 
 Lipid core enclosed by a drug-enriched outer shell; 
 Suitable for applications where drugs need to be released as a burst; 
 Drug is solubilized in the surfactant-water mixture at elevated temperatures; 
 When dispersion is cooled, drug solubility decreases, leading to drug enrichment in the nanoparticle shell.  
 
Drug-enriched core 
model 
 Drug-enriched core enclosed by a lipid shell. This is obtained when the drug has a tendency to crystallize before 
the lipid; 
 The drug is solubilized in the melted lipid in a concentration closed to its saturation solubility; 
 Subsequent cooling of the lipid emulsion causes super-saturation of the drug in the lipid melt, leading to lipid 
recrystallization and formation of a membrane around the already crystallized drug-enriched core.    
Homogenous matrix 
model 
 Drug is homogenously dispersed within the lipid matrix in molecules or amorphous clusters.  
 Suitable for incorporation of drugs that exhibit prolonged release from particles.  
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Table 16- Solid lipid nanoparticles for antimicrobial drug delivery against bacteria. 
Formulation Drug combination Targeted bacteria Main Findings References 
Stearic acid Rifampicin, isoniazid, 
pyrazinamide 
Mycobacterium 
tuberculosis 
 Increase residence time 
 Increase drug bioavailability 
 Decrease administration frequency 
 Prolong drug release 
 High physical stability 
 High encapsulation efficiency 
[288,289] 
Stearic acid, soy phosphatidylcholine, 
and sodium taurocholate 
Tobramycin Pseudomonas 
aeruginosa 
 Increase drug bioavailability 
 
[290] 
Tetradecanoic acid Enrofloxacin S. aureus  Sustain and prolong drug release 
 Increase bioavailability 
 Extend mean residence time in combination 
with fatty acid 
[291] 
Palmitic acid, stearic acid, 
hydrogenated castor oil 
Tilmicosin S. aureus  Sustain drug release 
 Enhance antibacterial activity 
 Decrease degree of inflammation (in vivo) 
[292] 
Compritol 888
®
 ATO Vancomycin MRSA  Ion pairing of vancomycin with antibacterial 
fatty acid (linoleic acid) 
 Enhance encapsulation efficiency 
 Increase antibacterial activity of vancomycin 
[293] 
Stearic acid Norfloxacin E. coli  Sustaine drug release 
 Enhance antibacterial activity 
[294] 
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2.4.1.5.3.2-  Nanostructured Lipid Carriers (NLC) 
NLC are prepared not from solid lipid only but from a blend of a solid lipid with 
liquid lipid (oils) in such a proportion that the mixture is solid at least at 40ºC [268]. NLC 
consists of an unstructured solid lipid matrix made of a mixture of blended solid and liquid 
lipids and an aqueous phase containing a surfactant or a mixture of surfactants. Different 
combinations of lipids and/or surfactants have been described (Table 17). They are 
commercially available and/or approved by different regulatory agencies such as 
Generally Recognized As Safe (GRAS) and FDA [264].  
The imperfections present in the solid matrix of NLC accommodate the drugs 
either as molecules or as amorphous crystals. The process of full-crystallization or 
recrystallization of solid lipid reduces the drug solubility and leads to drug expulsion from 
the lipid nanoparticles, especially when the drug concentration in the formulations is too 
high [284,285]. On NLC formulation, the liquid lipid is incorporated into the core of a solid 
lipid. This leads to a higher loading capacity and a better control in drug release since the 
drug was dissolved in the liquid lipid that was simultaneously encapsulated in the solid 
lipid [285]. The major advantage of NLC over SLN is that many drugs are more soluble in 
a liquid lipid than in a solid lipid [285]. 
Therefore, NLC overcome the SLN drawbacks, since they increase encapsulation 
efficiency, drug loading, and drug physical stability.  They seem to be a valuable option 
for improving the chemical stability and controlled release of functional lipophilic 
compounds [285,295]. NLC increase oral bioavailability when administered to mice [295].  
NLC can be produced using various methods, such as hot/cold homogenization, 
emulsification-sonication, solvent injection, high-pressure homogenization, microemulsion 
and solvent diffusion, and membrane contractor techniques (Table 18). Hot 
homogenization is the most used method for fabrication of both, SLN and NLC due to 
several advantages, including easy scale up, lack of organic solvents and short 
production time, compared to the other methods [264,285,295]. In this approach, the 
mixture of solid, liquid lipids and surfactant are melted to 5-10ºC above the temperature 
of the solid lipid, and then the drug is dissolved or dispersed in this mixture. The mixture 
is dispersed in aqueous solution at the same temperature by high-speed stirring/shearing, 
obtaining a hot emulsion. Then this emulsion is homogenized using a high pressure 
homogenized, a high-intensity ultrasonic probe/jet/bath or a microfluidizer, to produce a 
hot nanoemulsion. Subsequently, NLC are cooled in cold water, at room temperature or 
by a heat exchanger to crystallize lipid droplet and precipitate the lipid nanoparticles 
[284,285].  
Hot homogenization technique presents, however, some disadvantages like the 
high heating temperature which may promote degradation of the labile active compounds; 
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most surfactants have low cloud points and thus high temperatures may reduce their 
emulsifying capability and increase the NLC instability [285].  
Like SLN, NLC have been proposed to possess three different morphologies 
based on the location of incorporated drug molecules: NLC type I or imperfect crystal 
type; type II or amorphous type; and type III or multiple type [263,284,285]. Table 19 
summarizes the characteristics of each type of NLC. 
NLC have shown great therapeutic potentials against different microorganisms, 
as it is summarized in Table 20. 
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Table 17- Lipid and surfactants used for NLC production, brief description and examples of marketed products. Adapted from Beloqui et al (2016) [264], Shah et al.(2015) [284] and Tamjidi et 
al.(2013) [285] . 
Component Chemical name Trade name example Examples of 
marketed 
products 
Description 
Solid lipid Glyceryl 
palmitostearate 
Precirol ATO
®
5 Xifaxan
®
 The requirements that should be considered for the choice of a suitable lipid 
blend are: 
1. The solubility of the drug in lipid matrices. This influences the drug 
encapsulation efficiency and loading capacities, and subsequently the 
usefulness of lipid nanoparticles in drug delivery. 
2. The solid and liquid lipids must be miscible at the specific concentrations 
needed, i.e., the blend of bulk lipids should be homogeneous and the 
liquid lipid should be situated as nanoholes within the solid matrix.  
3. The lipid phase should be more stable to chemical degradation such as 
oxidation and lipolysis. 
4. Lipids should be biodegradable and capable to produce particles in the 
nanometric scale. This is easier when the liquid lipid phase has a low 
viscosity and/or interfacial tension than when it has a high viscosity 
and/or interfacial tension.  
5. Lipids should have an acceptable toxicological profile and should not 
lead to the production of any toxic residues during NLC preparation.  
Glyceryl dibeherante Compritol 
®
 888 ATO - 
Cetyl palmitate Crodamol
TM
 CP Azelex
®
 
Stearic acid - Viokace
®
 
Tripalmitin - Survanta
®
 
Liquid lipid Caprylic/capric 
triglycerides 
Miglyol
®
812 Avodart
TM
 
Vitamin E and 
derivatives 
- Neoral
® 
Monoacylglycerols Myverol 18-99K Terramycin
® 
Lauroyl 
Polyoxyglycerides 
Gelucire
®
44/14 Lipofen
®
 
Soy lecithin Epikuron
TM
200 Baycip
® 
(to be continued) 
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Component Chemical name Trade name example 
Examples of 
marketed 
products 
Important considerations 
Surfactants Polysorbates Tween
®
 20; Tween
®
60; 
Tween
®
 80 
Targrentin
® 
The requirements that should be considered for the choice of a suitable surfactant 
are: 
1. Amphipathic molecules that possess a hydrophilic moiety (polar) and a 
lipophilic moiety (non-polar),  
2. Able to form nanoemulsions spontaneously by low-energy methods 
3. Able to disperse the lipid melt in the aqueous phase during the 
production process,  
4. Stabilize the lipid nanoparticles in dispersion after cooling 
5. Non-ionic surfactants are preferred for oral and parenteral applications 
because they are less toxic, exhibit fewer side-effects and inhibit the in 
vivo degradation of lipid matrix than ionic surfactants.  
Poloxamers (188, 
407) 
Lutrol
®
 F68; Lutrol
®
 
F127 
Rapamune
®
 
Polyoxiethylene 
stearate 
Myrj 52 Dermazene
TM 
Polyoxyl castor oil Cremophor EL Kaletra
®
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER II 
49 
Table 18- Methods used in the preparation of NLC: mechanism of production, advantages, and disadvantages. Adapted from Shah et al. (2015) [284]. 
Technique Mechanism of nanoparticle formation Advantages Disadvantages 
High-pressure 
homogenization 
High mechanical shear due to strong 
turbulent eddies 
Lowering of pressure across the valves of 
homogenizers 
Hot homogenization 
 Well established technology 
 Effective dispersion of particles 
 Reproducible 
 High lipid content 
 Simple to scale-up 
 
Cold homogenization 
 Effective dispersion of particles 
 Suitable for thermo-sensitive drugs 
 No complex lipid modifications 
 Increase drug-loading due to rapid cooling 
 Suitable for hydrophilic drugs 
 Reduce lipid melting 
 Reduce drug loss 
 Simple to scale-up 
Hot homogenization 
 Extremely high energy inputs (heat and shear 
forces) 
 High polydispersity 
 Temperature-induced degradation of drugs 
 Complex crystallization, which leads to several 
lipid modifications and occurrence of 
supercooled melts 
 Inappropriate for hydrophilic drugs 
 Reduction in homogenization efficiency at 
elevated temperatures 
 
Cold homogenization 
  Extremely high energy inputs 
 Large particles with high polydispersity 
 Drug expulsion on storage 
Emulsification and/or 
sonication 
Shear between adjacent particles 
Formation, growth and implosive collapse 
of bubbles due to cavitation forces 
 Use of organic solvents can be avoided 
 Use of large amounts of surfactants can be 
avoided 
 Simple technique with lower production cost 
 Higher energy inputs 
 Unsuitable for higher lipid contents 
 High polydispersity 
 Physical instability due to high shearing 
 Metal contamination due to ultrasonication 
 Poor encapsulation efficiency 
(to be continued) 
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Technique Mechanism of nanoparticle formation Advantages Disadvantages 
Microemulsion Lipid crystallization due to rapid solidification   Sophisticated equipment not required 
 Low energy inputs 
 Higher temperature gradients, faster lipid 
crystallization, avoids particle aggregation 
 Simple to scale-up 
 Low lipid content 
Solvent injection Lipid crystallization due to rapid diffusion of 
solvent from internal organic phase to external 
aqueous phase 
 Sophisticated equipment not required 
 Pharmaceutically accepted organic solvents 
used 
 Highly efficient and versatile technique 
 Simples to scale-up 
 Solvent removal difficult 
 Low lipid content 
Solvent diffusion Lipid crystallization due to diffusion of solvent 
from internal organic phase to external aqueous 
phase 
 Sophisticated equipment not required 
 Use of pharmaceutically accepted organic 
solvents 
 Small particle diameters and low 
polydispersity 
 Simple to scale-up 
 Toxicological risks due to incomplete 
evaporation of organic solvents 
 Low lipid content 
Membrane 
contractor 
Solid/liquid lipid phase infuses through 
membrane pores into the tangentially flowing 
aqueous phase to form droplets 
Liquid lipid droplets crystallize to form lipid 
nanoparticles 
 Controlled particles size with selection of 
membrane with correct pore size 
 Simple to scale-up 
 
 Clogging of membrane pores, frequent 
replacement or cleaning procedures 
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Table 19- Brief description of the structure of NLC. Adapted from  Üner&Yener (2007) [263],  Tamjidi et al. (2013) [285] and Shah et al. (2015) [284].  
NLC structure Description 
Schematic 
illustration 
Imperfect 
crystal type 
 Matrix with many voids and imperfections that are able to accommodate the drug molecules ().  
 Mixing small amounts of chemically different and low compatible liquid and solid lipids to achieve the highest drug 
payload.  
 
Amorphous 
type 
 The amorphous type minimizes drug expulsion by maintaining the polymorphicity of the lipid matrix, i.e., the amorphous 
model is created when mixing special lipids (e.g. hydroyoctacosanyl-hydroxystearate, isopropylmyristate) that do not 
recrystallize after homogenization and cooling of the nanoemulsion.  
 Lipid core congeals in an amorphous state (rather than crystalline state), minimizing drug expulsion during storage time.  
 
Multiple type  The multiple type is related to the solubility of lipophilic drugs in liquid lipids, which is higher than that in solid lipids.  
 At low concentrations, liquid lipid molecules are easily dispersed into the lipid matrix.  
 By adding higher amounts of liquid lipid its solubility leads to phase separation, producing tiny oily nano-compartments 
() surrounded by the solid lipid matrix.  
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Table 20- NLC for antimicrobial drug delivery against bacteria. 
Formulation Drug combination Targeted bacteria Main Findings References 
Precirol ATO
®
5, Squalene and Pluronic 
F68 
Tretinoin  
Tetracycline 
S. aureus 
Pseudomonas aeruginosa 
Propionibacterium acnes 
 Enhance tetracycline permeation through skin 
 Unaffect tretinoin permeation after encapsulation 
 Increase of antibacterial activity of tetracycline  
[296] 
Precirol ATO
®
5, Miglyol
®
812, Tween
®
80 
and Poloxamer 188 
Colistin Pseudomonas aeruginosa  Increase the antimicrobial activity of colistin 
 More efficient in the eradication of biofilms 
[297] 
Precirol ATO
®
5, Compritol
®
 888 ATO, 
Miglyol
®
812, Tween
®
80 and Poloxamer 
188 
Tobramycin Pseudomonas aeruginosa  Increase antimicrobial activity 
 No cytotoxic 
 Able to penetrate mucus  
 Large pulmonary distribution and retention in the 
in vivo 
[298] 
Precirol ATO
®
5, Miglyol
®
812, Tween
®
80 
and Poloxamer 188 
LL-37 peptide E. coli  Increase antimicrobial activity 
 No cytotoxic  
 Improve healing in vivo in terms of wound 
closure, re-epithelization grade and restoration of 
the inflammatory process 
[299] 
Hexadecyl palmitate, glycerol stearate, 
grape seed oil, sea buckthorn oil, St. 
John’s wort oil, Syneperonic F68, 
Tween
®
20 and Tween
®
80 
 
Green Tea extract E. coli  Increased antioxidant activity 
 Improved antibacterial activity  
[300] 
Glycerol monooleate, oleic acid, and 
Lutrol F127 
Peptide: 
AP114 
DPK-060 
LL-37 
MRSA 
Pseudomonas aeruginosa 
E. coli 
Acinetobacter baumannii 
 Different structures have the capacity of 
solubilizing peptides 
 Differences on structure induced differences on 
antibacterial activity 
[301] 
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CHAPTER III 
 
THEORETICAL BACKGROUND OF TECHNIQUES USED 
A brief description of the different techniques applied for the lipid nanoparticles and 
bacteria characterization, in terms of morphology, characteristics features, namely size, surface 
charge, stability and interactions between nanoparticles and bacteria,  is provided in this 
chapter.  
3.1- Measurement of size and surface charge 
3.1.1- Dynamic Light Scattering (DLS) 
 
Particle size is the most basic information that can be obtained from nanoparticles. It is a 
determinant factor for nanoparticles biodistribution and retention at the targeted site [1]. Particle 
sizing in the submicrometer range is routinely performed using the DLS technique. This 
technique can provide, in a few minutes, an average of nanoparticles size and their distribution 
through the analysis of light scattering of a laser beam [1-3]. Submicrometer-sized particles 
suspended in a fluid are in constant random Brownian motion as result of the random collisions 
between the solvent molecules and the particles, causing fluctuations in the intensity of the light 
scattered at a certain detection angle (varying from 10º to 90º) [4,5]. This intensity of the 
fluctuation trace comprises a mixture of constructive and destructive interferences on the 
scattered light, through which the particle size can be determined by analyzing the motion-
dependent autocorrelation function using the Stokes-Einstein equation (Eq.1) [1,2]. 
𝑑(𝐻) =
𝑘𝑇
3𝜋ɳ𝐷
    (Eq.1) 
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where: 
d(H) = hydrodynamic diameter 
D = translational diffusion coefficient 
k = Boltzmann’s constant 
T = absolute temperature 
ɳ = viscosity 
 
 In the Stokes-Einstein theory of Brownian motion, particle motion at very low 
concentrations is determined by the suspending fluid viscosity and temperature, and particle 
size [3]. Usually, samples are diluted with purified water (type I) or a buffer solution at a suitable 
concentration, placed in an appropriate measuring cell and finally measured [4]. This technique 
is based on the principle that smaller particles move at higher speeds than larger particles 
(Figure 1), and thus the rate of fluctuation of the light scattered for the last is also slower (Figure 
1) [4,6]. The correlation between time and light intensity variation results in a diffusion 
coefficient that is converted to particle size, in the form of an average of effective hydrodynamic 
diameter and polydispersity index (a dimensionless parameter), which is a measure of the width 
of the distribution [1,4]. A polydispersity index value from 0.1 to 0.25 indicates a narrow size 
distribution, while values greater than 0.5 indicate a broad distribution [1]. 
 
Figure 15- The particles random motion in a liquid and their speed are used to determine the particle's size [6]. 
 
3.1.2- Nanoparticle Tracking Analysis: NanoSight® 
NanoSight
®
 offers the ability to visualize the size and determine the number of 
nanoparticles in a liquid suspension. This technique can analyze simultaneously a population of 
nanoparticles on an individual basis and is ideally suited for real-time analysis of polydispersity 
systems ranging from 10-30 nm up to 1-2 μm in size. Additionally, it is also allowed to acquire 
information on nanoparticles concentration, the relative intensity of light scattered and also to 
visualize and analyze fluorescently labeled particles [7]. NanoSight
®
 uses a finely focused laser 
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beam that is introduced into a liquid sample containing a dilute suspension of particles, through 
a glass prism. This beam refracts at a low angle as it enters the sample, resulting in a thin beam 
of laser light that illuminates the particles (Figure 2) [8].  
 
 
Figure 16- Schematic representation of the NanoSight
®
 instrument configuration [7]. 
 
The particles in suspension scatter light in such a manner that they can easily be 
visualized at 90º via a long working distance. The camera which operates at approximately 30 
frames per second captures a video file of the particles moving under Brownian motion in a field 
of approximately 100 μm ×80 μm ×10 μm [7,9]. 
Particles concentration can be measured from one video frame alone. Yet, in practice, data 
from all the recorded frames is used to determine the average concentration, eliminating this 
way concerns like counting the same particle over and over. The concentration is calculated by 
taking this average and dividing by the volume used in which the number of particles is 
measured [7]. It is important that a sufficient number of particles are analyzed within testing time 
to ensure that the data produced is statistically robust. A concentration in the region of 10
6
 to 
10
9
 particles per mL provides a statistically sound and repeatable particle size distribution within 
30-60 seconds (typical timescale) [7,9]. Under normal conditions, when analyzing optimal 
concentrations of nanoparticles with similar optical characteristics, concentration accuracies can 
be as good as 5-10% if the samples are diluted to a suitable concentration range [7,9].  
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3.1.3- Electrophoretic Light Scattering (ELS) 
Zeta potential refers to a particle surface charge. It can be determined using a combination 
of the measurement techniques electrophoresis and laser doppler velocimetry, that determine 
how fast a particle moves in a liquid when an electrical field is applied (electrophoretic mobility) 
[4,6]. The surface charge affects the ion distribution around the nanoparticles in the aqueous 
medium. Most liquids contain ions, which are negatively and positively charged atoms or 
cations and anions, respectively. When a charged particle is suspended in liquid, ions of an 
opposite charge will be attracted to the surface of the suspended particle forming a thin liquid 
layer.  This particle is also covered by an outer diffuse layer consisting of loosely associated 
ions [2,6,10]. In this sense, a negatively charged sample attracts positive ions from the liquid, 
while a positively charged sample attracts negative ions from the liquid [6]. Hence, the result is 
the creation of an electrical double layer formed by the charged surface and the counter-ions 
distributed in a diffuse way in the aqueous medium (Figure 3). Generally, particles with zeta 
potential more positive than + 30 mV or more negative than -30 mV have colloidal stability 
maintained by electrostatic repulsion, whereas, a low zeta potential value of less than 30 mV 
indicates a condition towards instability, aggregation, coagulation or flocculation [1,2,10].  
The zeta potential measurement depends on the strength and valence of ions contained in 
the nanoparticles suspension. High ionic strength and high valence ions compress the electric 
double layer, resulting in a reduction of the zeta potential. The pH, concentration of hydrogen 
ions in the medium, influence greatly the zeta potential as well. When the suspension is acidic, 
the nanoparticles acquire more positive charge and vice versa. Therefore, a zeta potential value 
without indication of solution pH is a virtually meaningless number [1].  
 
Figure 17- Schematic of the electrical double layer at the surface of solution-phase nanoparticles [6]. 
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3.2- Lipid Crystallinity by Differential Scanning Calorimetry 
(DSC) 
 
DSC is primarily used to determine the energetics of phase transitions and conformational 
changes and allows quantification of their temperature dependence. DSC provides also 
information on the physical state and crystallinity of lipid nanoparticles [11,12]. The degree of 
crystallinity of a particle is extremely important because it influences the encapsulation 
efficiency and the release rate and expulsion of the drug during storage. DSC analysis also 
provides the fusion temperature and enthalpy of the particles. A high value of fusion enthalpy 
suggests a high level of organization in the crystal lattice since the fusion of a highly organized 
crystal (perfect crystal) requires more energy to overcome the forces of cohesion in the crystal 
lattice [12]. In this sense, DSC is considered a thermal analytical technique commonly used to 
measure the heat capacity of a substance and the enthalpy variation, ΔH [13-15]. During 
measurements, the sample and reference are inside aluminum pans, which are located on the 
sample holder. The reference pan was empty and the sample pan contained the nanoparticles 
dispersion or the lipid bulk. The pan might be used with numerous inert atmospheres, as well as 
oxidizing and reducing atmospheres. Commercial sample pans can be hermetic, open or 
sealed. The sample size required for DSC analysis is very low with 2-10 mg being sufficient 
[11,15].  
The pans are heated or cooled with a constant scan rate and the temperature within the 
two pans is maintained constant. When phase changes occur in one pan but do not in the 
reference pan, this means the calorimeter requires different energies to heat or cool the 
reference pan and the sample pan and the isothermal energy necessary is registered as an 
electrical signal [11,15]. The signal resultant from DSC measurements is the heat flow as a 
function of temperature and the enthalpy variation, ΔH, can be calculated by the peak area 
determined by integration of the peak from the DSC thermograms [16].  
DSC analyses are easy and rapidly performed, and are frequently used to characterize the 
physical state, the degree of crystallinity, polymorphism, crystal ordering, eutectic mixtures or 
glass transition processes in lipid nanoparticle dispersions [13,16]. To compare the crystallinity 
between the developed formulations, the recrystallization index (RI) is a useful and commonly 
used parameter. RI is defined as the percentage of the lipid matrix that has recrystallized during 
storage time and can be calculated according to the following equation (Eq. 2), where ΔH is the 
molar melting enthalpy given by J/g and the concentration is given by the percentage of lipid 
phase [17]: 
𝑅𝐼(%) =
𝛥𝐻 𝑙𝑖𝑝𝑖𝑑 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝛥𝐻 𝑏𝑢𝑙𝑘 𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙 ×𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑙𝑖𝑝𝑖𝑑 𝑝ℎ𝑎𝑠𝑒
× 100     (Eq.2) 
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3.3- Bioimaging techniques 
 
There are various methods and techniques that evaluate the morphology of nanoparticles 
as well as of bacteria. In this work cryo-SEM, NanoSight
®
 and AFM were used to analyze the 
morphology and topography of nanoparticles, whereas bacteria morphology and interaction with 
nanoparticles were evaluated by scanning electron microscopy (SEM), transmission electron 
microscopy (TEM), atomic force microscopy (AFM) and flow cytometry image by 
ImageStream
X®
.  
3.3.1- Scanning and Transmission Electron Microscopy (SEM 
and TEM) 
Although there is no theoretical limit to the magnification power of a light microscope, the 
resolving power has a maximal value of about 200 nm due to the fixed minimal wavelength of 
visible light [18]. Electron microscopy uses beams of accelerated electrons and electrostatic or 
electromagnetic lenses to generate images of high resolution, based on the much shorter 
wavelengths of electrons than visible light photons [2]. The major limitation to using electron 
microscopy is that specimens must be fixed, dehydrated and chemically treated. Therefore, this 
technique cannot be applied to living cells or microorganisms. Usually, to diminish artifacts, 
specimens can be rapidly frozen, so the water and other components present in the cells or 
particles do not have time to rearrange or even crystallize into ice; this was conducted in this 
work to evaluate de lipid nanoparticles morphology [18]. There are two major types of electron 
microscopy, SEM, and TEM. 
SEM is an imaging method used for the detailed analysis of a specimen’s surface, in which 
an incident electron beam scans and interacts with the sample surface it to generate signals 
that reflect its atomic composition and topographic detail [2,18]. Interactions between the 
sample and the electron beam result in different types of electron signals emitted at or near the 
specimen surface. These electronic signals are collected, processed and translated as pixels by 
a monitor that forms a three-dimensional (3D) image of the specimen’s surface topography [18]. 
Then, the incident electrons emit elastic scattering electrons also referred to as backscattered 
electrons, inelastic scattering electrons also known as low-energy secondary electrons. 
Moreover, a characteristic X-ray emitted from below the specimen surface, providing 
information on the specimen composition [2,18]. Usually, the specimen surface is coated with a 
thin film of gold or platinum to improve contrast and the signal-to-noise ratio [2,18]. 
 
In TEM, an electron beam is aimed at a thin section of a specimen that has been 
chemically treated to enhance contrast. Negative staining for TEM has been considered for 
many years as the “gold standard” for imaging samples. This negative-stain TEM requires an 
adequate concentration of sample, bacterial cells or nanoparticles to adsorb to a thin support 
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film [2,18,19]. The thin sections (< 100 nm) of preserved tissue are stained with atoms of heavy 
metals, which are preferentially attracted to certain cellular components. When these heavy 
metal stains, which are electron dense, are hit by an electron beam, the electrons are absorbed 
or scattered, making electron-dense areas appear darker [18]. The magnification of TEM is 
mainly determined by the ratio of the distance between the objective lens and the specimen and 
the distance between the objective lens and its image plane, producing two-dimensional (2D) 
images of thin tissue sections [2]. The specimen thickness of less than 50 nm is required while 
doing high-resolution TEM or electron spectroscopy. However, the extensive preparation of thin 
specimens increases the possibility of altering the sample’s structure and makes TEM analysis 
a very time-consuming process. Moreover, TEM specimens can be damaged or even destroyed 
by intense, high-voltage electron beams [2].   
 
3.3.2- Atomic Force Microscopy (AFM) 
AFM is a versatile technique that allows for the investigation of the surface morphology of 
a biological specimen at an unprecedented level of resolution.  
AFM consists several parts, but one of the most important is the AFM tip, mounted at the 
end of a microfabricated flexible cantilever, which is then used to scan the sample’s surface 
(Figure 4) [20,21].  As the tip scans the sample surface, the cantilever deflects and this 
deflection is detected by means of a laser beam aligned at the back of the cantilever, being 
passed onto a position-sensitive photodiode, processed as a function of the position on the (x,y) 
plane and through that, a 3D morphology of the surface can be reconstructed [2,20-22]. A 
closed loop control system helps to keep the tip in proximity to the surface by adjusting de z 
position of the sample [2,21,22]. 
Like SEM and TEM, AFM technique can be used for investigating the size, shape, 
structure, sorption, dispersion and aggregation of nanomaterials [2]. One of the great 
peculiarities and advantages of the AFM technique in biology, namely in what concerns the use 
of live samples (such as cells, bacteria, etc) is the fact that it can work in any environmental 
condition, including in liquids, allowing to perform experiments in quasi-physiological conditions 
[20]. Moreover, the AFM offers substantial benefits in 3D real quantitative data acquisition, 
namely minimal sample preparation time, flexibility in ambient operating conditions ( i.e. no 
vacuum is necessary) and effective 3D magnification at the submicron level [22]. 
AFM can be applied to more sophisticated in vivo studies, namely studies concerning 
antibiotics efficacy and action mechanisms. The effectiveness of antibiotics that compromise 
the bacterial structure and integrity as an epiphenomenon of internal biochemical action, can be 
studied with AFM technique, by analyzing the bacterial morphology and structure at the 
nanoscale level or, in cases of resistance, to investigate their lack of activity[22].  
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Figure 18- Schematic representation of the AFM general principle. AFM imaging is performed by scanning a tip across 
the sample surface while the force of interaction between the tip and the sample is monitored with piconewton 
sensitivity. The sample is mounted on a piezoelectric scanner, which ensures three-dimensional positioning with high 
resolution, and the force between tip and surface is monitored by measuring the cantilever deflection using an optical 
method (i.e. laser, photodiode). Adapted from Hinterdorfer and Dufrene [23]. 
 
AFM can operate in a variety of topographical modes, including contact (the tip is in 
continuous contact with the surface), non-contact (the cantilever vibrates and variations from its 
resonance frequency are used to generate images), and intermittent (the cantilever moves 
rapidly with a large oscillation between the repulsive and attractive forces) (Figure 5) [21]. The 
most widely used imaging mode is the contact mode, in which sample topography can be 
measured in two ways: constant-height or constant-force. In the constant-height mode, 
cantilever deflection is recorded while the sample is scanned at a constant height. However, it 
is often necessary to minimize large deflections and, therefore, keep the applied force restricted 
to small values to prevent sample damage. In the constant-force mode, in which the sample 
height is adjusted to keep the deflection of the cantilever, the force that is applied to the tip is 
maintained constant using a feedback loop [24]. The drawback here is the lateral force exerted 
on the sample can be quite high, resulting in sample damage or the movement of relatively 
loosely attached objects, such as proteins. To overcome this problem is to oscillate the 
cantilever during imaging, which led to dynamic mode [25].  
In dynamic or Tapping
®
 mode, the tip is kept in constant oscillation driven by an oscillation 
piezo. When the tip is driven towards the surface, it begins to “touch or tap” the surface, 
recreating the sample morphology as previously explained. With the dynamic mode, the 
samples are less likely to be damaged by the tip due to the small tip-surface interactions, the 
lateral shear forces are greatly reduced and it is the most common used topographic mode 
when working in fluid environments [26]. The accuracy and reproducibility of the dynamic mode 
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height profiles for different surfaces have been verified by comparing AFM images with TEM or 
other electron microscopy micrographs. This mode has been used to image bacteria [26]. 
 
Figure 19- Schematic representation of the three AFM operating modes, contact, non-contact and dynamic or Tapping
®
 
mode. 
 
3.3.3- Imaging Flow cytometry by ImageStreamX® 
Imaging flow cytometry is distinguished from conventional flow cytometry by its ability to 
acquire images of cells in fluid flow. This very powerful image-based cytometric technology 
combines the high-throughput, multi-parameter capabilities of conventional flow cytometry with 
the capacity to capture up to 6 spatially registered multi-spectral images per cell at 40x 
magnification, using a combination of transmitted light, scattered light and fluorescence [27,28]. 
The introduction of multiple lasers, detectors, configurations of filters and beam splitters allow 
the detection of emitted fluorescence at various wavelengths through multiple channels, 
advanced software, and computers that perform compensation, as well as statical analysis and 
data display; these are the main functions/components of modern flow cytometric systems 
[29,30]. The time-delay-integration detection technology used by the ImageStream
X®
 CCD 
camera allows up to 1000 times more signal to be acquired from cells in flow than the 
conventional frame imaging approaches. Velocity detection and autofocus systems maintain a 
proper camera synchronization and focused during the process of image acquisition [30]. 
Figure 6 illustrates ImageStream
X®
 working process. Similar to flow cytometry, the 
ImageStream
X®
 analyzes cells in suspension. Samples are introduced into a fluidic system 
where cells are hydrodynamically focused into a core stream and illuminated by a brightfield 
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light source and a laser (orthogonally) [29,30]. A high numerical aperture objective lens collects 
fluorescence emissions, scattered and transmitted light from the sample. Additional 
fluorescence light is decomposed into six images in defined ranges of wavelengths by a 
dichroic filter stack [29]. Signals are further directed onto the surface of a CCD camera with six 
channels (Table 1) used as system detectors. The CCD camera operates in a time-delay-
integration mode that electronically tracks moving objects by moving pixel content from row to 
row down the 256 rows of pixels in synchrony with the velocity of the object in flow as measured 
by the velocity detection system [30].  
 
Figure 20- ImageStream
X®
 platform overview. Cells in laminar flow are hydrodynamically focused into a glass cuvette 
and illuminated by laser (488 nm) and brightfield illuminator light. Fluorescent, transmitted and scattered lights collected 
by the objective are then split into multi-spectral bands by an optical decomposition element. Six independent 
wavelengths are collected by a detector-charge coupled device (CCD) camera (channels 1-6) and digital images are 
saved for further analysis by IDEAS software. Adapted from Amnis Corp manual[30] and Zuba-Surma et al (2007) [29]. 
Table 21- The spectral bandwidth of the camera channel. Adapted from Amnis Corp manual [30].  
Channel Wavelength (nm) 
1 
2 
3 
4 
5 
6 
430-505 
505-560 
560-595 
595-660 
660-745 
745-800 
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ImageStream
X®
 has been used in various research fields, i.e. to localize and quantify 
molecules like peptides, proteins, protein complexes, nucleic acids (DNA, RNA, miRNA), 
glycolipids, etc., in single cells as well as in multicellular clusters or small aggregates, and to 
map their spatial distribution to the cellular compartments. Besides, by using fluorescent 
molecules as markers, ImageStream
X®
 allows the analysis of host-pathogen interaction, 
quantification of intracellular microorganisms, has the potential for providing high-throughput 
analysis of host protein interactions and to assess drugs action against microorganism and 
microbial infections [31]. This technique is very helpful in cases where live cells are associated 
with dead cells, for instance in apoptotic bodies, adherent platelets/platelet fragments, or 
extracellular vesicles, as well as in distinguishing false-positive events in cell death evaluation 
and during analysis of activated cells. Therefore, the applications of ImageStream
X®
 are 
extensive and include but not limited to immunophenotypic multiparametric analysis combined 
with a morphometric assessment of cells. It can also be applied to microbiology, oncology, stem 
cell differentiation, morphology, cell cycle and mitosis [29,31,32].  
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DOCOSAHEXAENOIC ACID LOADED LIPID 
NANOPARTICLES WITH BACTERICIDAL ACTIVITY AGAINST 
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Abstract 
 
Docosahexaenoic acid (DHA), an omega-3 polyunsaturated fatty acid present in fish oil, 
has been described as a promising molecule to the treatment of Helicobacter pylori gastric 
infection. However, due to its highly unsaturated structure, DHA can be easily oxidized 
loosing part of its bioactivity. This work aims the nanoencapsulation of DHA to improve its 
bactericidal efficacy against H. pylori.  
DHA was loaded into nanostructured lipid carriers (NLC) produced by hot homogenization 
and ultrasonication using a blend of lipids (Precirol
®
ATO5, Miglyol
®
 812) and a surfactant 
(Tween
®
60). Homogeneous NLC with 302±14nm diameter, -28±3mV surface charge 
(dynamic and electrophoretic light scattering) and containing 66±7% DHA (UV/VIS 
spectroscopy) were successfully produced. 
Bacterial growth curves, performed over 24h in the presence of different DHA 
concentrations (free or loaded into NLC), demonstrated that nanoencapsulation enhanced 
DHA bactericidal effect, since DHA-loaded NLC were able to inhibit H. pylori growth in a 
much lower concentrations (25μM) than free DHA (>100μM).  
Bioimaging studies, using scanning and transmission electron microscopy and also imaging 
flow cytometry, demonstrated that DHA-loaded NLC interact with H. pylori membrane, 
increasing their periplasmic space and disrupting membrane and allowing the leakage of 
cytoplasmic content. Furthermore, the developed nanoparticles are not cytotoxic to human 
gastric adenocarcinoma cells at bactericidal concentrations. DHA-loaded NLC should, 
therefore, be envisaged as an alternative to the current treatments for H. pylori infection. 
 
 
 
 
 
 
KEYWORDS: Docosahexaenoic acid (DHA), Helicobacter pylori, Nanostructured lipid carriers 
(NLC), polyunsaturated fatty acid (PUFA) 
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1. Introduction 
Gastric carcinoma, the third leading cause of cancer-related deaths worldwide [1], has been 
associated with persistent Helicobacter pylori (H. pylori) gastric infection. This bacterium, 
which colonizes the gastric mucosa of over half of world population, is also responsible for 
the development of gastritis and peptic ulcer [2-4]. It has been estimated that approximately 
75% of the global gastric cancer burden is attributable to H. pylori infection [5]. Therefore, H. 
pylori eradication is the most promising strategy to avoid H. pylori-related gastrointestinal 
disorders. The present recommended treatment is a combination of antibiotics [6-9], 
however, this therapy may fail due to several reasons but principally by bacterial resistance 
to available antibiotics [10].   
The use of natural compounds with H. pylori bactericidal effect, namely polyunsaturated fatty 
acids [11,12] and phenolic compounds [13-15] has been explored as an alternative to 
conventional antibiotics [6]. Fatty acids are attractive compounds due to their potency, a 
broad spectrum of activity and lack of typical resistance mechanisms against the actions of 
these compounds [16-18]. Particularly, polyunsaturated fatty acids (PUFAS) found naturally 
at high levels in many marine organisms, have been reported as having a high potent 
activity against H. pylori, including linolenic acid (C18:3) [11], eicosapentaenoic acid (C20:5) 
[19], and docosahexaenoic acid (DHA) (C22:6) [20]. Indeed, it was previously reported that 
some PUFAS, as the linolenic acid, can inhibit up to 50% of bacteria growth at 1 mM 
concentration [21], whereas 2 mM kills all bacteria [12,21]. This anti-bacterial activity of 
PUFA is dependent on many factors, including concentration, the target microorganism and 
its physiological state, the physiological conditions associated with delivery (e.g., pH and 
temperature) and interaction with the microbial cell [17]. 
DHA, an omega-3 polyunsaturated fatty acid present in fish oil, was able to inhibit H. pylori 
(26695, B128 and SS1) growth in vitro in a dose-dependent manner. Moreover, a study 
using gastric infected mice, demonstrated that free DHA treatment was able to decrease 
50% of H. pylori gastric colonization [20,22]. As a result of its highly unsaturated structure, 
DHA can be easily oxidized losing its bioactivity. Therefore DHA encapsulation is 
recommended for its protection against environmental factors (oxygen, light, humidity, 
gastric acid, etc.) [18,20,23]. 
The present work aims to evaluate if the encapsulation of DHA into nanostructured lipid 
carriers (NLC) can improve DHA activity against H. pylori in vitro. NLC are delivery systems 
suitable for the encapsulation of poorly water-soluble drugs. They are prepared by blending 
biocompatible and biodegradable solid and liquid lipids, stabilized in aqueous suspensions 
by hydrophilic surfactants. The advantage of NLC regarding other lipid nanoparticles, 
namely solid lipid nanoparticles (SLN), is their higher drug loading capacity, improvement of 
drug stability and controlled release. This is attributed to their partial-crystallized structure 
with imperfections in the core solid matrix that provides higher space for drug incorporation 
[24-26]. 
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2. Material & methods 
2.1. DHA nanoencapsulation and characterization 
2.1.1. NLC preparation 
NLC were produced by hot homogenization and ultrasonication [27] using 200 mg of 
Precirol
®
ATO5 (Gattefosé, France), 90 mg of Miglyol
®
 812 (Acofarma, Spain) and 60 mg of 
Tween
®
 60 (Merck, Germany). Briefly, the two lipids (Precirol
®
ATO5 and Miglyol
®
 812 and 
Tween
®
 60 were weighted and heated together at 65ºC to promote their mixture. Ultrapure 
water (4.2 mL) preheated at 65ºC was added, and the mixture homogenized using an ultra-
turrax (T25; Janke and Kunkel IKA-Labortechnik, Germany) under high speed stirring at 
12000 rpm during 20 seconds. Afterward, a sonicator was used (Vibra-Cell model VCX 130 
equipped with a VC 18 probe, Sonics and Materials Inc., Newtown, USA), with a tip diameter 
of ¼" (6 mm), at 60% amplitude for 5 minutes obtaining the NLC. For the production of DHA-
loaded NLC, DHA (Cayman Chemical Company, USA) was added in different 
concentrations (1.0, 2.0 and 2.5% v/v) before addition of hot ultrapure water, obtaining three 
different formulations.  
 
2.1.2. NLC size and charge measurement 
The size and surface charge (ξ-potential) of the produced NLC were characterized by 
dynamic light scattering (DLS) and electrophoretic light scattering (ELS) respectively, using 
a Malvern Zetasizer Nano ZS (Malvern Instruments, UK). Diluted NLC (1:50 in ultrapure 
water) were placed on a disposable capillary cell and triplicate measurements were 
conducted at a backscattering angle of 173º at 37ºC. DLS and ELS were acquired using 
equipment maintained by Biointerface and Nanotechnology Unit. 
 
 
2.1.3.  NLC morphology assessment 
The NLC morphology was evaluated by Cryo-Scanning Electron Microscopy (Cryo-SEM) 
and NanoSight
®
.  
For CryoSEM analysis, it was used a JEOL JSM-6301F (Tokyo, Japan) with an Oxford 
Instruments INCA Energy 350 (Abingdon, UK) and a Gatan Alto 2500 (Pleasanton, CA, 
USA). A diluted sample of NLC (1:100 in ultrapure water) was placed on a grid, rapidly 
cooled in liquid nitrogen slush (-210ºC), and transferred under vacuum to the cold stage of 
the preparation chamber. A fracture and sublimation for 120 seconds at -90ºC was then 
performed and the sample coated with a gold-palladium alloy by sputtering for 40 seconds. 
Finally, the sample was transferred under vacuum into the SEM chamber and observed at -
150ºC, at CEMUP (Centro de Materiais da Universidade do Porto). 
For NanoSight® analysis, NLC were diluted (1:20000) with ultrapure water and morphology 
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was evaluated using a NanoSight
®
 NS300 (Malvern Instruments, UK). 
 
2.1.4.  DHA entrapment efficiency 
DHA nanoencapsulation was quantified by UV/VIS-spectroscopy. Freeze-dried NLC were 
dissolved in absolute ethanol for 15 minutes, centrifuged during 30 minutes at 4000 rpm, at 
20ºC and its supernatant analyzed by measuring its absorbance using a UV/VIS 
spectrophotometer (Lambda 45, Perkin Elmer, USA) at 237 nm. All measurements were 
performed in triplicate. 
 The DHA loading was calculated using a calibration curve prepared with a concentration 
range between 0.01 and 3% v/v of DHA in absolute ethanol (0.08-22.80 mM), with a 
correlation coefficient of R=0.996. The amount of DHA in NLC and the entrapment efficiency 
(EE) were calculated according to the following equation (Eq.1). 
  
Eq.1 
𝐸𝐸 =
DHA measured (mM) 
DHA added during NLC production (mM)
× 100 
 
 
2.1.5. NLC stability 
2.1.5.1. In water 
The storage of NLC was evaluated in ultrapure water at 4ºC and 20ºC during 2 months by 
periodic measurements of their size and surface charge using the DLS and ELS techniques 
as described above. Measurements were performed at 4º and 20ºC and in triplicate. 
 
2.1.5.2. In bacteria growth medium 
NLC were incubated in Brucella Broth medium (BB, Oxoid, France) supplemented with 10% 
of Fetal Bovine Serum (FBS, Gibco, USA) (BB+10%FBS medium) during 3 hours at 37ºC 
and 150 rpm. At time-point 0 and 3 hours, samples were diluted (1:20000) ultrapure water 
and analyzed using the NanoSight
®
 NS300 (Malvern Instruments, UK). 
 
2.1.6.  DHA release in bacteria growth medium 
DHA-loaded NLC (formulation produced with 2% v/v of DHA) was incubated inside the 
Slide-A-Lyzer Dialysis Cassettes device (Thermo Scientific, USA), with a nominal molecular 
weight cut-off of 20 kDa filled with 2 ml of the sample in BB+10%FBS at 37ºC and 150 rpm. 
At regular intervals (0, 0.5, 1, 1.5, 2 and 3 hours), sample aliquots were withdrawn and 
replaced with the same volume of fresh medium. The DHA released was quantified using 
an ELISA Kit for DHA (Cloud-Clone Corporation, USA), according to the supplier 
 CHAPTER IV 
89 
 
instructions. DHA release was calculated from the optical density using a calibration curve 
in a concentration range from 12.35 to 4000 pg/mL, with a correlation coefficient of R= 
0.989. 
 
 
2.2. Evaluation of NLC antimicrobial proprieties 
2.2.1. H. pylori strains and culture conditions 
Human isolated H. pylori strain J99 (provided by Department of Medical Biochemistry and 
Biophysics, Umeã University, Sweden) and mouse-adapted H. pylori strain SS1 (provided 
by Unité de Pathogenèse de Helicobacter, Institute Pasteur, France) were cultured in spots 
in H. pylori medium plates, in a microaerophilic environment at 37ºC for 48 hours. The H. 
pylori medium plates were composed of blood agar base 2 (Oxoid, France) supplemented 
with 10% defibrinated horse blood (Probiológica, Portugal) and with 0.2% antibiotics-
cocktail of 0.155 g/L Polymixin B (Sigma-Aldrich, USA), 6.25 g/L Vancomycin (Sigma-
Aldrich, USA), 1.25 g/L Amphotericin B (Sigma-Aldrich, USA) and 3.125 g/L Trimethroprim 
(Sigma-Aldrich, USA). Afterward, some colonies of H. pylori were spread on H. pylori 
medium plates and incubated for 48 hours, under the same conditions. Then, bacteria were 
transferred to T-flask containing Brucella Broth medium (BB, Oxoid, France) supplemented 
with 10% of Fetal Bovine Serum (FBS, Gibco, USA) with an optical density (OD) adjusted to 
0.1 (λ= 600 nm; UV/VIS spectrophotometer, Lambda 45, Perkin Elmer, USA). H. pylori 
incubation was performed under microaerophilic conditions, at 150 rpm, 37ºC during 18-20 
hours and subsequently used in the following experiments.   
 
2.2.2. Effect of NLC on H. pylori growth 
H. pylori (~1x10
7 
bacteria/mL, OD 0.03) were incubated with different concentrations (0.5, 
1.25, 2.5, 5.0 and 25.0 %v/v) of unloaded- NLC and DHA-loaded NLC (formulation produced 
with 2% v/v of DHA), and free DHA (10, 25, 50, 100 and 500 µM). The cultures were grown 
for 24 hours into liquid BB + 10% FBS medium (20 mL), under microaerophilic conditions, 
37ºC, and 150 rpm.  
 
2.2.2.1. Colony forming units (CFU) 
At different time-points (0, 1.5, 3, 6, 9, 12, 18, 24 hours), 200 µL of each culture was 
collected, serially diluted and plated on H. pylori medium plates. After 5 days, at 37ºC, the 
number of viable bacteria was determined by colony forming unit (CFU) counting.  
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2.2.2.2. H. pylori morphology and NLC membrane interaction 
At time-points 3 and 12 h, samples of H. pylori strain J99 were incubated with 25 µM of free 
DHA, 1.25 %v/v of unloaded-NLC and 1.25 %v/v of DHA-loaded NLC (which contains 25 µM 
DHA) were washed in phosphate buffered saline (PBS, pH 7.4) and centrifuged (3000g, for 
5 minutes). The bacteria pellet was then fixed differently depending on the following 
described techniques to evaluate H. pylori morphology and/or interaction of NLC with 
bacteria membrane.  
 
2.2.2.2.1.  Scanning Electron Microscopy (SEM) 
The bacterial pellet was fixed with 2.5% v/v glutaraldehyde (Merck, Germany) in 0.14 M 
sodium cacodylate buffer (Merck, Germany) for 30 minutes at RT. Then, bacteria were 
allowed to adhere on glass coverslips during 2 hours at RT and afterward dehydrated with 
increasing ethanol/water gradient (50% v/v to 99% v/v) and subjected to critical point drying 
(CPD 7501, Poloran). Finally, samples were sputter-coated with a gold/palladium film over 
30 seconds and bacterial morphology visualized by SEM (JEOL JSM-6310F) at 
magnifications of 30000 and 60000×, at CEMUP (Centro de Materiais da Universidade do 
Porto). 
 
2.2.2.2.2. Transmission Electron Microscopy (TEM) 
The bacterial pellet was fixed with a mixture of 4% w/v of paraformaldehyde (Merck, 
Germany) with 2.5% v/v glutaraldehyde (Merck, Germany) in 0.14 M sodium cacodylate 
buffer (Merck, Germany) for 30 minutes at RT. Then, bacteria suspension were washed by 
centrifugation (3000g, for 5 minutes) with sodium cacodylate buffer and bacterial pellet 
were post-fixed in 2% osmium tetroxide (Electron Microscopy Sciences, UK) in sodium 
cacodylate buffer, embedded in a HistoGel (Thermo Scientific, USA) and processed in 
Epon resin (Electron Microscopy Sciences, UK). Ultrathin sections with 50 nm thicknesses 
were prepared using an Ultramicrotome (RMC PowerTome PC model, USA) with diamond 
knives (Diatome, USA). Sections were mounted on formvar-coated nickel grids, stained 
with uranyl acetate and lead citrate (Delta Microscopies, France) and examined by TEM 
(JEOL JEM 1400 transmission electron microscope; Tokyo, Japan) equipped with a CCD 
digital camera Orious 1100W (Tokyo, Japan) at the Histology and Electron Microscopy 
Service of Instituto de Biologia Molecular e Celular da Universidade do Porto. 
 
 
2.2.2.2.3.  Imaging flow cytometry 
For imaging flow cytometry, NLC were previously stained with 0.1% w/v of coumarin-6. The 
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bacterial pellet was fixed with 4% w/v of paraformaldehyde in PBS for 30 minutes. To label 
H. pylori DNA, bacterial suspensions were incubated with propidium iodide (0.1µg/mL) for 30 
minutes at RT, in the dark. The respective unstained negative controls were prepared. Each 
sample was filtered through a 70 µm mesh filter before running in the flow cytometer 
(ImageStream
X®
, Amnis, EDM Millipore, Darmstadt, Germany) equipped with a 488 nm 
laser, a 40× magnification objective of 0.75 N.A (image pixel 0.5 μm
2
), and one CDD 
camera. Images were acquired using the INSPIRE
TM
 software v4.0 (Amnis, EDM Millipore, 
Darmstadt, Germany), which included a brightfield image (Channel 1, 420-480 nm), a green 
fluorescence image corresponding to coumarin-6 (Channel 2, 480-560 nm), and an orange 
fluorescence image matching the propidium iodide fluorescence emission (Channel 4- 560-
595 nm). During the acquisition, bacterial debris and aggregates were limited by setting the 
area in channel 1 between 2 and 10 μm
2
. For each sample, 150 000 events were collected 
and two independent experiments were performed. All data was analyzed using the IDEAS
®
 
software (Amnis, EDM Millipore, Darmstadt, Germany, version 6.2.64.0). Shortly, for the 
quantification of the intensity of the coumarin-6 labeling, the fluorescence intensity on 
channel 2 was measured for every cell. This feature represents the sum of the intensity pixel 
values in the region of interest. The region of interest was limited to the area of fluorescence 
positive signal in channel 2. Control samples without coumarin-6 labeling were run in the 
same conditions in the imaging flow cytometer to define the positive coumarin-6 signal. 
Imaging flow cytometry data were acquired using equipment maintained by the Bioimaging 
Center for Biomaterials and Regenerative Therapies (b.IMAGE). 
 
2.3. Evaluation of NLC biocompatibility 
2.3.2.1.  MKN45 cell culture 
In order to access the biocompatibility of NLC, viability and cytotoxicity studies were 
performed using the MKN45 gastric carcinoma cell line.  
Cells were grown in RPMI 1640 with Glutamax and HEPES (Gibco, USA) supplemented 
with 10% inactivated FBS (Gibco, USA) and 1% penicillin-streptomycin (Gibco, USA) at 
37ºC and under 5% CO2 in humidified air. Cells were supplied with fresh medium every two 
days and trypsinized when 80-90% confluency was reached, followed by counting in a 
Neubauer chamber with trypan blue solution (0.4% w/v; Sigma-Aldrich). Cells were then 
seeded at a density of 5×10
5
 cells per well (12-well plate) in medium, during 48 hours.  
 
2.3.2.2.  MTT assay 
The metabolic activity of cell in the presence of NLC was assessed using the thiazolyl blue 
tetrazolium bromide (MTT) colorimetric assay. This test evaluates the metabolic activity of 
living cells via the measurement of the activity of the mitochondrial dehydrogenases.   
NLC effect was evaluated on MKN45 cells seeded in a 12-well plate as described above. 
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The culture medium was removed and different concentrations (0, 0.5, 1.25, 2.5 and 5%v/v 
in culture medium) of unloaded and DHA-loaded NLC (formulation produced with 2% v/v of 
DHA) were added and cells were incubated during 24 hours. Then, the supernatant was 
removed; cells were treated with 0.5 mg/mL of MTT (98%, Sigma-Aldrich, USA) and 
incubated for 3 hours at 37ºC, in the dark. Then, MTT solution was discarded and dimethyl 
sulfoxide (DMSO) was added to solubilize the formazan crystals formed by MTT reaction 
within the cells. The plate was shaken for 5 minutes, at RT, under light protection and then 
the optical density was measured at 590 nm and 630 nm in a microplate reader (Synergy™ 
H Multi-mode Microplate Reader, BioTek Instruments, USA). A positive control (cells 
growing in fresh culture medium) and a negative control (cells treated with 2% w/v Triton
TM
 
X-100; Sigma-Aldrich, USA) were included, in order to normalize the results. Metabolic 
activity was determined according to the following equation (Eq.2).  
Eq. 2  Metabolic activity (%)=
Experimental value- Negative control
Positive control-Negative control
×100 
 
 
2.3.2.3.  LDH assay 
Cell death was assessed by quantification of lactate dehydrogenase (LDH) that was 
released to the cell culture medium after cell lysis. After cell seeding and incubation with 
NLC, as described above, the supernatant was collected and centrifuged (250g, for 10 
minutes at RT) and placed in a 96-well plate with LDH Cytotoxicity Detection Kit (Takara Bio 
Inc, Japan) in a ratio 1:1. After 5 minutes of incubation, at RT and protected from light, the 
absorbance was measured at 490 and 630 nm using the microplate reader. NLC cytotoxicity 
was determined according to the following equation (Eq.3), where the positive control was 
cells treated with 2% w/v Triton
TM
 X-100 solution, and the negative control were untreated 
cells. 
Eq. 3   Cytotoxicity (%) =
Experimental value- Negative control
Positive control-Negative control
× 100 
 
 
2.4. Statistical analysis 
Data are reported as mean ± standard deviation (SD). Non-parametric Kruskal-Wallis test 
was applied to the data and statically significant differences were considered at p<0.05. The 
statistical analyses were performed using Graph Pad Prism 6.0 (Graph-Pad Software, La 
Jolla, USA). 
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3. Results 
3.1. DHA nanoencapsulation 
NLC size and ξ-potential were determined by DLS and ELS as described in Figure 1A.  
Unloaded-NLC (without DHA) presented diameters of 211±8 nm. After DHA incorporation, 
NLC diameter increased in a concentration-dependent manner (p<0.05) exhibiting diameters 
of 260±12, 302±14 and 323±41 nm for DHA-loaded NLC produced with 1, 2 and 2.5% of 
DHA, respectively. Moreover, NLC presented a homogeneous size distribution with low 
polydispersion index (~0.2) for NLC prepared with 1 and 2% of DHA. Surface ξ-potential of 
NLC in water were around -28 mV independently of DHA incorporation (p>0.05). Figure 1B 
shows the amount of DHA incorporated into NLC. The maximum of DHA incorporation (66±7 
%) was reached when 2% v/v of DHA was used in the formulation. These DHA-loaded NLC, 
which contain 2.02±0.23 mM DHA per suspension of NLC produced, were, therefore, used 
in all subsequent studies.  
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Figure 1. (A) NLC were characterized in terms of: diameter (bars), polydispersion index (dots) and charge surface 
(ξ-potential) (bars) performed using dynamic light scattering at 37ºC. *p<0.05; statically significant differences 
between unloaded-NLC and different concentrations of DHA added (Kruskal-Wallis test).  (B) NLC characterization 
in terms of DHA content (bars) and entrapment efficiency (values in percentage). *p<0.05; statically significant 
differences between concentrations of DHA added (Kruskal-Wallis test).  All data is reported as the mean ± 
standard deviation (n=3).  
 
The morphology of these NLC (unloaded and DHA-loaded) was observed by Cryo-SEM and 
NanoSight
®
. Images from Figure 2 demonstrate that NLC displayed an almost spherical 
morphology and were not aggregated.   
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Figure 2. Unloaded-NLC and 2% v/v DHA-loaded NLC morphology was evaluated by cryo-scanning electron 
microscopy (Cryo-SEM) (scale bar 500 nm) and NanoSight
®
 (scale bar 400 nm). 
 
NLC stability was followed by measuring the change of NLC size and charge after their storage 
in aqueous solution up to 2 months at 4ºC and 20ºC. As shown in Figure 3, NLC did not change 
their size until one month of storage, independently of the temperature. However, surface ξ-
potential of DHA-loaded NLC was only maintained during 2 weeks, suggesting that these NLC 
can be stored in water for at least 2 weeks, independently of the temperature. Figure 3 also 
demonstrated that unloaded-NLC were stable during all the storage period in both temperatures 
used.  
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Figure 3. Storage time effect regarding diameter and charge on unloaded-NLC and 2% DHA-loaded in water at 4ºC 
and 20ºC.  Data is reported as the mean ± standard deviation (n=3). *Statistically significance different from the same 
NLC at day 0 (p<0.05; Kruskal-Wallis test). 
 
Concerning the DHA release profile, studies were performed in bacteria liquid medium (BB + 
10% FBS medium), which is the medium used during NLC bactericidal evaluation. Figure 4A 
shows the concentration of NLC before and after incubation in bacteria medium during 3 hours. 
The decrease in DHA-loaded NLC concentration (~50%) after their incubation in medium 
indicates that DHA was released by NLC disruption. Figure 4B confers that this delivery was 
initially 3% of total amount of DHA from DHA-loaded NLC during the first 30 minutes incubation 
and approximate 40% of total amount of DHA, after 3 h.  
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Figure 4. (A) NLC stability in bacteria medium (Brucella-broth+10% FBS medium) was evaluated through the 
concentration of particles measured by NanoSight
®
. The values are given as mean ± standard deviation. * Statically 
significant differences between samples (p<0.05; Kruskal-Wallis test). (B) In vitro release curve of DHA from 2% DHA-
loaded NLC in bacteria medium (Brucella-broth+10% FBS medium) during 3 h. 
 CHAPTER IV 
96 
 
3.2. Antimicrobial proprieties of NLC against H. pylori 
Figure 5 shows the effect of NLC on the growth kinetic of H. pylori strain J99. Figure 5A 
demonstrated that the presence of free DHA (10, 25, 50, 100 and 500 µM) decreased H. 
pylori J99 growth in 1 log compared to control (H. pylori growth in liquid BB+10% FBS 
medium).  
Figure 5B and 5C also demonstrated that NLC (unloaded and DHA-loaded) are bactericidal 
against H. pylori J99 strain, as well as SS1 strain (Figure S1), in all concentrations tested 
since they were able to kill 99.9% (>3 logs) bacteria in 24 hours of incubation. However, 
DHA-loaded NLC displayed a faster bactericidal effect than unloaded-NLC. When low 
concentration (0.5% v/v) of NLC were used, the bactericidal effect on H. pylori J99 was 
reached after 6 hours for DHA-loaded NLC (corresponding to 10 µM DHA) and only after 18 
hours for the same concentration of unloaded-NLC. DHA-loaded NLC at 1.25% (25 µM 
DHA) and 2.5% (50 µM DHA) are bactericidal for both H. pylori strains, after 3 and 1.5 
hours, respectively. On the other hand, the lowest time needed to kill both bacteria, using 
the highest amount of unloaded-NLC (25%), was 9 hours. 
To evaluate if DHA-loaded NLC storage in water for 2 weeks at 4ºC would interfere in their 
effect towards H. pylori, bactericidal activity after storage in these conditions was also 
studied (Figure S2). Results demonstrated that the stored DHA-loaded NLC have the same 
profile of the freshly prepared NLC, killing bacteria after 3 and 1.5 hours at concentrations of 
1.25% and 2.5%, respectively.  
A       B    
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Figure 5.  H. pylori J99 growth over 24 hours in the presence of increasing concentrations of (A) free DHA, (B) 
unloaded-NLC (nanoparticles without DHA) and (C) 2% v/v DHA-loaded NLC. Data is expressed as mean ± 
standard deviation (n=3). * p<0.05, refers to significant differences in H. pylori growth between control (bacteria 
untreated) and bacteria treated with free DHA or unloaded or DHA-loaded NLC (Kruskal-Wallis test). 
 
Morphological changes of H. pylori J99 after exposition to free DHA (25 µM), unloaded-NLC 
(1.25%) and DHA-loaded NLC (1.25%; 25 µM DHA) for 3 and 12 hours were observed by 
SEM (Figure 6) and TEM (Figure 7). Figures 6A and 6E show H. pylori in its characteristic 
curved rod shape after 3 and 12 hours growing in bacterial medium (control). After bacteria 
incubation with free DHA for 3 hours (Figure 6B) and 12 hours (Figure 6F), H. pylori 
morphology was similar to the control. The same was observed when bacteria were grown 
for 3 hours in the presence of unloaded-NLC (Figure 6C). However, after 12 hours growing 
in the presence of unloaded-NLC (Figure 6G) or after 3 and 12 hours in the presence of 
DHA-loaded NLC (Figures 6D and 6H), SEM images suggest that bacteria released their 
cytoplasmic contents, although morphological changes were not observed.  
TEM images (Figure 7) corroborate with SEM results, showing H. pylori with the intact cell 
membrane and dense cytoplasm in controls, in the presence of free DHA (25 µM) (Figure 7B 
and 7F) and unloaded-NLC (1.25%) for 3 hours (Figure 7C). Moreover, TEM images also 
revealed H pylori cell membrane fragmentation, an increase of the bacterial periplasmic 
space and loss of cytoplasmic content in the presence of unloaded-NLC for 12 hours (Figure 
6G) and DHA-loaded for 3 and 12 hours (Figure 7D and 7H). 
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Figure 6. SEM images of H. pylori J99 after 3 hours (A to D) and 12 hours (E to H) exposure to the different treatments: 
control (untreated) (A and E), 25 µM of free DHA (B and F), 1.25 % v/v of unloaded-NLC (C and G) and 1.25 %v/v (25 
µM DHA) of DHA-loaded NLC (D and H). Scale bars represent 1 µm. 
 
 
Figure 7. TEM micrographs of H. pylori J99 after 3 hours (A to D) and 12 hours (E to H) exposure to different 
treatments: control (untreated) (A and E), 25 µM of free DHA (B and F), 1.25 % v/v of unloaded-NLC (C and G) and 
1.25 %v/v (25 µM DHA) of DHA-loaded NLC (D and H). Scale bars represent 400 nm. 
 
As in SEM and TEM, bacteria images obtained from imaging flow cytometry also 
demonstrated that H. pylori J99 are in rod shape as exemplified in Figure 8A. Figure 8A also 
shows that bacteria were labeled with coumarin-labelled NLC (presenting a green 
fluorescence), indicating that NLC have high affinity to H. pylori. However, although H. pylori 
were labeled with fluorescent NLC, the bactericidal effect of unloaded-NLC was not 
observed for 3 h, since only 30% of bacteria are dead. These results suggest that although 
the interaction between NLC with bacteria is similar with and without DHA, their bactericidal 
effect is faster in the presence of DHA.  
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Figure 8. (A) Representative images of individualized H. pylori with unloaded-NLC (1.25% v/v) and DHA-loaded 
NLC (1.25% v/v; 25 µM). The individual bacterial cells are shown by Brightfield images (BF, left column) and 
propidium iodide (PI, right column), and bacteria labelled by nanoparticles labelled with 0.1%w/v of coumarin-6, 
green fluorescence images (coumarin-6, centre column). (B) Quantification of green fluorescent bacteria labelled by 
NLC labelled with coumarin-6, incubated during 3 hours and 12 hours, obtained by flow cytometry and bacterial 
death quantified by colony-forming-unit (CFU) counting.   
 
 
3.3. Biocompatibility of NLC 
Figure 9 shows the effect of NLC on human gastric adenocarcinoma cells viability and lysis 
determined by MTT (Figure 9A) and LDH (Figure 9B) assays, respectively.   
Figure 9A demonstrated that there was not a significant decrease in cell viability by the 
presence of NLC concentrations up to 2.5% (unloaded and DHA-loaded NLC). However, a 
severe reduction in cell viability was observed when MKN45 cells were exposed to the 
highest concentration of DHA-loaded NLC tested (5.0% corresponding to 100 µM DHA). 
Concerning the effect of NLC on gastric cell lysis (Figure 9B), no toxicity was observed for 
NLC concentration up to 2.5% (unloaded and DHA-loaded NLC). For this concentration, only 
~20% of cell lysis was observed, independently of the presence of DHA. High toxicity was 
observed for 5.0% of DHA-loaded NLC (100 µM DHA).   
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Figure 9. MKN45 gastric carcinoma cell line (A) viability and (B) cytotoxicity were assessed by the MTT and LDH 
assays, respectively, after 24 h of exposure to different concentrations of unloaded and DHA-loaded NLC. Data is 
reported as mean ± standard deviation (n=3). * Statically significant differences of MKN45 gastric cells treated with 
DHA-loaded NLC between unloaded-NLC (p<0.05; Kruskal-Wallis test). 
 
4. Discussion 
The increase of H. pylori strains resistant to available antibiotics is a serious problem that 
affects its rate of eradication and clearly, demonstrates the urgent need of finding new drugs 
and different strategies to fight this bacterium. Correia et al [20] demonstrated that DHA 
reduced the ability of H. pylori to colonize the gastric mucosa in only 50% of mice. This could 
be explained by DHA poor solubility in water, low penetration through the mucus layer, low 
residence time in the stomach but also by its degradation in the gastric environment due to 
oxidation, carboxylic protonation, esterification or lipid-protein complexation [18]. To 
overcome these problems, in the present work DHA was encapsulated into NLC that are a 
promising delivery system for lipophilic drugs [24]. NLC are suitable for transport, and 
protect bioactive compounds against degradation, offering a liquid matrix with a 
nanostructure that improves drug loading and its preservation during storage. [27-29] In this 
study, NLC were synthesized using a hot homogenization and ultrasonication, avoiding the 
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use of organic solvents. In addition, they present low cytotoxicity due to their lipid 
biodegradable and biocompatible composition recognized by the FDA as safe [30-32]. 
Bactericidal DHA-loaded NLC with 302±14 nm of diameter, and negative charge (around -
28mV) were successfully produced with an entrapment efficiency of 66% (containing ~2 mM 
DHA/mL NLC; DHA-loaded NLC produced with 2% of DHA).  
This DHA-loaded NLC displayed a bactericidal activity against H. pylori J99 (Figure 5) and 
SS1 (Figure S1) strains at all concentrations tested. However, their efficacy rate was 
concentration dependent, taking 6 hours (J99) and 9 hours (SS1) to kill all the bacteria even 
with the lowest DHA concentration used (10 µM). We proved that the incorporation of DHA 
into NLC greatly improves DHA bactericidal effect since free DHA was only bactericidal at 
DHA concentrations around 500 µM, as also previously described for other H. pylori strains 
[20], and DHA was released (40% after 3h) from NLC (Figure 4B), due to destabilization and 
disintegration in bacteria medium (Figure 4A). Nevertheless, unloaded-NLC (211±8 nm) are 
also bactericidal to both H. pylori strains used in all the concentrations tested although with a 
lower efficiency rate than DHA-loaded NLC. This effect is not associated with NLC reagents, 
namely Precirol
®
ATO5
 
[33], Tween
®
60 [34,35] and Miglyol
®
812 (Figure S3), as they alone do 
not affect bacteria growth in the concentrations used during NLC production. Moreover, our 
results (Figure 4A) demonstrated that these unloaded-NLC did not dissolve after at least 3 h 
in bacteria liquid medium.  
The mechanism of action of DHA-loaded NLC is unclear, however, the mechanism of action 
of PUFAs can be related to their ability to disrupt the integrity of the cell membrane, leading 
to the leakage of important cellular metabolites and even bacteria lysis [11,12,17,18,20,21]. 
Aside from perturbation of membranes, PUFAs can interact with other intracellular targets 
and enzymes, including those involved in bacterial fatty acid synthesis. Free fatty acids can 
exert an effect, whereby the pH of the cytoplasm is reduced to such an extent that the cell 
ceases to function normally [17].   
Cleary, all NLC have high affinity to the H. pylori membrane, as shown by ImageStream® 
(Figure 8) where coumarin-labelled NLC adhered to bacteria enabling them to exhibit a 
green fluorescence. Coumarin-6, often used as a model for delivery systems, was used in 
this work since it is a non-cytotoxic lipophilic dye [36].  Furthermore, it was shown that NLC 
interact with H. pylori membrane and disrupt the cell membrane, allowing the leakage of the 
cytoplasmic content (Figure 5). NLC also induced the separation of the plasma membrane 
from the outer membrane, enhancing the periplasmic space (Figure 7). These morphological 
changes were similar to the described by Jung et al [37], for the effect of liposomes loaded 
with linolenic acid (C18:3) on H. pylori SS1 after 30 minutes of 400 µg/mL (220 µM) of 
linolenic acid. Jung et al proposed that these liposomes could fuse with bacteria membranes 
incorporating/releasing the linolenic acid directly into bacterial membrane, changing their 
phospholipid composition [37]. 
The morphological transition of H. pylori form a bacillary to a coccoid shape was not found 
by SEM, TEM nor ImageStream
X®
 images, where only bacillus shape was visualized, 
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indicating that DHA-loaded NLC have a fast effect on bacteria not allowing a modification of 
the bacterial cell wall peptidoglycan [38]. 
Highlighting its bactericidal effect, DHA-loaded NLC are not cytotoxic to human gastric 
adenocarcinoma cells (MKN45 cell line) at bactericidal concentrations, namely up to 50 µM 
(Figure 9), since an increase of cell lysis higher than 30% was not observed, the value 
defined in ISO 10993-5 [39] for cytotoxic materials. However, DHA-loaded NLC are cytotoxic 
for concentrations around 100 µM (5% v/v), the same concentration described in the 
literature as cytotoxic for free DHA [40,41]. Noteworthy, the maximum daily recommendation 
for DHA is 250 mg/day (762 µM/day) in humans [42], which is much higher than the values 
evaluated in this study. 
These DHA-loaded NLC can be stored in water at least during two weeks at 4ºC or 20ºC 
(Figure 3) without losing their H. pylori antimicrobial activity (Figure S2). For longer periods 
of time (3, 6 or 12 months of storage at 20ºC), NLC should be freeze-dried using a 
preservative agent [24,43,44]. 
 
5. Conclusion 
DHA-loaded NLC with ~300 nm of size and negative charge were developed. These 
nanoparticles enhanced the bactericidal effect of DHA against H. pylori in a concentration-
dependent way. Moreover, unloaded- NLC were also bactericidal against the bacterial 
strains tested although in a slower level. Its bactericidal effect is associated with changes in 
H. pylori membrane, namely by separation of plasma membrane from the outer membrane, 
increasing the periplasmic space and the leakage of cytoplasmic contents. Finally, NLC are 
not cytotoxic to human epithelial cells at bactericidal concentrations (below 50 µM of DHA) 
and can be stored in water for two weeks at 4ºC without any preservative agent. 
DHA-loaded NLC should, therefore, be explored as an alternative to the current treatment of 
H. pylori infection. 
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Appendix A. Supplementary data 
Supplementary data associated with this article can be found, in the online version, at 
http://dx.doi.org/10.1016/j. ijpharm.2017.01.014. 
 
Figure S1 
A       B 
 
C 
 
Fig. S1 H. pylori SS1 growth over 24 hours in the presence of increasing concentrations of (A) free DHA, (B) unloaded-
NLC (nanoparticles without DHA) and (C) 2% v/v DHA-loaded NLC. 100 µM of free DHA presented an inhibitory effect 
against SS1 strains and a bactericidal effect with 500 µM. In the presence of NLC (unloaded and DHA-loaded), a similar 
bactericidal profile against H. pylori SS1 strain was observed compared to the J99 strain. Data is expressed as mean ± 
standard deviation (n=3). * p<0.05, refers to significant differences in H. pylori growth between control (bacteria 
untreated) and bacteria treated with free DHA or unloaded or DHA-loaded NLC (Kruskal-Wallis test). 
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Figure S2 
 
Fig. S2  H. pylori J99 strain growth over 24 hours in the presence of increasing concentrations of 2% v/v DHA-loaded 
NLC after preparation and after 2 weeks storage in aqueous solution at 4ºC. The bactericidal profile of DHA-loaded 
NLC does not change after 2 weeks stored at 4ºC compared to the profile of the freshly prepared NLC, killing bacteria 
after 1.5h and 3h at concentrations of 1.25% (25µM DHA) and 2.5% (50 µM) of DHA-loaded NLC, respectively. The 
values are reported as mean ± standard deviation (n=3). * p<0.05, refers to significant differences in H. pylori growth 
between bacteria treated with DHA-loaded NLC stored at 4ºC and bacteria treated with DHA-loaded NLC freshly 
prepared (Kruskal-Wallis test). 
 
 
Figure S3 
 
Fig. S3 H. pylori J99 strain growth over 24 hours in the presence of two concentrations of Miglyol
®
812: concentration 
used on NLC production (90mg) and concentration correspondent to the amount of Miglyol
®
812 on 2.5%v/v of NLC. 
Data is expressed as mean ± standard deviation (n=2). 
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SPECIFIC BACTERICIDAL ACTIVITY OF UNLOADED-LIPID 
NANOPARTICLES AGAINST HELICOBACTER PYLORI 
 
This chapter was based on the following submitted paper: 
 
- SEABRA CL, Nunes C., Brás, M, Gomez-Lazaro, M., Reis, CA, Gonçalves IC, Reis S., Martins 
MCL. (2017) Specific bactericidal activity of unloaded-lipid nanoparticles against Helicobacter 
pylori, Submitted  
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Abstract 
 
Helicobacter pylori (H. pylori) chronic infection is one of the major risk factors for the 
development of gastric cancer and available antibiotic treatments are not efficient in all the 
patients.  
We recently demonstrated that lipid nanoparticles, namely nanostructured lipid carriers (NLC), 
even without any drug, display bactericidal proprieties against H. pylori. Subsequently, this work 
aims to evaluate if these NLC are selective to H. pylori, and to clarify their mode of action. 
NLC with around 200 nm and negatively charge (-28±3 mV) were produced by a high shear hot 
homogenization followed by ultrasonication method, using Precirol
®
ATO5 and Miglyol
®
812 as 
lipids and Tween
®
60 as a surfactant.  
Bactericidal assays, using bacteria that are different in their structural (Gram-positive vs Gram-
negative) and morphological features (rod vs spherical) and surface charge (from -2 mV to -30 
mV), demonstrated that the NLC bactericidal effect is specific to H. pylori since they did not kill 
any other bacteria tested, namely Lactobacillus, E. coli, S. epidermidis and S. aureus.  
Bioimaging assays, namely imaging flow cytometry, scanning and transmission electron 
microscopies (SEM and TEM, respectively) and atomic force microscopy (AFM), demonstrated 
that NLC rapidly bind to H. pylori surface and then, cross both bacteria membranes, 
destabilizing and disrupting bacterial membranes, allowing the leakage of cytoplasmic contents 
leading to bacteria death. Nevertheless, H. pylori maintained their typical bacillary shape.  
This study demonstrated that NLC with specific bactericidal effect to H. pylori shoud be 
considered for the development of a new antibiotic free therapy to fight H. pylori infection 
without affecting human microbiota.  
 
 
 
 
 
 
KEYWORDS: Helicobacter pylori, unloaded-NLC, disruption membrane   
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1. Introduction 
 Helicobacter pylori (H. pylori) are microaerophilic, Gram-negative, spiral and bacillus shape 
bacteria that colonize the gastric mucosa of half of the world population [1-3]. This bacterium 
is considered the strongest identified risk factor for the development of gastric cancer since 
78% of gastric cancer cases were attributed to chronic H. pylori infection [4-6]. Currently 
recommended antibiotic-based therapy is inefficient in 20% of the cases due to, principally, 
the increased H. pylori resistance to antibiotics and the low antibiotic bioavailability at local 
infection [7].   
Nanostructured lipid carriers (NLC) are lipid nanoparticles specially designed for the 
encapsulation of lipophilic drugs, enhancing oral bioavailability of drugs by protecting them 
against the hostile environment of the gastrointestinal tract [8]. NLC are prepared from a 
blend of a solid lipid with a liquid lipid and an aqueous phase which is stabilized by a 
surfactant [9-11]. The increasing interest in NLC is associated with their higher 
biocompatibility and lower toxicity compared to polymeric nanoparticles, due to the GRAS 
(generally recognized as safe) lipids used in their composition, the production in absence of 
organic solvents and their lower costs associated with large-scale production [9,11-15]. NLC 
have been described as a promising antibacterial drug delivery system, showing great 
therapeutic potential as delivery systems for antibiotics and natural compounds, against 
different microorganisms, such as Staphylococcus aureus, Escherichia coli, H. pylori, 
Propionibacterium acnes and Pseudomonas aeruginosa [16-21]. However, any direct 
bactericidal effect of NLC without drugs to these bacteria has never been studied, until 
recently by our research group. 
Docosahexaenoic acid (DHA), an omega-3 polyunsaturated fatty acid, has been described 
as a very effective bactericidal against H. pylori [22]. We recently demonstrated that the 
nanoencapsulation of DHA into NLC improved its bactericidal efficacy against different H. 
pylori strains [23]. However, NLC without DHA was also bactericidal to H. pylori J99 (human 
strain) and SS1 (mouse-adapted strain), although at a slower rate than DHA-loaded NLC 
[23].   
Taking this into consideration, the aim of this work was to evaluate if this NLC bactericidal 
effect was selective to H. pylori strain and to understand their mode of action. To assess 
their selectivity, NLC were tested against other bacteria presenting different structural 
(Gram-positive vs Gram-negative) and morphological (rod vs spherical) features, such as 
the gastrointestinal Lactobacillus casei and E. coli. Moreover, since NLC are also commonly 
used in topical applications, they were also tested against pathogenic bacteria from skin and 
mucosae, S. epidermidis and S. aureus.  
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2. Material & methods 
2.1. NLC preparation and characterization 
2.1.1. NLC production 
NLC were produced by a high shear hot homogenization followed by ultrasonication method 
according to Neves et al. [24] and Seabra et al.[23]. Briefly, 200 mg of glyceryl 
palmitostearate (Precirol
®
ATO5, Gattefosé, France), 90 mg of Caprylic/Capric Triglyceride 
(Miglyol
®
812, Acofarma, Spain) and 60 mg of polysorbate 60 (Tween
®
60, Merck, Germany) 
were weighted and heated together (65ºC) to promote their mixture. Then, 4.2 mL of Milli-Q
®
 
Integral ultrapure water (type 1) preheated at 65ºC was added to the lipid mixture. This 
mixture was homogenized under high speed stirring (12000 rpm, 20 s) using an T25 Ultra-
Turrax
® 
(IKA, Germany) and sonicated using a sonicator (Vibra-Cell model VCX 130 
equipped with a VC 18 probe, Sonics and Materials Inc., Newtown, USA) with a tip diameter 
of 6 mm at 60% amplitude for 5 min.  
 
2.1.2. NLC size and zeta potential determination 
NLC hydrodynamic size distribution and surface charge (ξ-potential) were characterized 
using dynamic and electrophoretic light scattering (DLS and ELS) (Zetasizer Nano ZS; 
Malvern, UK). NLC were diluted (1:50 in type 1 water) and placed into clear disposable 
folded capillary cells (DTS1070; Malvern, UK). Size and ξ-potential were measured in type 1 
water conducted at a backscattering angle of 173º at 37ºC. All measurements were 
performed in triplicate.  
 
2.1.3.  NLC morphology  
NLC morphology was evaluated by Atomic Force Microscopy (AFM) imaging. Freshly 
cleaned mica sheet was coated with 10 µL of an NLC suspension (diluted 1:200 in type 1 
water). Samples were dried during 24h at room temperature. 
Atomic Force Microscopy (AFM) images were obtained with a PicoPlus scanning probe 
microscope interfaced with a Picoscan 2500 controller (Keysight Technologies, USA) using 
the PicoView 1.20 software (Keysight Technologies, USA), coupled to an Inverted Optical 
Microscope (Observer Z1, Zeiss, Germany), in order to precisely choose the 
microorganisms to be observed. Each sample was imaged with a 100×100 µm
2
 
piezoelectric scanner. All measurements were performed in Tapping
®
 mode at RT using 
bar-shaped cantilever silicon tips (AppNano, USA) with a spring constant of 25 – 75 N/m. 
Scan speed was set at 2.3 l/s. 
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2.2. NLC bactericidal activity 
2.2.1. Microorganisms and growth conditions 
Microorganisms used in this study as well as their specific growth media are described in 
Table 1. In all cases, bacteria were first cultured in solid and only afterward grown overnight 
in their specific medium for use in all subsequent experiments.  
 
2.2.2. Bacteria zeta potential 
All bacteria were incubated overnight on their specific liquid medium (Table 1) and, after 
washed in PBS, were adjusted to approximately 1×10
7
 CFU/mL in MHB supplemented with 
10% of FBS. Bacteria samples were diluted (1:2) in type 1 water and placed into clear 
disposable folded capillary cells (DTS1070, Malvern). ξ-potential was determined using the 
ELS described above in section 2.1.2. 
 
2.2.3. NLC bactericidal activity on different bacteria 
All bacteria were incubated overnight on specific liquid medium (Table 1) at 37ºC and 150 
rpm. After washing (3000g, 5 min) with phosphate buffered saline (PBS 1x, pH 7.4), 
bacteria concentration was adjusted to approximately 1×10
7
 CFU/mL in Müeller-Hinton 
broth medium (MHB, Merck Millipore, Germany), recommended medium for the 
determination of minimal inhibitory concentration (MIC), according to guidelines recognized 
by CLSI (Clinical & Laboratory Standards Institute) and EUCAST (European Society of 
Clinical Microbiology and Infectious Diseases) organizations [25]. As H. pylori is a fastidious 
microorganism which requires a complex nutrient-rich growth media [26], the MHB medium 
was supplemented with 10% of FBS. H. pylori was also tested in its specific medium 
BB+10% FBS [27].  
Different concentrations of unloaded-NLC (0%, 1.25%, 2.5% and 5% v/v) were added to 
each bacteria suspension and incubated at 37ºC and 150 rpm. A sample of each bacterial 
culture was collected at different time-points (0, 3, 6, 9, 12, 15, 24 h), serially diluted and 
plated on specific solid medium plates (Table 1). Plates were incubated at 37ºC for 5 days 
for H. pylori, 2 days for L. casei and 24 h for the other bacteria. The number of viable 
bacteria per mL was determined by colonies forming unit (CFU) counting. 
 
 
 CHAPTER V 
113 
 
Table 1- Bacteria used in this study: characteristics and specific media used in their growth. 
Microorganism 
Solid medium Liquid medium 
Ref. 
Medium composition 
Growth 
conditions 
Medium composition Growth conditions 
Helicobacter pylori 
(J99
1
) 
 Blood agar base 2 (Oxoid, France) 
 Defibrinated horse blood (10%) 
(Probiológica, Portugal) 
 Antibiotics-cocktail (0.2%) (Sigma-
Aldrich): 
 0.155 g/L Polymixine B 
 6.25 g/L Vancomycin 
 1.25 g/L Amphotericin B 
 3.125 g/L Trimethroprim 
48 h in spots 
48 h in spread 
Static 
37ºC 
Microaerophilic 
conditions 
 Brucella Broth medium (BB, 
Oxoid, France) 
 Fetal Bovine Serum (10%) (FBS, 
Gibco, USA) 
Overnight (OD 0.1) 
150 rpm 
37ºC 
Microaerophilic 
conditions 
[23] 
Lactobacillus casei-01
2 
 De Man-Rogosa and Sharpe agar 
(MRS agar, Biokar, France) 
48 h in spread 
Static 
37ºC 
Aerobic conditions 
 De Man-Rogosa and Sharpe 
broth (MRS broth, Biokar, 
France) 
Overnight 
(1 colony) 
150 rpm 
37ºC 
Aerobic conditions 
[45] 
Escherichia coli (ATCC
®
 25922™) 
 Tryptic Soy Agar (TSA, Merck 
Millipore, Germany) 
24 h in spread 
Static 
37ºC 
Aerobic conditions 
 Tryptic Soy Broth (TSB, Merck 
Millipore, Germany) 
Overnight 
(1 colony) 
150 rpm 
37ºC 
Aerobic conditions 
[46] 
Staphylococcus epidermidis (ATCC
®
 
35984™) 
Methicillin-resistant Staphylococcus 
aureus (ATCC
® 
33591™; MRSA) 
Note: 
1
 H. pylori J99 strain provided by Department of Medical Biochemistry and Biophysics, Umeã University, Sweden; 
2
 Lactobacillus casei-01 provided Chr. Hansen, Hørsholm Denmark.  
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2.2.4. NLC interaction with H. pylori 
According to results obtained, H. pylori J99 (1×10
7
 bacteria/mL, OD 0.03, BB+10%FBS 
medium) were incubated with NLC (1.25%v/v) under microaerophilic conditions, 37ºC and 
150 rpm.  
 
2.2.4.1. Imaging flow cytometry 
NLC were previously stained with coumarin-6 (0.1% w/v, Sigma-Aldrich) and incubated 
according to conditions described above (section 2.2.4). At time-points 1.5, 3 and 12 h, 
bacteria were washed in PBS (3000 g, 5 min) and fixed with paraformaldehyde (4% w/v) in 
PBS for 30 min. To label H. pylori DNA, bacterial suspensions were incubated with 
propidium iodide (0.1 µg/mL) for 30 min at room temperature, in the dark (unstained 
negative controls were also prepared).  Before running in the imaging flow cytometer 
(ImageStream
X®
, Amnis, EDM Millipore, Darmstadt, Germany), samples were filtered 
through a mesh filter (70 µm). Images were acquired using the INSPIRE
TM
 software v4.0 
(Amnis, EDM Millipore, Darmstadt, Germany). For each sample, 150000 events were 
collected and two independent experiments were performed including a brightfield image 
(Channel 1, 420-480 nm), a green fluorescence image corresponding to coumarin-6 
(Channel 2, 480-560 nm), and an orange fluorescence image matching the propidium iodide 
fluorescence emission (Channel 4- 560-595 nm). Data was analyzed using the IDEAS
®
 
software (Amnis, EDM Millipore, Darmstadt, Germany, version 6.2.64.0), quantifying the 
intensity of the coumarin-6 labeling (fluorescence intensity on channel 2) for every bacteria. 
Bacterial debris and aggregates were limited by setting the area in channel 1 between 2 and 
10 μm
2
, and the interest region was limited to the area of fluorescence positive signal in 
channel 2. Control samples without coumarin-6 labeling were run in the same conditions in 
the imaging flow cytometer to define the positive coumarin-6 signal.  
 
2.2.4.2. Scanning Electron Microscopy (SEM) 
H. pylori J99 strain was incubated with NLC (1.25%v/v) in the conditions described above 
(section 2.2.4). At time-points 3 and 12 h, samples were washed in PBS (3000 g, 5 min). 
The pellet of bacteria was fixed in glutaraldehyde (2.5%; Merck) in sodium cacodylate buffer 
(0.14 M, Merck) for 30 min at room temperature. Fixed bacteria adhered on glass coverslips 
during 2 h at room temperature. Then, samples were dehydrated with an increasing 
ethanol/water gradient (50% v/v to 99% v/v) and subjected to critical point drying (CPD 
7501, Poloran). Finally, the samples were sputter-coated with gold/palladium film over 30 s. 
H. pylori samples were observed by scanning electron microscopy (SEM; JEOL JSM-
6310F), at magnification 30000 and 60000x. 
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2.2.4.3. Transmission Electron Microscopy (TEM) 
Gold nanoparticles (500 μL, Gold-NP, 10 nm, BBI Solutions, UK) were encapsulated into 
NLC according to the same NLC production method described in section 2.1.1. H. pylori J99 
strain was incubated with 1.25% v/v Gold-NP-loaded NLC for 3 and 12 h, in the conditions 
described above (section 2.2.4).The pellet was fixed by resuspending in a mixture of 
paraformaldehyde (4% w/v, Merck) with glutaraldehyde (2.5% v/v, Merck) in 0.14M sodium 
cacodylate buffer (0.14 M, pH 7.4 Merck). Samples were then washed with sodium 
cacodylate buffer, centrifuged and bacterial pellet post-fixed in 2% osmium tetroxide 
(Electron Microscopy Sciences, UK) in sodium cacodylate buffer was embedded in a 
HistoGel (Thermo Scientific, USA) and processed in Epon resin (Electron Microscopy 
Sciences, UK). Ultrathin sections of 50 nm thickness were performed using an 
Ultramicrotome (RMC PowerTome PC model), by using diamond knives (Diatome, USA). 
Sections were mounted on formvar-coated nickel grids, stained with uranyl acetate and lead 
citrate (Delta Microscopies, France) and examined using TEM (JEOL JEM 1400 
transmission electron microscope; Tokyo, Japan) equipped with a CCD digital camera 
Orious 1100 W. 
 
2.2.4.4. Atomic Force Microscopy (AFM) 
H. pylori J99 strain was incubated with NLC (1.25%v/v), for 3 and 12 h, in the conditions 
described above (section 2.2.4). Bacteria were fixed in glutaraldehyde (2.5% v/v, Merck) in 
sodium cacodylate buffer (0.14 M, Merck) for 30 min at room temperature. Fixed bacteria 
were adhered on glass bottom microwell dishes (MatTek Corporation USA) during 2 h at RT 
and dehydrated with an increasing ethanol/water gradient (50% v/v to 99% v/v). The 
samples underwent drying at RT, overnight.  
Atomic Force Microscopy (AFM) images were obtained using the same equipment described 
in section 2.1.3. Briefly, all measurements were performed in Contact mode at RT. A V-
shaped cantilever with a triangular silicon tip (AppNano, USA) was calibrated using the 
Thermal K tune method provided by PicoView 1.2 software, resulting in a spring constant 
value of 0.046 N/m. Scan speeds were set at 1.0 l/s, and scan sizes were taken within an 
interval range among 1.4 µm and 7.0 µm. The contact force used was 4.6 nN. The height 
profile measurements were obtaining using the Gwydion 2.36 software version using the full 
width at half height (FWHH) method.  
 
 
2.3. Statistical analysis 
Data are reported as mean ± standard deviation. Data from different groups were compared 
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statistically using non-parametric Kruskal-Wallis test. Analysis was performed with a 
significance level of 0.05 using Graph Pad Prism 6.0 (Graph-Pad Software, La Jolla, USA). 
 
3. Results 
3.1. NLC production and characterization 
NLC were successfully produced by hot homogenization and ultrasonication without the use 
of organic solvents. AFM images revealed that NLC are spherical and not aggregated (Figure 
1A). DLS and ELS characterization demonstrated their negative charge (around -28 mV) and 
diameter around 211 nm (Figure 1B). Moreover, the low polydispersion index (around 0.20) 
indicates an almost monodisperse distribution. 
 
A       B 
   
Figure 1- Nanostructured lipid carriers (NLC) characterization. (A) NLC visualized by Atomic Force Microscopy 
(AFM) (scale bar 200 nm) (B) NLC diameter, polydispersion index and ξ-potential determined by DLS at 37ºC. Data 
are reported as the mean ± standard deviation of 3 independent experiences.  
  
 
3.2. Bacterial characterization (zeta potential) 
Bacteria ξ-potential indicated that, in the conditions used during bactericidal assays, all 
bacteria were negatively charged (Table 2) having E. coli and S. epidermidis the most 
negative surface charge and L. casei-01 the less negative surface charge (almost neutral).  
 
 
 
Diameter (nm) 211 ± 8 
Polydispersion index 0.20 ± 0.02 
ξ-potential (mV) -28 ± 3 
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Table 2- Principal features of bacteria used: H. pylori, L. casei, E.coli, S. epidermidis and MRSA. 
 
Helicobacter pylori 
(J99 ) 
Lactobacillus casei-01 
Escherichia coli 
(ATCC® 25922™) 
Staphylococcus 
epidermidis 
(ATCC® 35984™) 
MRSA  
(ATCC® 33591™) 
Characteristics 
Gram-negative, spiral-
shaped, microaerophilic 
Gram-positive, rod-
shaped, facultative 
anaerobic or 
microaerophilic 
Gram-negative, rod-shaped, 
facultative anaerobic 
Gram-positive, coagulase-
negative cocci, aerobic 
Gram-positive, coagulase-
negative cocci, facultative 
aerobe, 
Most common 
Local (Human) 
Stomach 
 
Intestine and mouth 
 
Intestine 
 
Skin  Skin, nose and respiratory 
tract 
Associate 
Disease 
Gastric disorder: gastritis 
to gastric cancer 
Used a probiotic 
Some of the cases sepsis, 
meningitis, and infections 
localized in organs 
Cholecystitis, bacteremia, 
urinary tract infection, 
traveler’s diarrhea 
Intravascular devices such 
as prosthetics, catheter; 
septicemia and endocarditis 
Skin infections and sepsis to 
pneumonia to bloodstream 
infections 
Zeta potential 
(mV) * 
-17.3 ± 0.7 -2.4 ± 0.2 -30.0 ± 1.2 -31.1 ± 1.6 -19.9 ± 1.3 
* ξ-potential measured in Müller-Hinton Broth medium (pH 7) using ZetaSizer® (n=3). 
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3.3. NLC antimicrobial proprieties 
Bactericidal activity of developed nanoparticles was evaluated by following bacteria growth 
over  24 h in MHB medium supplemented with 10% FBS containing different NLC 
concentrations (0, 1.25, 2.5 and 5% v/v) (Figure 2). Minimal bactericidal concentration (MBC) 
is the minimal drug concentration to kill 99.9% (≥3 logs) bacteria in 24 h of incubation. Figure 
2A e 2B shows that these NLC are bactericidal against H. pylori J99 in all concentrations 
tested since after 24 h all bacteria are death. However, H. pylori dead rate was NLC 
concentration-dependent. Figure 2A shown that with specific H. pylori medium (BB+10% 
FBS), a bactericide activity after 12 h was observed with the lowest concentration tested 
(1.25%v/v). However, a slight delay in bactericide activity with MHB+10%FBS was observed, 
for the highest NLC concentration tested (5%v/v), H. pylori were killed after 12 h, and for 
lower NLC concentrations (1.25% and 2.5%), a reduction of 99.9% (>3log) was observed 
after 15 h (Figure 2B). Nonetheless, an inhibitory effect of 50% (> 1log) was detected after 9 h 
incubation with any NLC concentration tested (Figure 2B).  
NLC bactericidal effect was also evaluated against other bacteria, namely the gut bacteria L. 
casei-01 (Figure 2C) and E. coli (Figure 2D), and the infectious bacteria, S. epidermidis 
(Figure 2E) and S. aureus (Figure 2F). It was demonstrated that NLC are not bactericidal 
against L. casei-01, E. coli, and S. epidermidis at all concentrations tested. However, NLC 
was able to delay S. aureus growth when used in high concentrations (5% v/v) (Figure 2F). 
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Figure 2- Antibacterial activity of NLC on different bacteria. Bacteria growth in the presence of increasing 
concentrations of NLC in Brucella Broth supplemented with 10%FBS (A) H. pylori J99 and in Müller-Hinton broth 
supplemented with 10% FBS (B) H. pylori J99, (C) L. casei-01, (D) E. coli ATCC
TM
25922, (E) S. epidermidis 
ATCC
TM
35984, (F) S. aureus ATCC
TM
33591. Numerical data is reported as mean ± standard deviation (n=3).* 
p<0.05; statically differences between bacteria treated with NLC and untreated (bacteria with 0% v/v NLC) (Kruskal-
Wallis test).  
 
 
3.4. NLC interaction with H. pylori 
In order to understand NLC mechanism of action against H. pylori, different advanced 
imaging techniques, namely ImageStream
X®
, SEM, TEM, and AFM were used. Assays were 
performed in BB medium supplemented with 10% FBS (the best medium for H. pylori growth) 
incubating with NLC at 1.25%. This NLC concentration was chosen due to its high 
bactericidal effect despite low cytotoxicity towards gastric cells, as previously described [23].  
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Figure 3 shows ImageStream
X®
 results of H. pylori J99 after incubation with fluorescence 
green-labeled NLC (1.25% coumarin-labeled NLC) for 1.5, 3 and 12 h. These time-points 
were chosen in order to have samples where most of the bacteria are cultivable (1.5 and 3 h) 
and samples where all bacteria are dead (12 h) (Figure 2A). After 1.5 h, 99% bacteria are 
fluorescence green-labeled demonstrating the high affinity of NLC to H. pylori. Nevertheless, 
NLC bactericidal effect was only observed after 12 h incubation, since after 1.5 h and 3h, 
99% and 70% bacteria were alive, respectively.  
 
 
H. pylori J99 
Control Coumarin-loaded NLC (1.25%) 
  
Time  
(hours) 
NLC-labeled H. pylori (%) 
ImageStreamX® 
Viable H. pylori 
(%) 
CFU 
NLC-labelled H. pylori (%) 
ImageStreamX® 
 Viable H. pylori 
(%) 
CFU 
1.5 0 
0 
100 99 
99 
100 
99 
70 
0 
3 100 
100 12 0 
 
Figure 3- NLC interaction with H. pylori membrane after 1.5, 3 and 12 hours incubation with coumarin-labelled 
NLC (1.25%) determined by imaging flow cytometry (ImageStream
X®
). Representative histogram and H. pylori 
images in brightfield (Channel 1, 420-480 nm) and in green fluorescence corresponding to bacteria with adherent 
coumarin-6 labeled NLC (Channel 2, 480-560 nm) after 1.5 h of incubation. Scale bar represents 10 µm. Table 
describing percentages of green fluorescence bacteria quantified by flow cytometry and the correspondent viable 
bacteria quantified by CFU counting, after 1.5, 3 and 12 h of H. pylori exposure to NLC. 
 
 
 
SEM images (Figure 4) revealed that when growing in the absence of NLC (control), bacteria 
present their characteristic bacillus shape (Figure 4A and 4C) and no morphological changes 
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were detected in most H. pylori after 3 h incubation with NLC (Figure 4B). However, after 
growing during 12 h in contact with NLC, most bacteria suffer a disruption of parts of their 
membrane although maintaining the bacillar shape (Figure 4D). 
Untreated
A B
1 μm 1 μm
C D
1
2
h
1 μm 1 μm
1.25% v/v NLC
3
h
 
Figure 4. H. pylori morphology. Scanning Electron micrographs of H. pylori untreated and treated with 1.25% v/v of 
NLC for 3 (A and B) and 12h (C and D) respectively. Scale bar in the SEM image represents 1 µm. 
 
TEM images also show H. pylori J99 with intact membrane and dense cytoplasm when 
bacteria grew in the absence of NLC (controls) (Figure 5A and 5D). After 3 h growing with 
1.25% NLC (Figure 5B), H. pylori maintained their intact membrane and dense cytoplasm as 
observed in controls, although Gold-NP-loaded NLC were visualized in their periplasmatic 
space (red arrows at Figure 5C). After 12 h incubation with this NLC concentration, bacteria 
display a separation between the outer and inner membrane with loss of cytoplasmic contents 
(Figure 5E). At this time-point, Gold-NP-loaded NLC were observed inside bacteria, namely at 
their cytoplasm (red arrows at Figure 5F). 
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D
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F
3
h
1
2
h
Untreated 1.25% v/v NLC 1.25% v/v Gold_NP loaded NLC
 
Figure 5- Transmission Electron micrographs of H. pylori J99 incubated with NLC (B and E) and Gold-NP-loaded 
NLC(C and F) for 3 and 12 h, respectively. Untreated H. pylori J99 were used as control at the same time-points (A 
and D). Red arrows point to Gold nanoparticles (Gold_NP). Scale bar in the SEM image represents 100 nm. 
 
AFM was used to identify changes in bacteria morphology of H. pylori J99 upon NLC 
treatment. Figure 6 shows AFM deflection images of H. pylori in bacillus shape after 3 and 12 
h growing in the absence (6A and 6B, respectively) and the presence of 1.25% NLC (6C and 
6D, respectively) in the medium. Although in a bacillary shape, when incubated for 12 h with 
NLC, the wall of H. pylori is not uniform along their length (Figure 6D). 
Untreated
A B
C D
1
2
h
1.25% v/v NLC
3
h
 
Figure 6- AFM deflection images of H. pylori J99 incubated with 1.25% v/v of NLC for 3 (B) and 12 (D) hours. 
Untreated H. pylori J99 were also tested at 3 (A) and 12 (C) hours. Scale bar in the AFM image represents 2 µm.  
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The height of untreated bacteria was ~214 nm in all the bacteria length, while the height of 
treated bacteria with 1.25% NLC suffered a reduction of height ~200nm and a hole can be 
observed with a bacteria height of ~160 nm (Table 3). Nevertheless, the number of H. pylori-
treated, found in AFM samples prepared using H. pylori that grew with NLC for 12h, was very 
low and most of the adhered bacteria were completely lysed, with their cytoplasmic content 
spread on the surface (Petri dish), although maintaining their bacillary shape (Figure S1).  
 
Table 3- AFM topographic image of H. pylori J99 after growing during 12 h with NLC (1.25%). The height 
measurements of two selected cross-section of H. pylori J99 untreated and treated with 1.25% v/v of NLC over 12 h. 
Scale bar of AFM topography image represents 2 µm. 
 2D topography 3D topography 
Height (nm) 
Section 
1 
Section 
2 
Untreated 
 
 
214 213 
Treated 
with 
1.25% 
unloaded-
NLC 
 
 
160 200 
 
 
4. Discussion 
NLC are a relatively new class of drug nanocarriers (100-400 nm) developed for the 
incorporation of lipophilic drugs. These nanoparticles present low cytotoxicity since are 
composed by FDA approved biodegradable and biocompatible lipids [14,15,28]. Moreover, they 
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are produced without organic solvents. Concerning infection treatments/prevention, NLC have 
been used for the encapsulation of different antibiotics, peptides and natural compounds with 
activity against several bacteria, namely S. aureus, Pseudomonas aeruginosa, E. coli and 
Propionibacterium acnes [16-21].  
We previously demonstrated that the bactericidal effect of docosahexaenoic acid (DHA) against 
H. pylori was improved after its NLC encapsulation [23]. However, we verified that unloaded-
NLC (with diameter ~211 nm and a negative charge around -28 mV) were also bactericidal 
against H. pylori J99 (human strain) and SS1 (mouse-adapted strain) although at a slower rate 
than DHA-loaded NLC [23]. This direct bactericidal effect of unloaded-NLC was not expected 
and justifies further investigation, namely regarding its effect in other bacteria.  
To investigate their selectivity against H. pylori, NLC were tested against other bacteria that 
present different morphological characteristics regarding shape (rod vs spherical), membrane 
structure (Gram-positive vs Gram-negative) and surface charge (from -2mV to -30 mV). Assays 
were performed following bacteria growth over 24 h using Müller-Hinton Broth (MHB) medium, 
which is the recommend medium for determination of the minimal inhibitory concentration (MIC) 
according to the guidelines recognized by CLSI (Clinical & Laboratory Standards Institute) and 
EUCAST (European Society of Clinical Microbiology and Infectious Diseases) organizations 
[25]. However, since H. pylori is a fastidious microorganism that requires a complex nutrient-rich 
growth media, the MHB medium was supplemented with 10% of fetal bovine serum (FBS) [26]. 
Therefore, for comparative studies between bacteria, all antimicrobial assays were performed 
using MHB supplemented with 10% FBS. In this medium, NLC bactericidal activity against H. 
pylori J99 was similar to Brucella Broth medium (BB) also supplemented with 10% FBS (Figure 
2A), the recommended medium for H. pylori culture [27]. However, a slight delay in the 
bactericidal activity of NLC was observed with MHB+10%FBS medium. NLC did not affect the 
growth of other bacteria tested, except in S. aureus, where NLC at 5% was able to decrease 
bacteria growth after 6 h, although without a bactericidal effect. Nevertheless, NLC 
concentration as high as 5% v/v was previously associated with some cytotoxicity (~50%) in 
human gastric adenocarcinoma cells [23].   
Thus, this specific bactericidal effect of NLC against H. pylori cannot be explained by 
differences in bacteria morphology and surface charge, but rather through H. pylori specific 
features. H. pylori has specific and unique characteristics that are very different from all the 
other bacteria. To be able to colonize human gastric mucosa and to survive in the adverse 
environment of host stomach, H. pylori present several structural and morphological 
characteristics that favor their penetration through the mucus layer, namely their flagella and 
their spiral form [29]. This spiral morphology needs a less rigid cell envelope than other non-
spiraled bacteria. This fact could be related to the composition of their peptidoglycan and cell 
membranes that differ substantially from other bacteria. Their peptidoglycan has a unique and 
less complex muropeptides composition than other Gram-negative bacteria. It contains a high 
proportion of muropeptides, with a pentapeptide side chain ending in glycine and containing 
anhydro-N-acetylmuramic acid, which is very different than E. coli [30]. Concerning their 
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membrane composition, H. pylori have an unusual fatty acid profile and have glycosylated 
cholesterol which is a unique characteristic of Helicobacter sp.[30]. According to literature, H. 
pylori steal host cholesterol, modifies it by alpha-glycosylation and incorporates it into its 
surface to resist multiple stresses [31]. H. pylori lipopolysaccharides (LPS), is also an important 
component of the wall of H. pylori that differs substantially from other bacteria. H. pylori LPS are 
composed by an unusual cellular fatty acid, lipid profile and molecular mimicry of Lewis 
antigens[30,32]. The lipid A component of H. pylori LPS is different of lipid A of many bacterial 
species by the absence of 3-hydroxytetradecanoic (β-hydroymyristic) acid [14:0(3-OH)], as well 
as the underphosphorylation and underacylation of the lipid A [33]. Moreover, the core 
oligosaccharide of H. pylori strains exhibit an unusual conformation, compared with other 
bacterial species. A branching occurs from the D-glycerol-D-manno-heptose (DD-Hep) residue 
in the inner core through a second such a residue to which the first repeating unit of the O-
polysaccharide chain is attached [33]. Additionally, H. pylori have several adhesins on its outer 
membrane to bind specific glycosylated compounds found in gastric mucosa [34]. Periplasmic 
pH homeostasis of H. pylori contrasts with the patterns in E. coli and other Gram-negative 
bacteria. The periplasmic pH is thought to be in equilibrium with the medium and not regulated 
in concert with the cytoplasm. H. pylori express the highest level of urease of any known 
microorganism, a key component of periplasmic pH homeostasis, thus elevating the pH to 
neutral as necessary for its survival [35]. The production of urease by the bacterium results in 
the production of ammonia, maintaining periplasmic and cytoplasmic pH of the bacterium near 
to neutral even in the presence of acid shocks [29,36].  
Nanoparticles that have been designed to directly interact with bacteria are usually cationic in 
order to bind any bacteria via electrostatic interactions, since pathogenic bacteria have a 
negative surface charge under physiological conditions [37]. These NLC are negatively charged 
so, their interaction with bacteria via electrostatic interactions is not expected. In addition, all the 
individual compounds used in NLC production (Tween
®
60, Miglyol®812 and Precirol
®
ATO5) are 
not bactericidal at concentrations used [23,38-40] demonstrating that the bactericidal effect is 
related with nanoparticle 3D format.   
In order to understand NLC mechanism of action against H. pylori, different bioimaging 
techniques were applied. These assays were performed using NLC at 1.25% and H. pylori J99 
cultured in BB medium supplemented with 10% FBS, recommended medium for H. pylori 
growth. In these conditions, NLC were bactericidal against H. pylori in 12h. Studies using 
ImageStream
X®
 revealed the high binding affinity of NLC to H. pylori membrane since, after 
1.5h in contact with fluorescent labeled NLC, all bacteria were fluorescent labeled. However, 
their bactericidal effect was only observed after 12h, demonstrating that this bactericidal 
process although being concentration-dependent is also time-dependent.  
TEM studies using Gold-NP-loaded NLC showed that NLC can be internalized by H. pylori in a 
time-dependent process. After 3 h, NLC were found in bacterial periplasmic space and after 12 
h in the cytoplasm showing their ability to cross both membranes of H. pylori. TEM images also 
revealed a separation between the outer and cytoplasmic membrane of H. pylori after 3 and 12 
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h incubation with NLC. A leakage of bacterial cytoplasmic content and a decrease in bacteria 
thickness (AFM) was also observed using SEM and AFM. Nevertheless, although these 
morphological alterations, bacteria maintained their typical bacillary shape. These results 
suggest that after their physically binding to H. pylori surface, NLC are able to cross both 
bacterial plasma membranes destabilizing them or creating pores in their structure which allow 
cytoplasmic leakage without destroying bacteria wall.  
The non-visualization of H. pylori in coccoid shape, as observed in other studies when bacteria 
were exposed to a hostile environment [41], can support the idea that the binding process NLC-
H. pylori is fast not allowing their morphological transition. Similar H. pylori morphological 
changes were described by Jung et al (2015) for liposome containing linolenic acid [42]. Their 
bactericidal effect was explained by liposomal fusion into H. pylori outer membrane allowing the 
incorporation of linolenic acid in the membrane and thus affecting their permeability due to the 
alteration of the phospholipid composition. Interestingly, these liposomal have negative zeta-
potential (-73 ± 2 mV), like our NLC, Their negative charge did not avoid their integration/fusion 
into the bacteria membrane. Moreover, although negatively charged, NLC have on their surface 
the hydrophilic moiety of the non-ionic surfactant (Tween
®
60) used during the production as a 
nanoparticle stabilizer. This non-ionic surfactant may decrease the surface tension between 
nanoparticle and bacteria enabling their interaction with proteins and lipids of H. pylori 
membrane [43]. NLC surface surfactant can also facilitate their interaction/travel through H. 
pylori LPS since Gram-negative bacteria only allows a limited diffusion of hydrophobic 
substances through their LPS-covered surface [44]. Moreover, NLC lipid composition may also 
allow the insertion of NLC into the bacterial membrane, causing an excessive enhance of 
membrane fluidity and it to become more permeable, allowing internal contents to leak from the 
cell and consequently bacteria death. Notwithstanding, the surfactant effect may solubilize 
sections of the cell membrane, which may cause cytoplasm leakage and consequently cell 
lysis. 
This specific NLC bactericidal activity against H. pylori is an advantage for the development of 
new and alternative therapies for H. pylori infection since, in opposite to the antibiotic therapy; it 
will not affect human microbiota.  
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Appendix A. Supplementary data 
   
Figure S1- AFM deflection image of H. pylori J99 incubated with 1.25% v/v of NLC for 12 h. Scale bar in the AFM 
image represents 5 µm  
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Abstract 
Persistent Helicobacter pylori (H. pylori) infection may lead to several gastric complications 
such as gastritis, peptic ulcer, and gastric carcinoma. Current antibiotic-based treatments 
are unsuccessful in approximately 20% of the patients due, principally, to the increase 
number of H. pylori strains resistant to available antibiotics. We recently demonstrated that 
lipid nanoparticles, namely nanostructured lipid carriers (NLC) loaded with 
docosahexaenoic acid (DHA), an omega-3 fatty acid with anti-H. pylori activity and 
unloaded-NLC were both bactericidal against H. pylori. 
The major goal of this work was to evaluate if these NLC may be used in the treatment of 
H. pylori infection.  For that, their stability in simulated gastric fluidic and their ability to cross 
gastric mucus layer was firstly evaluated using in vitro mice model, respectively. 
Nanoparticles toxicity and efficacy in H. pylori eradication were assessed using C57BL/6 
mice infected with mouse-adapted H. pylori strain (SS1). Additionally, in vitro assays were 
done to assess the crystalline structure of these lipid nanoparticles and to estimate their 
effect on H. pylori membrane permeability.  
Homogenous and spherical negatively charged DHA-loaded NLC (302±14 nm) and 
unloaded (211±8nm) were stable in simulated gastric fluid for 3h. DSC results 
demonstrated a crystallinity reduction of DHA-loaded NLC relatively to unloaded-NLC 
meaning that DHA -loaded NLC have a lower crystal organization than unloaded-NLC and 
their bulk material. 
 A fast (30 min) bactericidal activity of DHA-loaded NLC was observed, which was 
explained by their higher effect on the permeability of bacteria membrane than unloaded-
NLC at this time point. In vivo efficacy assays, using H. pylori-infected C57BL/6 mice 
treated with nanoparticles (2.5% v/v) during 14 days, demonstrated a reduction in H. pylori 
colonization of around 92.6% when mice were treated with DHA-loaded NLC (50 μM DHA) 
and 82.5% when treated with unloaded-NLC. This reduction of infection was verified without 
causing gastric or hepatic toxicity. However, 1/3 of infected but untreated mice (control) 
were not infected after the 14 days treatment (with water), demonstrating the need for 
further assays.  
This work demonstrated that these lipid nanoparticles, mainly the ones containing DHA, are 
very effective in vitro against H. pylori due to their action on the increase of bacteria 
membrane permeability. In vivo, preliminary results also suggested that lipid nanoparticles 
should be considered as a promising alternative for the treatment of H. pylori gastric 
infection. 
 
  
 
 
KEYWORDS: Helicobacter pylori, NLC, in vivo efficiency, gastric mucosa  
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1. Introduction 
Helicobacter pylori (H. pylori) is one the most common bacterial pathogen Worldwide, with 
a strong association to several gastric diseases, including gastritis, peptic ulcers, and 
gastric cancer. Gastric cancer is the fifth most incident type of cancer and the second 
leading cause of cancer-related deaths in the world [1,2]. The increasing prevalence of 
antibiotic-resistant strains has led to a significant decrease in the success of H. pylori 
eradication [3-5]. Different regimen treatments, including antibiotics combinations, have 
been used to overcome this problem. However, poor patient compliance, side-effects and 
high cost associated with multiple antibiotics used are also related to therapy failure [6], 
demonstrating the urgent need for alternative treatments.   
Several antibiotic-free approaches have been investigated to fight H. pylori infection such 
as antimicrobial peptides [7-9], lipophilic compounds [10-14], the use of probiotics [15-18], 
the application of bioengineering strategies for drug delivery or binding bacteria [19-24] and 
also, the development of vaccines [25-28]. However, although very successful in vitro, none 
of these alternatives were sufficiently effective to be used, by itself, in the H. pylori infection 
eradication.  
Some polyunsaturated fatty acids (PUFA), namely docosahexaenoic acid (DHA), linolenic 
acid (LA) and eicosapentaenoic acid (EPA) are bactericidal against a broad range of 
bacteria and have a lower tendency to induce bacteria resistant than conventional 
antibiotics [29-31]. Although some PUFA as DHA have been very effective against H. pylori 
in vitro [29,32-36], their poorly bioavailability in vivo needs to be overcome. This can be 
related to their low stability, namely high susceptibility to oxidation, or their low ability to 
cross gastric mucus layer to reach the infection site.  
The development of local delivery systems may improve PUFA in vivo bioavailability. It was 
recently demonstrated by us that nanostructured lipid carriers (NLC) containing DHA (DHA-
loaded NLC) are highly bactericidal against H. pylori by membrane disruption. However, 
unloaded-NLC were also bactericidal, demonstrating that the DHA-loaded NLC bactericidal 
effect was not only due to the DHA released, but due to a synergistic effect of NLC and 
DHA [37].  
The main goal of this work was to evaluate if NLC (unloaded and DHA-loaded) may be 
used in the treatment of H. pylori infection. In vivo studies, using C57BL/6 mice infected 
with mouse-adapted H. pylori strain (SS1) were then performed. The toxicity profile of 
developed nanoparticles in mouse stomach was also evaluated through histological 
analysis. Additionally, we evaluate the effect of NLC in the permeability of bacteria 
membrane, to understand how NLC may disrupt bacteria membrane. To evaluate the 
physical state of the lipid core in the produced NLC and to correlate this parameter with the 
DHA incorporation, additional NLC characterization was performed by DSC analysis.  
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2. Material & methods 
2.1. Preparation and characterization of NLC 
2.1.1. NLC production 
NLC was prepared by hot homogenization and sonication as described by Seabra et al 
(2017) [37]. Briefly, 200 mg of Precirol
®
ATO5 (Gattefosé, France), 90 mg of Miglyol
®
812 
(Acofarma, Spain) and 60 mg Tween
®
60 (Merck, Germany) were weighted and heated 
together at 60ºC. Then 84μL of DHA and 4.2 mL of water type I (preheated at 60ºC) were 
added and mixed using an ultra-turrax (T25, Janke and Kunkel IKA-Labortechnik, 
Germany) at 12000 rpm, over 20 s, and sonicated using a Vibra-Cell model VCX 130, with 
a VC 18 probe of ¼’’ (6 nm), at 60% amplitude for 5 min (Sonics and Materials Inc, 
Newtown, USA), obtaining DHA-loaded NLC. 
2.1.2. NLC characterization 
DHA-loaded NLC was characterized in terms of size and morphology as described by 
Seabra et al  (2017) [37]. 
2.1.2.1. Differential Scanning Calorimetry (DSC) 
Differential scanning calorimetry (DSC) analysis was performed using a Perkin-Elmer Pyris 
1 DSC differential scanning calorimeter (Perkin-Elmer Analytical Instruments, Waltham, 
USA). The samples were weighed directly in aluminum pans (7-23 mg) and scanned 
between 10ºC and 80ºC at a heating rate of 5ºC/min and cooling rate of 40ºC/min under a 
stream of nitrogen gas. An empty aluminum pan was used as reference. DSC analyses 
were performed for the lipid nanoparticles, as well as for the bulk materials used in the 
preparation of the nanoparticles. The melting point (peak maximum) and the enthalpy (ΔH) 
were calculated using the PerkinElmer software.  
 
2.1.2.2. Stability in simulated gastric fluid 
DHA-loaded NLC stability was performed using a simulated gastric fluid (SGF) prepared 
with HCl 0.2M and NaCl 0.2M (pH1.2). DHA-loaded NLC were incubated with SGF over 3 h 
at 37ºC and 150 rpm. At time-point 0 and 3 h, samples were diluted (1:20000) in water type 
I and analyzed in terms of particle concentration using NanoSight
®
 NS300 (Malvern 
Instruments, UK). The measurements were performed in triplicate.  
 CHAPTER VI 
136 
 
2.2. Anti-Helicobacter pylori activity: in vitro study 
2.2.1. H. pylori culture 
H. pylori J99 strain (human isolate provided by Department of Medical Biochemistry and 
Biophysics, Umeã, Sweden) were cultured as described by Seabra et al. (2017) [37]. 
Briefly, H. pylori J99 spots and spreads were subsequently incubated at 37ºC for 48 h, 
under microaerophilic conditions. H. pylori  medium plates were prepared using 20g of 
blood agar base 2 (Oxoid, France) supplemented with 10% v/v of defibrinated horse blood 
(Probiológica, Portugal) and with 0.2% v/v antibiotics-cocktail composed of 0.155 g/L 
polymixin B (Sigma-Aldrich, USA), 6.25 g/L vancomycin (Sigma-Aldrich, USA), 1.25 g/L 
amphotericin B (Sigma-Aldrich, USA) and 3.125 g/L trimethroprim (Sigma-Aldrich, USA). 
Afterwards, the optical density of bacteria was adjusted to 0.1 (λ=600 nm) and H. pylori 
were incubated in Brucella Broth medium (BB, Oxoid, France) supplemented with 10% of 
fetal bovine serum (FBS, Gibco, USA), at 37ºC, 150 rpm, under microaerophilic conditions, 
over 18-20 h.  
 
2.2.2. NLC activity against H. pylori membrane 
The H. pylori optical density was adjusted to 0.03 (1×10
7
 bacteria/mL) and incubated with 
unloaded-NLC (2.5% v/v) and DHA-loaded NLC (2.5% v/v containing 50μM DHA). The 
respective control was performed with untreated bacteria (incubated with water). Bacteria 
culture was performed at 15, 30, 90 and 150 minutes in bacteria medium, under 
microaerophilic conditions, at 37ºC and 150 rpm. 
 
2.2.2.1. Colony forming units (CFU) 
At different time-points (15, 30, 90 and 150 min), 200 µL of each culture (control, unloaded 
and DHA-loaded NLC) was collected, serially diluted and plated on H. pylori medium plates 
and incubated at 37ºC. After 5 days, the number of viable bacteria was determined by 
colony forming unit (CFU) counting.   
2.2.2.2. Permeability assay 
2.2.2.2.1. Outer membrane 
The outer membrane permeability was evaluated by adapting the methods described 
by Loh et al (1984)[38] and Alakoni et al. (2006) [39], measuring the uptake of the 
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fluorescent probe 1-N-phenylnaphthetlamine (NPN). After 30 min of incubation with 
unloaded- and DHA-loaded NLC, as described above (2.2.2.), bacteria were collected 
by centrifugation at 3000 g at 25ºC for 5 min and washed twice with 0.01M phosphate 
buffer (PBS 1x; pH 7.4). A negative control (bacteria growing in bacteria medium) and a 
positive control (bacteria treated with 10% v/v of Triton TM X-100) were included, in 
order to normalize the results. The bacterial pellet was resuspended in 5 mM of n-
heptadecanoic acid methyl ester buffer (HEPES buffer; pH 7.2).  For NPN assay (at 
room temperature), 50μL of NPN (10μM final concentration) were added and mixed 
with 150μL of bacteria suspension. Fluorescence was measured after shaking for 3 
minutes, using a microplate reader (Synergy™H Multi-mode Microplate Reader, BioTek 
Instruments, USA) at an excitation wavelength of 350 nm and an emission wavelength 
of 420 nm. The measurements were repeated three times.  
 
2.2.2.2.2. Inner membrane 
The plasma membrane permeability was evaluated by measuring the ATP release from 
bacterial cells, using BacTiter-Glo microbial cell viability assay kit (Promega Inc, USA), 
as described by Parsons et al (2012) [40] and Jung et al. (2015) [10]. After H. pylori 
treatment with unloaded and DHA-loaded NLC for 30 min, as described above (2.2.2), 
bacteria were centrifuged at 14 000 g for 5 minutes and the supernatant containing 
released ATP was collected. Then, 100 μL of supernatant were placed in a 96-well 
plate and BacTiter-Glo reagent was added directly to the supernatant at ratio 1:1. The 
mixture was shaken for 2 minutes and using a microplate reader (Synergy™ H Multi-
mode Microplate Reader, BioTek Instruments, USA), the luminescence was measured. 
The measurements were repeated three times.  
2.3. Anti-Helicobacter pylori activity: in vivo study 
2.3.1. Mice infection 
Six-week-old specific pathogen-free C57BL/6 male mice (Charles Rivers, France) were 
divided into six groups: non-infected mice (negative control group; n=3),  two non-infected 
mice and treated group with unloaded (n=2) and DHA-loaded NLC (n=2) for toxicity 
evaluation,  H. pylori-infected mice (positive control group, n=12) and two H. pylori-infected 
groups that were treated with unloaded (n=12) and DHA-loaded NLC (n=12). H. pylori SS1 
(mouse-adapted strain provided by Unité de Pathogenèse de Helicobacter, Institute 
Pasteur, France) was cultured as described in section 2.2.1. Mice received 100μL of 1×10
10
 
CFU/mL of H. pylori strain SS1 in peptone water (Sigma-Aldrich, USA) administrated 
intragastrically through oral gavage twice with a 2 dyes interval and infection was allowed to 
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develop for 4 weeks. The control groups of mice were given peptone water alone.  24 h 
before infection, mice were weighted and food and bedding were removed. Water was 
removed 6 h before administration. 3 h after H. pylori administration, mice were switched 
back to the original cages with food, water, and bedding. All animal procedures were 
performed in compliance with the laws and institutional guidelines of the Ethical Committee 
of i3S Animal Facilities. 
 
2.3.2. NLC treatment and mice sacrifice 
Four weeks after infection, treatment was performed with unloaded-NLC (2.5% v/v) and 
DHA-loaded NLC (2.5% v/v containing 50 μM DHA). For the treatment, mice were first 
fasted for 6 h and then 100μL of NLC (unloaded or DHA-loaded) were administrated 
through oral gavage once a day for consecutive 14 days. The control groups of mice were 
given water. The treatment plan applied to the mice is represented in Scheme 1.  
 
 
Scheme 1- Experimental protocol including the H. pylori SS1 inoculation, infection development, and treatment of 
C57BL/6 infected mice.  
 
After the last administration, mice were fasted for 18 h and then euthanized by cervical 
dislocation, with previous anesthesia (50-75 mg/kg Ketamine and 0.5-1 mg/kg 
Medetomidine) through intraperitoneal injection. The abdominal cavity was opened and a 
liver section was removed. Then, mouse stomach was removed, rinsed in 0.9% NaCl (to 
remove food) and opened transversally. The mouse stomach was divided into 4 
longitudinal sections (Scheme 2): one section for cryopreservation, another for histological 
analysis and the two other sections (part A and B) were placed in a tube containing 400 μL 
of peptone water, for CFU counting, evaluating the reduction of H. pylori colonization. Each 
stomach section (part A and B) was smashed with a tissue homogenizer using sterile 
pistons, and then serial dilutions (10
1
, 10
2
, and 10
3
) were made and plated on H. pylori 
medium plates, described above, and supplemented with 20 mg/mL of naladixic acid 
(Sigma-Aldrich, USA) and 50mg/mL bacitracin (Sigma-Aldrich, USA). After 15 days, at 
37ºC under microaerophilic conditions, the number of colony forming units (CFU) per mice 
stomach was determined.  
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Scheme 2- Mouse stomach segments for cryopreservation, histological analysis, and CFU counting evaluation. 
Liver section and longitudinal section of mice stomach were fixed in formalin and then 
embedded in paraffin and cut transversally in to 3 µm sections and gastric mucosa and 
liver sections were placed on glass slides.  
Sections were deparaffinated with xylene and hydrated in ethanol (100%, 96%, and 70%), 
running water and the hematoxylin and eosin (H&E) staining was performed. After staining 
sections were mounted with mounting medium (Entellan®, Merck, Germany) and observed 
using an optical microscope, evaluating the NLC (unloaded- and DHA-loaded NLC) toxicity 
2.4. Statistical analysis 
The statistical analysis was performed using Graph Pad Prism 6.0 Software (La, Jolla, 
USA) applying non-parametric Kruskal-Wallis test or One-way ANOVA (Tukey test), 
considering statically significant differences at p<0.05.  
 
3. Results 
3.1. NLC production and in vitro characterization 
DHA was loaded into NLC forming homogeneous and spherical nanoparticles with a 
hydrodynamic diameter of 302 ± 14 nm (Figure 1B and 1D). Unloaded-NLC were also 
produced as a control of DHA encapsulation, having a diameter of 211±8 nm (Figure 1A 
and 1C).  
NLC thermometric behavior was compared with their physical mixture of their excipients 
(bulk material). DSC thermograms and respective thermometric parameters as melting 
point, enthalpy, and recrystallization index (RI) for the bulk materials and NLC are shown in 
Figure 1B. For bulk materials of unloaded and DHA-loaded NLC, the melting process took 
place at 57.1º and 58.3ºC, respectively. When NLC are produced, the melting transition 
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peak and onset temperature are lower than that of the bulk material, as well as the melting 
enthalpy values that decrease, from 83.5 to 8.2 J/g in unloaded-NLC and 87.2 to 6.7 J/g in 
DHA-loaded NLC. The presence of DHA caused a decrease in the melting enthalpy, from 
8.2 to 6.7 J/g. These melting enthalpy values were calculated from the area under the 
curve by integrating the peak beneath the baseline and dividing by the mass of sample in 
each case (Figure 1B). The degree of crystallinity or recrystallization index (RI) of NLC 
formulations were calculated from the enthalpy of the NLC dispersion compared with the 
enthalpy of their bulk materials. The enthalpy of bulk material was set at 100% crystallinity 
and this value was used as a reference to determine the degree of crystallinity of the NLC. 
As shown in the table of Figure 1B, the RI of the unloaded- and DHA-loaded NLC 
decreased to 77% and 56%, respectively, in comparison with each own bulk material. The 
reduction of maximum temperature peak and melting enthalpy can be related to distorted 
crystallization due to the presence of surfactant distributed in the melted lipid phase. 
The developed NLC seem to be suitable for oral administration as observed in the 
assessment of NLC stability in gastric fluid (Figure 1C), which was followed by measuring 
the concentration of NLC before and after incubation in simulated gastric fluid (pH1.2) over 
3 h. No changes of NLC concentration were observed after their incubation in simulated 
gastric fluid, indicating that the NLC are not disrupted in gastric pH (Figure 1C).  
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Figure 1. NLC characterization. Morphology and average of size (d, nm) of unloaded- and DHA-loaded NLC 
measured using NanoSight
®
 image (scale bar 400 nm) and NanoSizer
® 
Malvern, respectively. (B) Differential scanning 
calorimetry thermograms and thermometric parameters as melting point, enthalpy, and recrystallization index (RI) of 
bulk material blends and NLC. (C) NLC stability in simulated gastric fluid for 3 h, measuring the particle concentration 
changes by NanoSight
®
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3.2. Anti-H. pylori in vitro efficiency 
The bactericidal effect of NLC, unloaded and DHA-loaded, against H. pylori in vitro was 
previously reported by us [37]. However, due to their high bactericidal potency, their kill-time 
kinetics was further investigated for very short times (15, 30, 90 and 150 min) and using a 
bactericidal concentration (unloaded-NLC (2.5% v/v) and DHA-loaded NLC (2.5% v/v 
containing 50 μM DHA) that was not toxic to gastric human cells [37]. DHA-loaded NLC rapidly 
decreased the number of viable bacteria within 30 min of incubation, having a reduction of 3 
logs (99.9%) of H. pylori at 2.5% v/v (50 μM), while with unloaded-NLC no bactericidal activity 
against bacteria was observed up to 150 min (Figure 2A). No viable bacteria were detected, 
when bacteria was treated with this concentration of DHA-loaded NLC after 90 min.  
As anti-H. pylori activity of DHA-loaded NLC was fast, the possible mechanism of action was 
explored by evaluating permeability of the outer and inner membrane. To evaluate de outer 
membrane permeability, NPN was used. This is a hydrophobic fluorescent probe, which can 
enter into the hydrophobic interior of the outer membrane when membrane integrity is 
compromised [38,39]. After 30 min incubation, H. pylori treated with DHA-loaded NLC had a 
significant increase in the fluorescence signal of NPN (NPN uptake) compared to the control 
and unloaded-NLC, indicating DHA-loaded NLC increased rapidly the outer membrane 
permeability of H. pylori, explaining their more effective bactericidal activity than unloaded-NLC. 
Nevertheless, unloaded-NLC also affected the outer membrane permeability of H. pylori but in a 
slower way.    
The plasma membrane permeability was also examined using a BacTiter-Glo microbial cell 
viability assay kit, evaluating the disrupting of the plasma membrane as a result of the 
immediate collapse of the proton gradient accompanied with a fast release of intracellular ATP 
into the medium [40]. Treatment with DHA-loaded NLC enhanced ATP release from H. pylori 
comparing to control and unloaded-NLC. Once again, unloaded-NLC increased also the plasma 
permeability of H. pylori, but with a lower efficiency rate than DHA-loaded NLC.  
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Figure 2. H. pylori growth and membrane permeability. (A) In vitro bactericidal activity of 2.5% v/v unloaded and 
DHA-loaded NLC against H. pylori strain J99 evaluated by colony forming unit counting. *p<0.05, refers to significant 
differences in H. pylori growth between control (bacteria untreated) and bacteria treated with NLC (Kruskal-Wallis test). 
(B) Outer and inner membrane quantification by uptake of N-phenylnapthylamine (NPN) and release of ATP from H. 
pylori J99 due to treatment with of 2.5% v/v unloaded and DHA-loaded NLC for 30 minutes. * p<0.05, **p<0.001, 
statically significant differences between samples (One-way ANOVA, Tukey test). 
 
3.3. Anti-H. pylori in vivo efficiency 
NLC were administered to C57BL/6 mice, as described in Scheme 1, evaluating their 
efficiency in the treatment of H. pylori infection. Infection was confirmed by CFU counting 
and toxicity by hematoxylin and eosin (H&E) staining of stomach and liver sections (Figure 
4). By CFU counting (CFU/mice stomach), it was possible to notice the presence of H. 
pylori SS1 strain in infected mice that were administered with only water, presenting 
average infection levels of CFU/mice of ~1.98×10
5
 (Figure 4C). Regarding NLC efficiency 
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to reduce the bacteria infection, significant differences were observed when mice were 
treated with 2.5% unloaded and DHA-loaded NLC (50 μM DHA), comparing with untreated 
mice (mice received only water) (Figure 4C). The reduction of infection in these cases was 
82.5% (~3.34×10
4
 CFU/mice) and 92.6% (~1.40×10
4 
CFU/mice), respectively, a reduction 
of 1 log.  
To evaluate NLC toxicity, gastric and liver histopathology by H&E staining was performed 
as showed in Figure 4A and 4B. Stomach sections of non-infected mice presented normal 
gastric architecture, with an organized structure, an intact epithelial layer and glandular 
cells with continuous gastric pits, even when treated with NLC. In what concerns infected 
and treated mice, some inflammatory infiltrates can still be found, although less 
pronounced. The gastric mucosa morphology and structure of untreated H. pylori-infected 
shows more disorganized epithelium with a slight atrophy comparing with non-infected 
mice. Regarding the histological analysis of the liver, in all groups, a normal architecture of 
the tissue can be observed, with a normal distribution of hepatocytes around central veins 
and some accumulation of hepatic fat (steatosis) in some mice.  
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Figure 3. Anti-H. pylori efficacy in vivo. (A) Stomach and (B) liver toxicity characterized by histology (H&E 
staining) of C57BL/6 mice infected with H. pylori SS1 treated with, water, unloaded and DHA-loaded NLC. Scale 
bar: 200μm. (C) Quantification of H. pylori burden in the stomach of infected mice treated with water, unloaded 
and DHA-loaded NLC (n=12 per group). Bars represent mean values. * p<0.05, refers to significant differences 
between infected mice non-treated and treated mice (One-way ANOVA, Tukey test). 
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4. Discussion 
Due to the rapid rise of H. pylori strains resistant to the existing antibiotics, current 
treatment regimens present a rapid decline in their eradication rates [41]. The bactericidal 
potential of DHA, as a safe and natural bacteria inhibitor, was well described [35]. Correia 
et al. [35] demonstrated that DHA after oral administration was able to eradicate H. pylori 
from 50% of H. pylori-infected mice.  
We previously demonstrated that DHA loading into NLC strongly promotes its anti-H. pylori 
activity. However, this effect was associated with a synergistic effect between the released 
DHA and the lipid nanoparticle, since unloaded-NLC were also bactericidal to H. pylori [37]. 
During this work, we demonstrated that these unloaded- (~211nm) and DHA-loaded (~300 
nm) NLC, were both stable in simulated gastric fluid (pH 1.2) for 3h. However, we 
previously demonstrated that DHA-loaded NLC, containing 66% DHA entrapment 
efficiency, were unstable in bacteria medium (Brucella broth supplemented with 10%FBS), 
releasing 40% of their DHA after 3h [37]. This may be explained by our DSC results that 
demonstrated that when DHA was incorporated into NLC matrix, creates a less order 
crystalline structure, nanoparticle is less rigid, which will favor their disintegration and DHA 
released [37]. DHA-loaded NLC have a faster bactericidal activity against H. pylori J99 
(human strain) than unloaded-NLC. This was explained by their higher ability to increase 
the permeability of the outer and inner H. pylori membrane in a short period of time (30 
min). This fact can explain the faster disruption of H. pylori membrane and leakage of 
cytoplasmic contents when H. pylori was treated with DHA-loaded NLC instead of unloaded 
NLC [37]. Similar bactericidal results were described by Jung et al [10] for liposomes 
containing linoleic acid (LA). They proposed that the high bactericidal potential of these 
liposomes were related to their ability to rapidly fuse and incorporate LA into H. pylori 
phospholipid membrane, promoting membrane disruption and causing bacterial death [10]. 
Moreover, due to their fast bactericidal effect (30 min), DHA-loaded NLC at 2.5% (v/v) have 
low propensity to induce resistant H. pylori strains since 30 min is a relatively short time 
compared with the 2.5 h needed for H. pylori to complete a replication cycle [30,42]. 
Another advantage of these NLC (unloaded and DHA-loaded), is the absence of 
cytotoxicity against human adenocarcinoma gastric cells at bactericidal concentrations 
(2.5% v/v) [37] and both NLC were also stable in simulated gastric fluid (pH1.2) 
In what concerns NLC oral administration, data revealed no changes in morphology in 
mouse stomach and liver histological sections, comparing with the histological section in 
the literature [43,44] after 14 days treatment with 2.5% (v/v) NLC. These results suggest 
that this NLC concentration is safe and well-tolerated, with no toxic effect observed, in 
agreement with several clinical trials that have used DHA supplementation at higher doses 
with no reports of toxicological effects [45].  However, some of the mice presented liver 
steatosis, which was associated with the diet rich in carbohydrates that mice are subjected 
to in the animal facility.  
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Regarding gastric infection treatment, C57BL/6 mice were infected with an H. pylori mouse-
adapted strain (H. pylori SS1), since these mice are not infected by H. pylori-human strains 
[46]. A similar bactericidal effect of developed NLC (unloaded and DHA-loaded) against 
both bacteria H. pylori strains (SS1 and J99) was previously demonstrated by us [37]. 
Treatment with DHA-loaded NLC reduced H. pylori number in the gastric mucosa of 
infected mice in around 92.6%, while treatment with unloaded-NLC have only a decrease in 
82.5% compared with untreated mice. These findings suggest that, although NLC were 
able to decrease H. pylori gastric colonization, DHA-loaded NLC was more effective than 
unloaded-NLC. However, four in twelve mice of the control untreated group (mice infected 
but treated with water) were H. pylori negative after 14 days. This H. pylori clearance in the 
untreated group may be associated with H. pylori SS1 quality that may have lost its ability 
to infect mice. Several parameters may affect H. pylori SS1 mice colonization and strain 
virulence namely the frequency of dosing, volume of inoculum, and excessive passage of 
the SS1 strain [46]. Another hypothesis is related to the immunity of mice to H. pylori 
because a persistent H. pylori infection in mice typically results in an H. pylori immunization 
due to the presence of some of the antibodies that may participate to the H. pylori 
clearance [47,48].  
 
5. Conclusion 
DHA-loaded NLC, at concentrations around 2.5% v/v (50 µM DHA), were bactericidal 
against H. pylori in a very short time (30 min). NLC (unloaded- and DHA-loaded) were able 
to affect the permeability of the outer and the inner bacteria membrane in 30 min, although 
this effect was more effective for DHA-loaded NLC.  Unloaded and DHA-loaded NLC were 
both stable in acidic conditions and may be able to use for oral administration. In vivo, 
preliminary data suggest that both, unloaded and DHA-loaded NLC, were able to reduce H. 
pylori infection in mice (~1 Log), although DHA-loaded NLC has been more efficient. 
Moreover, these NLC did not demonstrate any toxicity to mice in the concentrations used. 
Overall, the results indicate the therapeutic potential of DHA-loaded NLC for the treatment 
of H. pylori infection.  
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CHAPTER VII 
 
GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
7.1- General Discussion 
 
Despite the wide success of antibiotics, the treatment of H. pylori infection still faces 
significant challenges, particularly through the rapid emergence of H. pylori strains resistant to 
existing antibiotics. Current treatment regimens show a fast decline of their eradication rates, 
being inefficient in 20% of patients [1,2]. Alternative therapeutic approaches and treatment 
strategies have been developed, aiming to overcome H. pylori resistance strains. A series of 
free PUFA including linolenic acid (LA), eicosapentaenoic acid (EPA), docosahexaenoic acid 
(DHA) have attracted much attention as they have shown antibactericidal activities a diverse 
range of bacteria including H. pylori [3]. In addition, PUFA induce lower drug resistance in H. 
pylori than conventional antibiotics [4]. Despite promising results have been reported, the use of 
PUFA in inhibiting H. pylori remains challenging. Correia et al. [5] demonstrated that an omega-
3 PUFA, DHA, has the ability to inhibit H. pylori growth in vitro. Concentrations of 100 µM of free 
DHA only decreased H. pylori growth, whereas concentrations higher than 250 µM were 
bactericidal against this bacterium. However, free DHA (50µM) efficiency in the eradication of H. 
pylori from mice gastric mucosa was lower than the standard antibiotherapy and failed in 50% of 
infected mice [5]. This reduced DHA efficiency in vivo could be related to its low stability (easy 
oxidation and gastric degradation), its low penetration through the mucus layer, its low 
residence time in the stomach and its low bioavailability at the infection site [6,7]. Moreover, it 
was described that the acidic pH in the stomach decreases PUFA solubility, making these 
molecules ineffective [3]. Therefore, the development of a DHA local delivery system could be 
essential to overcome these challenges, namely to protect DHA from gastric oxidation and 
degradation.  
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The main goal of this work was the development of an antibiotic-free engineered system 
for the treatment of H. pylori gastric infection. The strategy is based on the development of lipid 
nanoparticles to create a DHA delivery system that after oral administration will kill H. pylori at 
the infection site.  
   Several types of nanoparticles, such as polymeric, inorganic, dendrimers and lipid-
based colloidal carriers can be used for drug encapsulation. Taking into consideration the 
lipophilic character of DHA, lipid nanoparticles were chosen due to their i) ability to incorporate 
hydrophobic and lipophilic drugs into their lipid matrix, ii)  biocompatibility and safety of lipids 
used for their production (FDA approval), and iii) low cytotoxicity [8-11]. The increasing interest 
in lipid nanoparticles has been also associated with their production in absence of organic 
solvents, and the low cost of their large-scale production comparing to other types of 
nanoparticles [8,12-16]. 
As a first approach, solid lipid nanoparticles (SLN) without DHA (unloaded-SLN) were 
produced and optimized in terms of size, polydispersion, and reproducibility (Appendix 1). 
During optimization of the SLN production, different reagents (solid lipids with different melting 
points and surfactants) and reaction conditions (ratio between lipids and surfactants, 
homogenization time and sonication time and intensity) were tested. The first exclusion criterion 
was nanoparticles size, since, according to Lin et al., nanoparticles with sizes between 130 and 
300 nm are able to reach H. pylori at the infection site, infiltrate cell-cell junctions and interact 
with H. pylori in intercellular spaces [17]. Polydispersion index values greater than 0.5 were also 
an exclusion criterion. Due to micelles formation when Tween
®
80 was used, SLN optimizations 
were proceeded using Tween
®
60.  
Due to the lack of reproducibility during SLN production, another type of lipid 
nanoparticles, nanostructured lipid carriers (NLC), were optimized as a second approach. NLC 
differ from SLN by the integration of a liquid lipid that is blended to solid lipid and incorporated in 
the core of nanoparticle [8,9]. The major advantage of NLC over SLN is that many drugs like 
DHA, are more soluble in a liquid lipid than in a solid lipid, leading to a higher loading capacity 
and controlled release of drugs [18]. Here, the production of NLC was firstly optimized using the 
solid lipids that were selected during the optimization of SLN (cetyl palmitate and 
Precirol
®
ATO5). NLC production was optimized basing on Neves et al. study [19], using 
Miglyol
®
812 as liquid lipid and Tween
®
60 as surfactant. The proportion between solid and liquid 
lipid and surfactant were optimized until NLC, with size around 200 nm and charge around -30 
mV, was obtained. Negatively charged around -30 mV is an indicator of colloidal stability 
maintained by electrostatic repulsion [20-22]. Comparing to SLN, NLC production was more 
reproducible in terms of size and charge, independently of solid lipid used.  
DHA was then incorporated into NLC prepared using cetyl palmitate or Precirol
®
ATO5 as 
solid lipid (Appendix 2). NLC size and charge were dependent on the amount of DHA used 
during NLC production. DHA entrapment efficiency was higher than 52% for all NLC produced, 
independently of solid lipid used. However, NLC prepared with Precirol
®
ATO5 presented higher 
stability and higher DHA release than NLC prepared with cetyl palmitate. Moreover, in opposite 
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to cetyl palmitate, Precirol
®
ATO5 is FDA approval, have a GRAS status, and is already used in 
pharmaceutical products, namely Serenelfi
®
. Therefore, NLC prepared with Precirol
®
ATO5 were 
used in all biological studies described in this thesis.  
 In the subsequent part of study, DHA-loaded NLC, containing around 60% of DHA (NLC 
produced with 2% v/v) in its matrix, with ~302 nm of size and negative charge (~28 mV) were 
successfully produced and characterized using several techniques (DLS, ELS, NanoSight
®
, 
cryo-SEM, DSC). Unloaded-NLC with ~211 nm of size and negative charge (~28 mV) were also 
produced as a control to DHA incorporation. These NLC are suitable for oral administration, 
since both NLC were stable in simulated gastric fluid (pH 1.2) over 3 hours.  
 We demonstrated that DHA-loaded NLC were bactericidal against H. pylori J99 
(human) and SS1 (mouse-adapted) strains. DHA loading improved bactericidal activity, since 
DHA-loaded NLC were bactericidal at all concentrations tested (10 to 500 µM), although free 
DHA was only bactericidal at concentrations higher than 100 µM. However, we also observed 
that unloaded-NLC, used as control of DHA encapsulation, were also bactericidal to H. pylori at 
all concentrations tested although in a slower rate than in the presence of DHA. This effect of 
unloaded-NLC is not associated with individual compounds used in NLC production 
(Precirol
®
ATO5, Tween
®
60
 
and Miglyol
®
812), because when they alone are not bactericidal at 
concentrations used during our H. pylori experiments [23-26], demonstrating that bactericidal 
effect may be related with nanoparticles 3D format. 
NLC time-killing of H. pylori was dependent on NLC concentration and on the presence 
DHA. The bactericidal effect of 0.5% (v/v) DHA-loaded NLC (containing 10 µM DHA) against H. 
pylori J99 was observed after 6h, while for the same amount of unloaded-NLC this bactericidal 
effect was only observed after 18h. A faster bactericidal effect was demonstrated for higher 
NLC concentrations. DHA-loaded NLC at 2.5% v/v (containing 50 µM DHA) were bactericidal in 
30 min, while any effect was observed for the same concentration of free DHA and unloaded-
NLC. It important to notice, this concentration is not toxic to human gastric cells, and it is safe 
and well-tolerated by mouse gastric mucosa. Moreover, due to this shorter killing time (30 min), 
it is not probable that bacteria develop resistance to these nanoparticles, because H. pylori 
need to 2.5 h for its complete replication cycle [3,27].  
H. pylori adopt two major morphologies, spiral and coccoid form. H. pylori in coccoid 
form can play a critical role in disease transmission (for example oral-oral or oral-fecal routes) 
and subsequent treatment [28,29]. The coccoid form of the bacteria was also show to contribute 
to the development of relapses following antimicrobial therapy in H. pylori infection [30]. In 
comparison with linolenic acid liposome [31] that bacteria adopt both morphologies, in our 
study, the morphology transformation of H. pylori from spiral form to coccoid form was not 
observed. H. pylori treated with NLC shown a bacillary form, while Correia et al [5] reported that 
H. pylori treated with free DHA displayed coccoid form which was associated with lower bacteria 
viability. These results suggest that the morphological transition of H. pylori from spiral to 
coccoid form may be prevented by the fast bactericidal effect of these NLC.  
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 The mechanisms of action of NLC (unloaded and DHA-loaded) against H. pylori were 
also studied by us. Results showed that both NLC were able to bind to H. pylori membrane, 
increasing their permeability (outer and inner membrane), which leads to the disruption of 
membrane integrity and bacteria killing. This increase of membrane permeability could be 
related with nanoparticles integration into the bacteria membrane, as described by Jung et al. 
[32] for liposomes containing LA. Moreover, it is known that free DHA is rapidly incorporated 
into phospholipids of the cell membrane and mitochondria. Due to its incorporation into 
mitochondria, free DHA has a larger effect in bioenergetics proprieties, namely ATP production, 
H
+
 permeability and membrane potential [33]. Free DHA concentrations higher than 100 µM 
have a significant impact on H. pylori ATP production, decreasing drastically its metabolic 
activity as well as in their protein profile [34]. This DHA effect can suggest that when DHA is 
released from NLC, beyond to increase membrane permeability, it may also be incorporated 
into bacteria mitochondria, which can explain the faster bactericidal effect of DHA-loaded NLC 
than unloaded-NLC.  
All developed NLC (unloaded and DHA-loaded) are negatively charged and have on their 
surface the hydrophilic moiety of the non-ionic surfactant used in nanoparticle production. This 
non-ionic surfactant may decrease the surface tension between NLC and bacteria enabling their 
interaction with proteins and lipids of H. pylori membrane [35], allowing their adhesion and entry 
in bacteria membrane.  
Using gold nanoparticles loaded into NLC, it was visualized by TEM that, unloaded-NLC 
were internalized by bacteria, being found in bacterial periplasmic space after 3h (promoting an 
increase of periplasmic space and separation between the outer and inner membrane) and in 
the cytoplasmic after 12h. At the same time, a decrease of bacteria thickness was observed by 
AFM. This NLC internalization associated with changes in the outer and inner bacteria 
membrane allows the leakage of bacterial cytoplasmic content as showed by SEM and AFM. 
These results suggest that NLC enter as a 3D particle in periplasmic space and, as DHA-loaded 
NLC is more unstable than unloaded-NLC, DHA is released over there, allowing a faster 
bacterial membrane disruption and consequently the leakage of cytoplasm and bacteria death. 
This entering of NLC on bacteria membrane may be helped by the presence of surfactant on 
NLC surface that may solubilize sections in the bacteria membrane, disrupting them. The faster 
bactericidal activity of DHA-loaded NLC could be also explained by the decrease of pH related 
with DHA release into bacteria. Similar to fatty acids and metronidazole mechanism, DHA may 
also inhibit bacterial growth by creating an acidic environment in the cytoplasm that damages 
pH-sensitive intracellular enzymes or amino acid transporters [36]. Such antibacterial activities 
are physical, broad and unspecific, which may explain a lower frequency of resistance 
development observed when bacteria are treated with fatty acids.  
Although their bactericidal effect, NLC are not cytotoxic to human gastric 
adenocarcinoma cells (MKN45 cell line) at bactericidal concentrations, namely up to 2.5% v/v 
NLC (50 µM DHA). As expected, DHA-loaded NLC decreases metabolic activity of cells at 100 
µM of DHA, as well is reported for free DHA [34,37].  
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Attending that the main goal of this work is the development of an antibiotic-free 
alternative to fight H. pylori gastric infection, an exploratory in vivo study was performed using 
1.25% v/v (25 µM DHA) of DHA-loaded NLC, to evaluate nanoparticles toxicity and dosage for 
the treatment of H. pylori-infected mice. Histological sections of stomach and liver revealed no 
changes in gastric morphology and a normal architecture of gastric mucosa. Regarding 
treatment efficiency, mice treated with 1.25% v/v (25 µM DHA) of DHA-loaded NLC had a 
reduction of 63.8% of H. pylori colonization. However, this reduction was not statistically 
significant compared with untreated mice.  
Taking these results into consideration, the same assay was performed using a higher 
dosage of DHA-loaded NLC (2.5% v/v [50 µM of DHA]). This concentration is within the range of 
concentration reachable with diet in the human stomach for any PUFA [38]. An enhance of 
efficiency was observed, obtaining a reduction of H. pylori colonization of 92.6% with treatment 
of DHA-loaded NLC and 82.5% with unloaded-NLC, compared with untreated mice. This 
reduction of H. pylori colonization was higher than 50% reduction reported by Correia et al [5]. 
However, at the end of treatment, four mice (in twelve) were not infected in the untreated H. 
pylori-infected group (group that only received water). This result may be related to several 
factors associated with H. pylori SS1 strain that can reduce the infection reproducibility in the 
laboratory. Culture viability, frequency of dosing or volume of inoculum, and excessive passage 
of the isolates may affect H. pylori SS1 strain colonization and virulence [39]. Another 
explanation is related to the immunity of mice to H. pylori. Despite C57BL/6 mice used are 
specific-pathogen-free, its persistent H. pylori infection over more than one month (one month of 
infection establishment plus 14 days of treatment), may result in an H. pylori clearance due to 
immunization mice that began between 8 to 16 weeks of exposure to H. pylori [40-42]. This 
reduction in bacterial load is associated with gastric inflammation that subsides over time [42]. 
Unloaded-NLC treatment was less efficient in vivo than DHA-loaded NLC, which could be 
related to their low efficiency in vitro.  
The concentration of NLC (2.5% v/v) given to mice in our experiments are also within 
safe and well tolerated range of concentrations with no toxic effect observed maintaining a 
gastric mucosa without changes in the gastric morphology and normal architecture [43,44]. 
These results are in agreement with several clinical trials that have used DHA supplementation 
at higher doses with no reports of toxicological effects [45,46] 
In the subsequent part of this study, the selectivity of unloaded-NLC to fight H. pylori 
was evaluated using other bacteria with different structural (Gram-positive vs Gram-negative) 
and morphological (rod vs spherical) features and different surface charge. Gastrointestinal 
bacteria, such as Lactobacillus casei and Escherichia coli, were used.  NLC were also tested on 
pathogenic bacteria from skin and mucosae, namely Staphylococcus epidermidis and 
Staphylococcus aureus, trying to find a novel application of these unloaded-NLC, as a topical 
application. Results demonstrated that unloaded-NLC did not affect the growth of other bacteria 
tested, except in S. aureus, where unloaded-NLC at 5% (v/v) were able to decrease bacteria 
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growth after 6h, although without a bactericidal effect. However, this concentration was 
cytotoxic for human gastric adenocarcinoma cells.  
One explanation for NLC selectivity to H. pylori could be associated to their unique and 
specific features, such as their LPS that have an unusual cellular composition based on fatty 
acid, lipid profile and molecular mimicry of Lewis antigens [47,48]. Moreover, H. pylori is 
cholesterol-dependent [49,50]. A depletion of cholesterol levels in epithelial cells, leading to a 
lower synthesis of cholesteryl glucosides by H. pylori and interfere in the bacteria survival and 
their ability to colonize, namely in the translocation of H. pylori virulence factors, such as 
vacuolating cytotoxin (VacA) and cytotoxin-associated gene A (CagA) [51,52].  
Overall, we demonstrated that NLC can profoundly change H. pylori growth, survival, 
and morphology. The abovementioned changes decrease H. pylori in vitro and reduce H. pylori 
mice gastric colonization, opening new perspectives to the management of this bacterial 
infection. Altogether, these results highlight that NLC, unloaded and DHA-loaded, should be 
explored as a new alternative treatment for H. pylori eradication. 
 
7.2- Future Perspectives 
 
In the follow-up of the work described in this thesis, we will repeat the in vivo study, 
testing the same and higher concentration than the used before in comparison with standard 
antibiotic treatment. In parallel, it would be very interesting to study the retention time of NLC 
and their ability to cross mucus layer. If NLC would have low retention time, we can coat NLC 
using a mucoadhesive polymer, as chitosan, in order to increase their retention time in mouse 
stomach and/or develop a pH sensitive delivery system.   
Another issue that needs further elucidation is evaluation of NLC effect against isolates of 
H. pylori strains from patients resistant to standard antibiotic therapies and to evaluate if NLC 
can induce bacteria resistance.  
Biocompatibility of NLC using normal gastric cells instead of gastric adenocarcinoma cell 
line used in this study and intestinal cells should be tested, aiming to evaluate if NLC may have 
a side-effect to this type of cells.  
Despite free DHA activity against E. coli (at concentration higher than 1mM), DHA-loaded 
NLC safety to human microbiome will be tested, using E. coli, and Lactobacillus. 
Additional experimentation is needed to clarify the mechanisms of action of DHA effects 
on bacteria membranes as well as, mechanism of action of NLC as a 3D particle. This 
additional experimentation could be done by biophysics assays using membrane models that 
mimic the mammalian and bacterial lipid composition.  
Finally, gerbils could be considered in animal experiments, since they are known for 
mimicking human’s gastric progression of the gastric disease, allowing a more broad knowledge 
of NLC effects.   
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APPENDIX 
APPENDIX 1 
1. Lipid nanoparticles optimization 
 
Lipid nanoparticles production and DHA loading were optimized in terms of size, charge, 
and entrapment. During the optimization process, several parameters were tested, including 
different solid lipid with a different melting point, different surfactants (Tween
®
80 and 
Tween
®
60), ratios of lipids and surfactant, time of sonication, and intensity (or amplitude) of 
sonication.  
Table 1 summarizes the different solid lipid tested and respective melting point measured.  
 
Table 1- Different solid lipid and respective melting point tested for lipid nanoparticles production 
Solid Lipid Melting point (ºC) 
Witepsol
® 
S51 30 
Witepsol
®
 S58 33 
Witepsol
® 
E76 37 
Witepsol
®
 E85 42 
Cetyl palmitate 50 
Precirol
®
 ATO 5 56 
Compritol
®
E ATO 70 
 
The first choice of lipid nanoparticles was solid lipid nanoparticles (SLN), produced by hot 
homogenization and ultrasonication, using 4.2 mL of ultrapure water (type 1) and testing 
different amounts of solid lipid and surfactant (Tween
®
80). SLN production was firstly optimized 
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without DHA, using Witepsol
®
 as solid lipid due to its melting point around 30 to 37ºC. However, 
SLN aggregated after cooling and two different populations: ~30 nm and higher than 300 nm to 
8000 nm were identified (Table 2), probably due to the presence of micelles of surfactant.  
 
Table 2- Production of SLN of using Witepsol
®
 S51, S58, H32, E76 as a solid lipid, testing different mass of solid lipid 
and surfactant and time of sonication. Time of homogenization was the same for all SLN produced (30 s of ultra-turrax 
at 1200 rpm). 
Parameters tested 
Solid lipid (mg) 100 200 200 
Tween
®
80(mg) 20 60 80 
Sonication (min) at 
80% of amplitude 
2 3 3 
Results of  
size (nm) by DLS 
Witepsol
®
 
S51 
No results 
(aggregates) 
30-300 24-825 
S58 157.5-1000 16-6439 
H32 300-1300 21-7456 
E76 60-501 21-8635 
 
Due to persistent small sizes of SLN produced with Witepsol
®
 solid lipid S51, S58, H32 
and E76, and the high amount of micelles of Tween
®
80, this surfactant was substituted by 
Tween
®
60 and other solids lipids, namely Witepsol
®
E85, cetyl palmitate, Precirol
®
ATO5 and 
Compritol
®
E ATO were tested. The time of sonication was decreased to 30s in order to increase 
of size of SLN (Table 3).  
 
Table 3- Characterization of SLN using Witepsol
®
E85, cetyl palmitate, Precirol
®
ATO5 and Compritol
®
E ATO as solid 
lipid, in terms of size and polydispersion index (PDI).  
Parameters tested 
Solid lipid (mg) 200 200 200 
Tween
®
60 (mg) 100 100 100 
Sonication (30 s) at amplitude (%) 80 70 60 
Results of 
 size (nm)[PDI] by DLS  
Witepsol
®
E85 41 [0.10] 30.9 [0.33 NT 
Cetyl palmitate 85 [0.18] 139 [0.32] 245 [0.23] 
Precirol
®
ATO5 41 [0.36] 100 [0.18] 358 [0.20] 
Compritol
®
E ATO 577 [0.18] 816 [0.03] 718 [0.06] 
Abbreviations: NT- non-tested; PDI- polydispersion index 
 
Taking in consideration that nanoparticles with 130-300 nm of size are able to adhere to 
and infiltrate cell-cell junctions and interact locally with H. pylori infection in intercellular spaces 
[1], we selected the SLN with 245 to 718 nm of size. These SLN was produced by hot 
homogenization (30 s of ultra-turrax) and sonication (30s at 60% of amplitude), using 200 mg of 
solid lipid, 100 mg of surfactant (Tween
®
60) and 4.2 mL of ultrapure water. Afterward, we 
proceeded to DHA-loaded SLN production, using 1% v/v of DHA, and their characterization in 
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terms of size, polydispersion, and zeta potential. Two independent assays were performed in 
order to evaluate the reproducibility of DHA-loaded SLN. Table 4 summarizes two independent 
productions of unloaded and DHA-loaded SLN using three different solid lipids.  
 
 Table 4- Characterization in terms of size, polydispersion index (PDI) and charge of unloaded and DHA-loaded SLN of 
cetyl palmitate, Precirol
®
ATO5, and Compritol
®
E ATO. 
   SLN 
  Assay Size (nm) PDI Zeta potential (mV) 
unloaded Cetyl palmitate 1 26 0.24 -1.72 
  2 40 0.26 +10.87 
 Precirol
®
ATO5 1 727 0.08 -7.10 
  2 550 0.36 -14.76 
 Compritol
®
E ATO 1 580 0.085 -12.80 
  2 1040 0.23 +10.87 
DHA-loaded Cetyl palmitate 1 55 0.27 +11.58 
  2 186 0.15 +13.20 
 Precirol
®
ATO5 1 814 0.05 -1.62 
  2 337 0.39 -18.08 
 Compritol
®
E ATO 1 742 0.10 -2.70 
  2 337 0.39 -18.08 
 
Due to the lack of reproducibility during the production of SLN, with and without DHA, 
nanostructured lipid carriers (NLC) were produced. It is known that NLC differ from SLN by the 
inclusion of a liquid lipid that is incorporated into their solid structure. Liquid lipid confers to the 
nanoparticle a less ordered crystalline structure, greater physical stability and avoids drug 
expulsion during storage [2,3]. The conditions of NLC production was optimized basing on 
Neves et al study [4] and the previous results obtained during SLN optimization. Thus, NLC 
were produced using cetyl palmitate or Precirol
®
ATO5 as solid lipid, Miglyol
®
812 as liquid lipid 
and Tween
®
60 as surfactant. Nevertheless, Compritol
®
E ATO was not used as solid lipid for 
NLC production due to its high melting point that would avoid DHA released at 37ºC.  
NLC were produced using 200 mg of solid lipid, 90 mg of liquid lipid and 60 mg of 
Tween
®
60. Figure 1 demonstrated that NLC can be produced with higher reproducibility in 
terms of size and charge than SLN (Figure 1).  
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Figure 1- Characterization of unloaded-SLN and NLC of cetyl palmitate and Precirol
®
 ATO5 in terms of size and charge. 
 
After NLC optimization, DHA loading was performed using cetyl palmitate and 
Precirol
®
ATO5 as a solid lipid as described in Appendix 2 and Chapter IV, respectively.  
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APPENDIX 2 
2. Bactericidal effect of nanostructured lipid carriers 
composed of cetyl palmitate solid lipid 
 
During this work the production and characterization of NLC, with and without DHA, were 
firstly optimized using cetyl palmitate as solid lipid, and Miglyol
®
812 as liquid lipid and 
Tween
®
60 as surfactant. The bacterial activity and biocompatibility were also evaluated as 
described in Chapter IV.  
This appendix shows a comparison between NLC prepared with cetyl palmitate (NLC_CP) 
and Precirol
®
ATO5 NLC (NLC_P).  
In terms of characterization, the size and charge of NLC_CP change with the incorporation of 
different DHA concentrations (Figure 2A). However, a similar DHA loading and entrapment was 
observed independently of solid lipids used on NLC production. A higher DHA entrapment 
efficiency was obtained when NLC was produced with 2% v/v of DHA (Figure 2B).  
NLC stability was followed by measuring the change of NLC size and charge after their 
storage in aqueous solution up to 8 weeks (2 months) at 4ºC and 20ºC. As shown in Figure 3, 
NLC_CP were not stable, since it was observed alterations in their size after 1 week of storage, 
independently of the temperature. However, the surface zeta potential of DHA-loaded NLC_CP 
was only maintained during 1 week, independently of the temperature. These results suggest 
that Precirol
®
ATO5 confer more stability to NLC than cetyl palmitate.  
Concerning the DHA release profile, studies were performed in bacteria liquid medium 
(BB + 10% FBS medium), which is the medium used during NLC bactericidal evaluation. Figure 
4 shows that DHA was released in slow rate from DHA-loaded NLC_CP (22%) than DHA-
loaded NLC_P (40%) after 3h.  
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Figure 2- (A) NLC were characterized in terms of diameter (bars), polydispersion index (dots) and charge surface (zeta 
potential) (bars) performed using dynamic light scattering at 37ºC. *
, #, α
 p < 0.05; statically significant differences of NLC 
of cetyl palmitate and Precirol
®
ATO5, in terms of diameter, PDI and zeta potential, respectively (Kruskal-Wallis test). (B) 
NLC characterization in terms of DHA content (bars) and entrapment efficiency (values in percentage). No statically 
differences were observed (Kruskal-Wallis test). All data is reported as the mean ± standard deviation (n = 3). 
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Figure 3- Storage time effect regarding diameter and charge on unloaded-NLC and 2% DHA-loaded NLC produced with 
cetyl palmitate and Precirol
®
ATO5 in water at (A) 4ºC and (B) 20ºC. Data is reported as the mean ± standard deviation 
(n = 3). *Statistically significance different from the same NLC at day 0 (p < 0.05; Kruskal-Wallis test). 
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Figure 4- In vitro release curve of DHA from 2% DHA-loaded NLC produced with cetyl palmitate and Precirol
®
ATO5  in 
bacteria medium (Brucella-broth + 10% FBS medium) during 3 h. 
 
Figure 5 shows the effect of NLC_CP (unloaded and DHA-loaded) on H. pylori J99 
growth. Both NLC_CP were bactericidal against H. pylori, however DHA-loaded NLC_CP 
(Figure 5A) had a faster bactericidal activity than unloaded-NLC_CP (Figure 5A). Figure 5B also 
demonstrated that DHA-loaded NLC_CP had a similar bactericidal profile against H. pylori J99 
strain than DHA-loaded NLC_P, in all concentrations tested since they were able to kill 99.9% 
(>3 logs) bacteria in 24 h of incubation.  
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Figure 5- H. pylori J99 growth over 24 h in the presence of increasing concentrations of (A) unloaded-NLC_CP (cetyl 
palmitate NLC) and (B) 2% v/v DHA-loaded NLC_CP. Data is expressed as mean ± standard deviation (n = 3). * p < 
0.05, refers to significant differences in H. pylori growth between control (bacteria untreated) and unloaded or DHA-
loaded NLC (Kruskal-Wallis test). 
 
The effect of NLC_CP on human gastric adenocarcinoma cells viability and lysis 
determined by MTT (Figure 6A) and LDH (Figure 6B) assays, respectively was determined as 
previously described in Chapter IV. Figure 6A demonstrated that NLC_CP had a higher 
reduction in cell viability than NLC_P, independently of concentration used. A well as observed 
with NLC_P, a severe reduction in cell viability was observed when MKN45 cells were exposed 
to the highest concentration of DHA-loaded NLC tested (5.0% corresponding to 100 mM DHA). 
In relation to the effect of NLC on gastric cell lysis (Figure 6B), a lower damage on the cell was 
observed for NLC_CP comparing to NLC_P. No toxicity was observed for NLC concentration up 
to 2.5% (DHA-loaded NLC). High toxicity was observed for 5.0% of DHA-loaded NLC (100 µM 
DHA). These results suggest that NLC_CP decrease the cell viability on human gastric cells, but 
they does not damage to cells. 
APPENDIX 
170 
 
 
Figure 6- MKN45 gastric carcinoma cell line (A) viability and (B) cytotoxicity were assessed by the MTT and LDH 
assays, respectively, after 24 h of exposure to different concentrations of unloaded and DHA-loaded NLC produced with 
cetyl palmitate and Precirol
®
ATO5. Data is reported as mean ± standard deviation (n = 3). * Statically significant 
differences of MKN45 gastric cells treated with cetyl palmitate NLC between Precirol
®
ATO5 NLC (p < 0.05; Kruskal-
Wallis test). 
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APPENDIX 3 
3. Patent: Specific bactericidal activity of unloaded- 
nanostructured lipid carriers against Helicobacter 
pylori 
 
Attending to unexpected effect of unloaded-NLC and their specificity to fight H. pylori 
growth in vitro, without affecting human microbiota, we submitted a national patent, opening a 
new perspective for the development of an antibiotic-free treatment against H. pylori gastric 
infection.  
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FIELD OF THE INVENTION 
This invention discloses the bactericidal activity of nanostructured lipid carriers (NLCs) or lipid 
nanoparticle shells, without carrying pharmacological agents, the characterization of said 
antibacterial NLCs, and their use as an agent to kill Helicobacter pylori. These NLCs do not 
affect other bacteria, such Lactobacillus casei, Staphylococcus epidermidis and Escherichia 
coli. Moreover, these NLCs are not cytotoxic to gastric cells at bactericidal concentrations. This 
invention opens new perspectives for the development of an antibiotic-free treatment against H. 
pylori gastric infection.  
 
 
BACKGROUND OF INVENTATION 
Helicobacter pylori is a Gram-negative bacteria that infect one-half of the World population. This 
bacterium is the major etiological factor in chronic active gastritis, gastric ulcers, and gastric 
cancer [1-3]. 
The currently recommended treatment includes a combination of two antibiotics, commonly 
clarithromycin plus amoxicillin or metronidazole, and a proton-pump inhibitor [4]. However, this 
therapy fails in 20% of patients for several reasons, but principally due to poor patient 
compliance and bacteria resistance to the antibiotics used [5]. More complex regimens, 
including the use of non-bismuth or bismuth-containing quadruple therapies, were also 
recommended as a second-line option [4], but their complexity potentiates patient non-
compliance and bacterial resistance, leading to treatment failure. The exacerbated increase of 
antibiotic resistance has generated alarming impact and new antibiotic-free strategies are 
necessary.    
The application of nanotechnology, especially, the use of nanoparticles as drug nanocarriers 
has generated a significant impact in medicine. The increasing interest by lipid nanocarriers is 
associated with their higher biocompatibility and lower toxicity compared to polymeric 
nanoparticles, as well as lower production cost and scalability [6-9]. Nanostructured lipid 
carriers (NLCs) are lipid nanoparticles specifically designed and patented as delivery systems 
for pharmaceutical, cosmetic and/or alimentary active ingredients [10]. They are characterized 
by a solid lipid core consisting of a mixture of solid and liquid lipids. The resulting particles 
matrix displays a melting depression when compared with the original solid lipid but is still solid 
at body temperature [6, 7].  NLCs can be prepared using a wide variety of lipids including fatty 
acids, glyceride mixtures or waxes, stabilized with selected biocompatible surfactants (non-ionic 
or ionic). Moreover, most of NLCs ingredients are safe and under the Generally Recognized as 
Safe (GRAS) status issued by the Food and Drug Administration (FDA) [11, 12]. Using spatially 
different lipids induces many imperfections in the crystal and if a proper amount of liquid lipid is 
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mixed with the solid lipid, a phase separation and the formation of oily nanocompartments within 
the solid lipid matrix can occur [13].  
This invention describes the specific bactericidal activity of NLCs without any active ingredient 
(unloaded-NLC), prepared using glyceryl palmitostearate as solid lipid, caprylic/capric 
triglyceride as liquid lipid and polysorbate 60 as a surfactant against Helicobacter pylori. This 
effect was not observed against other bacteria, such as the Gram-positive Staphylococcus 
epidermidis and Lactobacillus casei and the Gram-negative Escherichia coli. The behavior of 
unloaded-NLCs against H. pylori was not expected, since results described in the literature, that 
only uses unloaded-NLCs as controls of the drug-loaded NLCs, always demonstrated their null 
or very low activity against other bacteria [14, 15]. Moreover, the utilization of NLCs, with and 
without drugs, for the treatment of H. pylori gastric infection was not previously reported.  
 
 
DESCRIPTION OF THE INVENTION 
This invention describes the unexpected specific bactericidal effect of unloaded-NLCs 
(Nanostructured Lipid Carriers) on H. pylori without affecting other bacteria, such as the Gram-
positive Staphylococcus epidermidis and Lactobacillus casei, and the Gram-negative 
Escherichia coli. NLCs were developed to be used in the preparation of pharmaceutical, 
cosmetics and/or alimentary compositions as delivery systems for an active ingredient. 
Therefore, their bactericidal effect per sees (without any active ingredient/drug) was not 
expected and was not previously described.  
 
 
EXPERIMENTAL SECTION  
Nanostructured lipid carriers preparation 
Nanostructured Lipid Carriers (NLCs) were produced using 200 mg of glyceryl palmitostearate 
(Gattefosé) as solid lipid, 90 mg of Caprylic/Capric Triglyceride (Acofarma) as liquid lipid and 60 
mg of polysorbate 60 (Merck) as a surfactant. NLCs were produced using hot homogenization 
and ultrasonication technique. Briefly, lipids (solid and liquid) and surfactant were weighted 
together and heated at a temperature above the solid lipid melting point to promote their 
mixture. A nanoemulsion was obtained after adding to the lipid mixture, Milli-Q water preheated 
above the solid lipid melting point under high speed stirring (12000 rpm, 20s) using an ultra-
turrax T25 (Janke and Kunkel IKA-Labortechnik). This microemulsion was homogenized using a 
sonicator (Vibra-Cell model VCX 130 equipped with a VC 18 probe, Sonics and Materials Inc., 
Newtown), with tip diameter ¼" (6 mm), at 60% amplitude for 5 minutes. Nanoemulsion was 
cooled to room temperature under gentle magnetic stirring allowing the inner phase of NLCs to 
solidify forming nanoparticles dispersed in the aqueous phase without aggregates. 
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Nanostructured lipid carriers size and zeta potential determination  
The hydrodynamic size distribution and surface charge (ξ-potential) of NLCs were characterized 
by dynamic light scattering (DLS) using the Malvern Zetasizer Nano ZS. Clear disposable folded 
capillary cells (DTS1070) from Malvern were used for all samples. Samples were diluted (1:50) 
with Milli-Q water conducted at a backscattering angle of 173º at 37ºC. All measurements were 
performed in triplicate. 
 
Nanostructured lipid carriers morphology determination 
The morphology of NLC was observed by Cryo-Scanning Electron Microscopy (CryoSEM) using 
a JEOL JSM-6301F, an Oxford Instruments INCA Energy 350 and a Gatan Alto 2500. A drop of 
nanoparticles was placed on a grid, rapidly cooled in a liquid nitrogen slush (-210ºC), and 
transferred under vacuum to the cold stage of the preparation chamber. The sample was 
fractured, sublimated for 120 seconds min at -90ºC to reveal greater detail, and coated with a 
gold-palladium alloy by sputtering for 40 seconds. Finally, the sample was then transferred 
under vacuum into the CryoSEM chamber where they were observed at -150ºC. 
 
Storage stability of nanostructured lipid carriers 
NLCs were storage in Milli-Q water during 2 months at two different temperatures: 4ºC and 
20ºC. Nanoparticles stability was evaluated by periodic measurements of their size and surface 
charge using the Malvern Zetasizer Nano ZS, as described above. All measurements were 
performed in triplicate. 
 
Microorganisms and growth conditions 
Microorganisms used in this study were the following: Helicobacter pylori J99 (H. pylori; 
obtained from the Department of Medical Biochemistry and Biophysics, Umea University, 
Sweden [16]), mouse-adapted H. pylori strain SS1 (obtained from Unité de Pathogenèse de 
Helicobacter, Institute Pasteur, France), Lactobacillus casei-01 (Chr. Hansen, Hørsholm 
Denmark) (L. casei), Staphylococcus epidermis ATCC 35984 (S. epidermidis), Staphylococcus 
aureus ATCC 33591 (methicillin resistant) (S. aureus MRSA) and Escherichia coli ATCC 25922 
(E. coli). Each bacterium was grown on specific solid medium plates and overnight on a liquid 
medium, as described in Table 1.  
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Table 1- Specific solid and liquid medium of each bacteria used in this study. 
Microorganism Solid medium Liquid medium 
H. pylori J99 
and 
H. pylori SS1 
 
Blood agar base 2 (Oxoid) plates 
supplemented with 10% defibrinated 
horse blood (Probiológica) and with an 
antibiotics-cocktail of 0.155g/L 
Polymixine B (Sigma-Aldrich), 6.25 g/L 
Vancomycin (Sigma-Aldrich), 1.25g/L 
Amphotericin B (Sigma-Aldrich) and 
3.125g/L Trimethroprim (Sigma-Aldrich) 
Brucella Broth (BB, Oxoid) 
supplemented with 10% of 
Fetal Bovine Serum (FBS, 
Gibco) 
L. casei 01 
De Man-Rogosa and Sharpe agar (MRS 
agar, Biokar) 
De Man-Rogosa and Sharpe 
broth (MRS broth, Biokar) 
S. epidermidis ATCC 35984  
S. aureus ATCC 33591 
E. coli ATCC 25922  
Tryptic Soy Agar (TSA, Merck Millipore) 
Tryptic Soy Broth (TSB, 
Merck Millipore) 
 
Antibacterial activity of nanostructured lipid carriers  
Bacteria were pre-cultured on specific liquid medium (Table1) overnight at 37ºC and 150 rpm. 
After washing with phosphate buffered saline (PBS 1x, pH 7.4), bacteria were adjusted to 
approximately 1×10
7
 CFU/mL in Müeller-Hinton broth (MHB, Merck Millipore) supplemented 
with 10% of FBS. H. pylori was also tested in BB+10% FBS.   
Different NLC concentrations (0%, 1.25%, 2.5% and 5% v/v) were added to bacteria culture and 
they're incubated during 24h, at 37ºC, 150 rpm, and in the case of H. pylori under 
microaerophilic conditions. At different time-points (0, 3, 6, 9,12, 15, 24h), a 200 µL sample of 
each bacterial culture was isolated, serially diluted, plated on solid medium plates (Table 1) and 
incubated at 37ºC for 5 days for H. pylori, 2 days for L. casei and 24h for the other bacteria. The 
number of viable bacteria per mL was determined by colonies forming unit (CFU) counting. 
 
Scanning Electron Microscopy (SEM) analysis 
Morphological changes of H. pylori J99 were studied by SEM, analyzing the effect of unloaded-
NLCs on bacteria. Bacteria were incubated with unloaded-NLC (1.25% v/v) for 3 and 12h as 
previously described using BB medium supplemented with 10%FBS. After incubation, samples 
were washed in phosphate buffered saline (PBS 1x, pH 7.4) and fixed in 2.5% glutaraldehyde 
(Merck) in 0.14M sodium cacodylate buffer (Merck) for 30 min at room temperature. Fixed 
bacteria adhered on glass coverslips in a 24-well suspension plate during 2h at room 
temperature. Then samples were dehydrated with an increasing ethanol/water gradient (50% 
v/v to 99% v/v) and subjected to critical point drying (CPD 7501, Poloran). Finally, the samples 
were sputter-coated with gold/palladium film over 30s. H. pylori samples were observed by 
scanning electron microscopy (SEM; JEOL JSM-6310F), at magnification 30000 and 60000x, at 
the CEMUP (Centro de Materiais da Universidade do Porto). 
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Transmission Electron Microscopy (TEM) analysis 
The effect of unloaded-NLCs on the structure of H. pylori J99 was also analyzed by TEM. 
Incubation time and concentrations were similar as described for SEM analysis. After 
incubation, bacteria suspension was centrifuged (3000g, 5min) and the supernatant removed. 
The bacterial pellet was fixed by resuspending in a mixture of 4% w/v of paraformaldehyde 
(Merck) with 2.5% v/v glutaraldehyde (Electron Microscopy Sciences) in 0.14M sodium 
cacodylate buffer (Merck) (pH 7.4).  Samples were then washed with sodium cacodylate buffer, 
centrifuged and bacterial pellet post-fixed in 2% osmium tetroxide (Electron Microscopy 
Sciences) in sodium cacodylate buffer was embedded in a HistoGel (Thermo Scientific) and 
processed in Epon resin (Electron Microscopy Sciences). Ultrathin sections of 50 nm thickness 
were performed on a Ultramicrotome (RMC PowerTome PC model), by using diamond knives 
(Diatome). Sections were mounted on formvar-coated nickel grids, stained with uranyl acetate 
and lead citrate (Delta Microscopies) and examined using TEM (JEOL JEM 1400 transmission 
electron microscope) equipped with a CCD digital camera Orious 1100W at i3S (Instituto de 
Investigação e Inovação em Saúde da Universidade do Porto). 
 
Effect of nanostructured lipid carriers on gastric cells line 
Gastric carcinoma cell line MKN45 was grown in RPMI 1640 with Glutamax and HEPES (Gibco) 
supplemented with 10% inactivated FBS (Gibco) and 1% penicillin-streptomycin (Gibco) at 37ºC 
under 5% CO2 in humidified air. The medium was changed every two days.  For subculturing, 
cells were trypsinized and counted in a Neubauer chamber diluted (1:10) in a Trypan Blue 
solution (0.4% w/v) (Sigma-Aldrich). Cells were expanded in 75 cm
2
 T-flasks with appropriate 
aliquots of the cell suspension with a sub-cultivation ratio of 1:3. NLC effect on MKN45 gastric 
cells was evaluated using direct contact assay. MKN45 cells were seeded in a 12-well plate 
(5×10
5
 cell per well) in RPMI 1640 with Glutamax and HEPES supplemented with 10% 
inactivated FBS and 1% PenStrep, at 37ºC and under 5% CO2 in humidified air, during 48h. 
Then, the culture medium was changed and NLCs were added with different concentrations (0, 
0.5%, 1.25%, 2.5%, 5.0% v/v). Well-plate was incubated at 37ºC and under 5% CO2 in 
humidified air, during 24h. Cells in Triton
TM
 X-100 (2% w/v) (Sigma-Aldrich) and cells in fresh 
culture medium were used as a control, in order to normalize the results. After 24h, the 
supernatant was removed (transferred to 12-well plates and stored for cytotoxicity assay) and 1 
mL of 5 mg/mL of Thiazolyl Blue Tetrazolium Bromide (MTT, 98%, Sigma-Aldrich) in PBS 
solution was added to the cultures, diluted to a final concentration of 0.5 mg/L in culture medium 
and incubated for 3h at 37ºC in the dark. Then, MTT solution was discarded and 1 mL of DMSO 
was added, to solubilize the formazan crystals formed by MTT reaction. The plate was shaken 
for 5 min, at room temperature, under light protection and then, the optical density was 
measured at 590 nm and 630 nm using a microplate reader (Synergy™ H Multi-mode 
Microplate Reader, BioTek Instruments). MTT assay evaluates the activity of cellular 
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oxidoreductase enzymes inside mitochondria by converting the MTT tetrazolium dye into its 
insoluble formazan (purple) that is directly proportional to the number of viable cells. The 
percentage of cell viability was calculated according to the following equation: 
 
Cell viability (%)=
Experimental value- Triton control
Medium control-Triton control
×100 
 
 
Lactate dehydrogenase (LDH) is released to the cell culture medium when the cytoplasmic 
membrane is damaged. Consequently, its quantification allows having an assessment of cell 
death.  Hence, the 12-well plates containing the cell culture supernatant collected for the MTT 
assay was centrifuged (250g, 10min at room temperature). Carefully, without disturbing the 
pellet, 100µl of the sample were transferred to the 96-well plate and 100 µl of the LDH 
Cytotoxicity Detection Kit (Takara Bio Inc) were added. After 5 min of incubation, at room 
temperature and protected from light, the absorbance was measured at 490 and 630 nm using 
the microplate reader. The percentage of cytotoxicity was calculated according to the following 
equation: 
Cytotoxicity (%) =
Experimental value- Medium control
Triton control-Medium control
× 100 
 
 
Statistical analysis 
Data are reported as means ± standard deviation. Data from different groups were compared 
statistically using non-parametric Kruskal-Wallis test. Analyses were performed with a 
significance level of 0.05 using Graph Pad Prism 5.0 (Graph-Pad Software). 
 
 
RESULTS AND DISCUSSION 
NLCs were synthesized using a modified hot homogenization technique with no use of organic 
solvents [17]. Results obtained by DLS demonstrated that NLCs have a homogenous size 
distribution with a mean diameter of 211 ± 8 nm (Figure 1A). Polydispersion index was around 
0.2 suggesting low size variability (monodisperse distribution) and no visible aggregation that 
was confirmed by Cryo-SEM. However, when observed by Cryo-SEM (Figure 1B), NLCs are 
slightly smaller, which could be related to the sublimation process used in this technique to 
remove the surface water that can also remove the water present in the nanoparticle matrix 
causing particle shrinkage. NLCs size can be important for H. pylori treatment since it was 
described that particles with sizes between 130 and 300 nm are able to infiltrate gastric cell-cell 
junctions and interact locally with H. pylori infection sites in intercellular spaces [18].  
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ξ-potential is a very important factor in the analysis of colloidal dispersions stability. Figure 1A 
also shows that NLCs have a ξ-potential around -28mV. According to literature, colloidal 
dispersions are stable when they are strongly charged (|30 mV|) (i.e., aggregation is avoided) 
[19], whereas ξ-potential values in the range of -10<0<+10mV are considered neutral [20]. 
Since ξ-potential is near -30mV, these NLCs can be considered physically stable.   
NLCs are stable during storage in aqueous suspension for at least 1 moth at 4º and 20ºC in 
terms of size and charge (Figure 1C). However, at 20ºC and after 1 month of storage, there is a 
slight increase of the ξ-potential from -27 to -23 mV. Nevertheless, these negative charges are 
enough to maintain their physical stability and avoid nanoparticles aggregation.  
NLC bactericidal activity was evaluated following bacteria growth during 24h in the presence of 
different NLC concentrations (Figure 2) using Müller-Hinton Broth (MHB), which is the 
recommended medium for the determination of the minimal inhibitory concentration according to 
the guidelines proposed by two recognized organizations: CLSI (Clinical & Laboratory 
Standards Institute) and EUCAST (European Society of Clinical Microbiology and Infectious 
Diseases) [21]. However, since H. pylori is a fastidious microorganism and requires a complex 
nutrient-rich growth media, MHB had to be supplemented with 10% of fetal bovine serum (FBS). 
This supplement may act as an additional source of nutrient and also protect against the toxic 
effects of long-chain fatty acids [22]. Nevertheless, for comparison and to demonstrate the 
specific bactericidal activity of NLCs to H. pylori, this FBS-supplemented medium was also used 
for bactericidal assays performed with other bacteria.  
Minimal bactericidal concentration (MBC) was defined as the minimal drug concentration to kill 
99.9% (>3 logs) bacteria in 24h of incubation.  Figure 2A shows that NLCs are bactericidal 
against H. pylori at all concentrations used, since after 24h in the presence of NLCs, there are 
no live bacteria. For the highest concentration tested (5% v/v), H. pylori was killed after 15h of 
incubation time. Nonetheless, an inhibitory effect of 50% (> 1log) was detected after 9h of 
incubation with this NLC concentration. 
NLC bactericidal effect was not detected on Lactobacillus casei-01 (Figure 2B), Gram-positive 
rod-shaped and nonpathogenic bacteria found on the human gut microbiota. This bacterium has 
an importance for gut microbiota which enhances the integrity of the intestinal barrier, decrease 
translocation of bacteria across the intestinal mucosa and disease phenotypes such as 
gastrointestinal infections [23, 24]. This specific bactericidal activity of unloaded-NLCs against 
H. pylori (without affecting L. casei) opens new routes for the treatment of H. pylori infection 
without affecting gut microbiota. 
NLCs were also tested on other Gram-positive cocci bacteria, Staphylococcus epidermidis 
(Figure 2C) and methicillin-resistant Staphylococcus aureus (MRSA) (Figure 2D). No 
bactericidal effect was observed for both bacteria on the concentrations used. However, the 
higher NLCs concentration (5% v/v) had an inhibitory effect on MRSA growth. Other bacterium 
tested was Escherichia coli, a Gram-negative rod-shaped bacterium, is the most prevalent 
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commensal inhabitant of the human intestinal tract and lives in a mutually beneficial association 
with hosts [25, 26].  E. coli is not usually pathogenic. NLC bactericidal effect was not detected 
on E. coli (Figure 2E); therefore, unloaded-NLCs can be used without to affect the normal flora 
of the gut.  
The NLC bactericidal effect against H. pylori was also tested using a growth medium (BB) 
indicated for H. pylori growth [27]. Figure 3 shows that all bacteria are killed after 12h of 
incubation with NLCs for all the concentrations used. The bactericidal effect of NLC on H. pylori 
was faster when bacteria were growing in this medium than in MHB medium.  
In order to understand the interaction of NLCs with H. pylori, their morphology after growing in 
the presence and absence of NLCs was evaluated by SEM and TEM. Samples were prepared 
after 3 and 12h of incubation with 1.25% of NLCs, since after 3h mostly of the bacteria are alive 
and after 12h all bacteria are dead.  
SEM images of H. pylori grown during 3h (Figure 4A) and 12h (Figure 4C) in the absence of 
NLCs (control) show their characteristic bacillus shape with 2-4µm of length and 0.5-1µm wide 
[4-6]. When bacteria were incubated with NLCs for 3h (Figure 4B) their morphology was similar 
to the controls, demonstrating the integrity of its membrane. However, after 12h incubation with 
NLCs (Figure 4D), although high morphological changes were not observed using this 
technique, it was possible to visualize the leakage of their cytoplasmic contents. These results 
suggest that NLCs can interact with H. pylori by disrupting its cell membrane.   
TEM images (Figure 5) corroborate with SEM images, showing H. pylori with the intact cell 
membrane and dense cytoplasm in controls (Figure 5A and 5C) and after 3 hours growing with 
NLCs (Figure 5B). After 12h of incubation with NLCs, TEM images revealed a disseverance of 
outer membrane and plasma membrane with parts of bacteria without cytoplasmic contents 
(Figure 5D). 
NLCs cytotoxicity was evaluated against a gastric carcinoma cell line (MKN45) using thiazolyl 
blue tetrazolium bromide (MTT) and lactate dehydrogenase (LDH) assays (Figure 6A and 6B, 
respectively). Figure 6A shows that for NLC concentrations up to 2.5%v/v, the reduction of 
MKN45 cell viability was lower than 30%. Figure 6B demonstrated that despite its strong 
bactericidal activity against H. pylori, NLCs are not cytotoxic against MKN45 cells at 
concentrations up to 2.5%v/v (~20% cell lysis). These results also demonstrated that NLCs at 
bactericidal concentrations (1.25% v/v) have a negligible lactate dehydrogenase release and did 
not induce apoptosis and mitochondrial dysfunction after 24h of incubation. These NLCs, at 
bactericidal concentrations, are biocompatible according to ISO 10993-5 [12] since the 
decrease of cell metabolic activity and increase of cell lysis due to the presence of NLCs in 
comparison with control were lower than 30%. 
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FIGURES 
Figure 1. NLCs characterization in terms of (A) diameter (bars), polydispersion index and 
charge surface (ξ-potential) performed using dynamic light scattering at 37ºC, (B) morphology 
evaluated by cryo-scanning electron microscopy (Cryo-SEM) (scale bar 500nm, 50000x 
magnification) and (C) effect of time of storage in water at 4ºC and 20ºC on diameter and 
charge (ξ-potential) of unloaded-NLC produced. Data is reported as the mean ± standard 
deviation (n=3). *p<0.05 compared to different time-points on day 0 (Kruskal-Wallis test). 
 
A        B 
Diameter (nm) 211 ± 8 
Polydispersion 
index 
0.2±0.02 
ξ-potential (mV) -28 ± 3 
  
C 
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Figure 2.  The growth of bacteria in increasing concentrations of unloaded-NLC in Müller-Hinton Broth medium supplemented with 10% FBS: (A) H. pylori 
J99, (B) Lactobacillus casei-01, (C) Staphylococcus epidermidis ATCC35984, (D) Staphylococcus aureus ATCC 33591 (methicillin resistant) and Escherichia 
coli ATCC 25922. Numerical data is reported as mean ± standard deviation (n=3). All concentrations tested with unloaded-NLCs were significantly different 
compared to each bacteria growth treated with unloaded-NLCs and bacteria untreated (control) (p<0.05, Kruskal-Wallis test). 
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Figure 3.  The growth of (A) H. pylori J99 and (B) H. pylori SS1 in increasing concentrations of unloaded-NLC in Brucella Broth medium supplemented with 
10% FBS. Numerical data is reported as mean ± standard deviation (n=3). All concentrations tested with unloaded-NLCs were significantly different compared 
to each bacteria growth treated with unloaded-NLCs and bacteria untreated (control) (p<0.05, Kruskal-Wallis test). 
A           B 
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Figure 4. Scanning Electron micrographs of H. pylori J99 incubated during 3h (A to B) and 12h 
(C to D) with unloaded-NLC. In A and C, SEM images of H. pylori J99 was not treated (control); 
in B and D, H. pylori J99 was treated with 1.25 %v/v of unloaded-NLC. The scale bar in the 
SEM image represents 1 µm, 60 000 x magnifications. 
 
 
 
Figure 5. Transmission Electron micrographs of H. pylori J99 incubated during 3h (A to B) and 
12h (C to D) with unloaded-NLC. In A and C, TEM images of H. pylori J99 was not treated 
(control); in B and D, H. pylori J99 was treated with 1.25%v/v of unloaded-NLC. The scale bar in 
the TEM image represents 200 nm, 50 000 x magnifications. 
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Figure 6. Effect of unloaded-NLCs of gastric carcinoma cell line in increasing amounts. MKN45 
gastric carcinoma (A) cell line viability and (B) cytotoxicity assessed by the MTT and LDH 
assay, respectively, after 24h exposure to different amounts of NLCs.  Data is reported as 
mean ± standard deviation (n=3). * p<0.05, refers to significant differences of MKN45 gastric 
cells treated cells with unloaded-NLC and cells untreated (control) (Kruskal-Wallis test). 
A       
 
B  
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CLAIMS  
1. A nanostructured lipid particle comprising particles in the form of a shell, hollow nanoparticles 
or lipid vesicles, and wherein said nanoparticles are capable of killing Helicobacter pylori. 
2. A nanostructured lipid particle according to claim 1, wherein the particles can be produced by 
mixture of several lipids forming a nanoemulsion, using techniques that may include the use of 
hot homogenization and ultrasonication,  
3. A nanostructured lipid particle according to claim 1, wherein the particles present with 
diameters between 50 and 400 nanometers, preferably between 150 and 250 nanometers, as 
determined by their hydrodynamic size using dynamic light scattering, at 37ºC.  
4. A nanostructured lipid particle according to claim 1, wherein the particle is formed by 
mixtures of different lipids, selected from solid and liquid lipids and mixed with a surfactant to 
produce a nanoemulsion. The lipids are preferably glyceryl palmitostearate, cetyl palmitate and 
Caprylic/Capric Triglyceride and the surfactant polysorbate 60.  
5. Nanostructured lipid particle produced according to the previous claims, wherein the 
therapeutically effective amount of Helicobacter pylori infection is administrated orally.  
6. Nanostructured lipid particles produced according to the previous claims that can be stored 
during 1 month, in aqueous suspension at 4º and 20ºC. 
7. Nanostructured lipid particles produced according to the previous claims, wherein the 
therapeutically effective amount against Helicobacter pylori does not affect other bacteria, 
particularly Lactobacillus casei, Staphylococcus epidermidis and Escherichia coli. 
8. An oral formulation containing the nanostructured lipid particles produced according to the 
previous claims, in combination with one or more therapeutically active substance(s) selected 
from the group of gastrointestinal protectants (particularly proton pump inhibitors) and 
antibiotics (particularly amoxicillin, clarithromycin, metronidazole, tetracycline) used in the 
treatment of Helicobacter pylori infection.  
9. An oral formulation containing the nanostructured lipid particles produced according to the 
previous claims, wherein the dosage form can be administrated in any formulation adapted for 
stomach delivery, particularly incorporated/combined with gastric retentive polymers such as 
chitosan or other pharmaceutical compounds able to release the particles in the stomach.    
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APPENDIX 4 
4. Review: The potential utility of chitosan 
micro/nanoparticles in the treatment of gastric 
infection 
 
During this work, a brief description of the use of chitosan in H. pylori treatment was 
reviewed. This review was used in the introduction of this thesis.  
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Gastric infections are mainly caused by Helicobacter pylori (H. pylori), a bacterium that
colonizes the gastric mucosa of over 50% of the world’s population. Chronic H. pylori
infection has been associated with gastric diseases such as chronic gastritis, peptic ulcer and
gastric adenocarcinoma. Current eradication treatment relies on antibiotic-based therapies
that are unsuccessful in approximately 20% of the patients. Chitosan, a natural and cationic
polysaccharide has been investigated in the treatment of H. pylori infection. Due to its
mucoadhesive properties, it has been used in the form of micro/nanoparticles, polyelectrolyte
complexes or coatings as antibiotic encapsulation systems for gastric delivery, but alternative
molecules may also be incorporated. It has been recently proposed that chitosan can also be
used for H. pylori binding and scavenging from the host stomach due to its antimicrobial/
binding properties. In this manuscript, a brief description of the use of chitosan in H. pylori
treatment is reviewed.
KEYWORDS: biomaterials • chitosan • crosslinking • drug delivery • gastric cancer • Helicobacter pylori • microspheres
• mucoadhesion • nanoparticles • polyelectrolytes
Helicobacter pylori gastric infection
Helicobacter pylori (H. pylori), a spiral-shaped
gram-negative bacterium, is one of the most
common infectious agents in the world, coloniz-
ing the gastric mucosa of over 50% of the
human population [1]. Although most of the
infected individuals show no or few symptoms,
this infection is the strongest known risk factor
for gastroduodenal ulcer progression (60–80%
of the cases), being also related to the develop-
ment of gastric adenocarcinoma (1–3% of the
cases) [1], the second leading cause of cancer-
related deaths worldwide [2]. H. pylori was
classified as a type I carcinogen by the Interna-
tional Agency for Research on Cancer [3], and it
was recognized that its elimination is the most
promising strategy to reduce the incidence of
gastric cancer [4].
Due to its flagellar motility, H. pylori is
able to escape the acidic pH of the stomach
(pH 1.2–2.5) crossing the mucus layer that
covers and protects the gastric cells, reaching
the gastric epithelium where the pH is more
neutral (pH ~7.4). In a healthy human
stomach, the median thickness of the adher-
ent mucus is 180 mm with 67% polymeric
mucin, but in patients with gastric carcinoma
there is an increase of thickness to 240 mm
despite becoming a structurally very weak
gel with only 23% polymeric mucin [5].
Furthermore, H. pylori can secrete urease,
which converts endogenous urea into ammo-
nia and carbon dioxide, thereby buffering
gastric acid in the immediate vicinity of the
organism [6].
Although most of H. pylori can be found
free-swimming in the mucus layer, bacteria is
also found adherent to the mucus layer and to
the surface of gastric epithelial cells, in the
intercellular spaces and even, as suggested in a
few studies, inside the gastric cells [7].
Nonadherent H. pylori can produce and
release a vacuolating cytotoxin, VacA, which
induces multiple structural and functional
alterations in cells, such as the formation of
large intracellular vacuoles and the increase in
membrane permeability [1].
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H. pylori adhesion to gastric mucosa protects the bacteria from
displacement by forces such as those generated by peristalsis and
gastric emptying. Adhesion to the host is mediated by lectins,
bacterial surface-bound adhesins, which recognize glycans
expressed on the gastric mucosa [8]. H. pylori can express several
different adhesins that are not only responsible for adhesion but
for the communication system that enables H. pylori response to
the gastric environment [9]. The best characterized adhesin–gly-
can interactions are the blood group antigen-binding adhesin
(BabA) that recognizes the Lewis blood group antigens, such as
Lewis b (Leb) and H-type 1, and sialic acid-binding adhesin
(SabA) that mediates the adherence of H. pylori to inflamed gas-
tric mucosa by binding sialylated carbohydrate structures such as
sialyl Lewis a (sLea) and sialyl Lewis a [10]. However, neutro-
phil activating protein was also identified as responsible for
H. pylori binding to sulfated mucins, such as sulfo-Lea, sulfo-
Gal and sulfo-GalNAc [11]. The two adherence-associated
lipoprotein A and B [12] as well as the outer inflammatory pro-
tein A [13], expressed in all bacteria strains, are also important
in H. pylori adhesion to gastric mucosa, although their host
receptors are not well known. It was also described that
H. pylori can bind damaged tissue, where the basement mem-
brane is exposed, through the extracellular matrix proteins, such as
laminin, type IV collagen, vitronectin and heparan sulfate proteo-
glycan. This could be important for H. pylori adherence to host
intercellular junctions [9].
After adhering to epithelial cells, H. pylori is able to assemble a
type IV secretion system, encoded by the cag pathogenicity
island, which translocates the cytotoxin-associated gene protein
into gastric epithelial cells, conducing to numerous cellular alter-
ations and inducing strong gastric inflammation [14].
Current treatments
Current available treatments to H. pylori infection rely on a
triple treatment, which includes the combination of two
antibiotics, such as clarithromycin and
amoxicillin or metronidazole and a proton
pump inhibitor (PPI) such as omeprazole.
The administration of the three antibiotics
together with a PPI (nonbismuth quadru-
ple therapy) has also been considered as
well as the bismuth-containing quadruple
therapy (bismuth salts, tetracycline,
metronidazole and a PPI) [4].
Current antibiotic eradication therapy is
unsuccessful in nearly one in five patients
(FIGURE 1) [15]. This low rate of success is
mainly related to H. pylori resistance to
the antibiotics and poor patient compli-
ance. Furthermore, antibiotic degradation
in the acidic environment of the gastric
lumen or poor penetration of the antibi-
otic through the viscoelastic mucosal gel
could lead to sub-bactericidal concentra-
tion of antibiotics in the infection site
and therefore incomplete eradication of H. pylori, which could
also induce bacterial resistance.
Alternative treatments
Several alternative treatments are being investigated in order to
overcome the abovementioned problems related to antibiotic
therapies. A vaccination strategy would be a valuable option to
fight H. pylori infection [16]. However, despite several attempts
to develop an H. pylori vaccine for humans, progress has been
slow. Special attention has been given to compounds obtained
from natural sources, including polyunsaturated fatty acids,
terpenes and terpenoids, polyphenols and antimicrobial pepti-
des [17,18]. The use of polyunsaturated fatty acids as co-adjuvant
of the current available therapies was suggested as a promising
approach [19].
Encapsulation of conventional antibiotics, for a local and
controlled delivery at the infection site, has been thoroughly
investigated to improve the effect of antibiotics against
H. pylori [20,21]. These systems protect the drug from rapid
degradation or clearance, extending its half-life and solubility,
which may lead to lower administration frequency and hence
better patient compliance [20–22]. A different strategy has been
recently proposed by our group, based on the use of H. pylori
binding systems that, after oral administration, will attract/bind
bacteria and remove them from the host stomach, through the
intestinal tract, after gastric mucus turnover [23].
Chitosan is a nontoxic, biodegradable and biocompatible
natural polymer that has been quite investigated in the treat-
ment of H. pylori infection, namely, for drug encapsulation
due to its mucoadhesive properties and for H. pylori binding
due to its antimicrobial/binding properties. Nevertheless,
chitosan has also been described as adjuvant for an H. pylori
vaccine [24]. In this manuscript, a brief description of the use
of chitosan micro/nanoparticles in H. pylori treatment is
reviewed.
7000 million people World population
3500 million people Infected withH. pylori
50% [1]
20% symptomatic [79]
700 million people Have recommendation forH. pylori  treatment
140 million people H. pylori treatment isinefficient
20% [15]
1% [1]
35 million people Developgastric cancer
Figure 1. Helicobacter pylori infection and treatment figures.
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Chitosan in the treatment of H. pylori infection
Properties of chitosan
Chitosan (FIGURE 2), a naturally occurring polysaccharide com-
posed of D-glucosamine and N-acetyl-D-glucosamine units [25],
is obtained by alkaline deacetylation of chitin, which is the
second most abundant polysaccharide after cellulose and the
major component of the exoskeleton of crustaceans, squid pen
and cell walls of some fungi [26]. Chitosan molecular weight
(MW) and degree of deacetylation (DD), which is the propor-
tion of D-glucosamine units with respect to the total number
of units, are the main factors that affect its chemical and
biological properties [25]. The increase of chitosan DD will
increase the number of free amine groups (–NH2) that confer
chitosan its almost unique properties of being positively
charged and easily chemically modified.
Chitosan is stable in neutral conditions due to the strong inter-
and intramolecular hydrogen bonds formed between its amine
and hydroxyl groups [27]. Still, chitosan is soluble in acidic condi-
tions, namely, below its pKa value (~6.5), due to the protonation
of the free amine groups from the glucosamine residues [28].
Mucoadhesive properties of chitosan
The mucoadhesive properties of chitosan are related with the
strong electrostatic interactions established between its proton-
ated glucosamine residues and glycoproteins from gastric
mucosa that, due to their sialic acids and ester sulfates [29], are
negatively charged at the acidic stomach pH. These interactions
are then followed by mechanical interlocking of the polymer
chains, van der Waal’s forces and hydrogen bonding.
Antimicrobial properties of chitosan
Chitosan antimicrobial properties are also consequence of the
electrostatic interactions between chitosan cationic amine groups
and the anionic groups on the bacterial wall, which leads to the
inhibition of bacterial proliferation [30].
The antimicrobial activity of chitosan and its derivatives was
able to inhibit the growth of fungi, parasites and several bacte-
ria, including H. pylori strains NCTC 11639, NCTC 11637
and SS1 [31]. Luo et al. [31] have shown in vitro that chitosan
with a DD of 95% presents higher antimicrobial activity
against H. pylori than chitosan with a DD of 88.5%, indicating
that the higher the deacetylation of chitosan the better its anti-
microbial action. Furthermore, the in vivo administration of
chitosan as solution and as nanoparticles (both DD 95%) to
H. pylori infected BALB/c mice eradicated the bacteria in
55 and 75% of the animals, respectively.
Chitosan as drug encapsulation system
Several antibiotics have been encapsulated to treat H. pylori
infection, although amoxicillin and clarithromycin are the most
common ones. The encapsulation of two antibiotics and a PPI
(omeprazole) has also been described [32].
The selection of the encapsulation technique is primarily
determined by the solubility of the drug and the polymer in
the solvents, and by the particle size requirements [33,34].
Chitosan micro/nanoparticles
Chitosan micro and nanoparticles have been used for gastric
drug delivery in the treatment of H. pylori due to its mucoad-
hesive properties. Besides protecting the drugs from enzymatic
and acidic degradation, by adhering to gastric mucus barrier,
particles residence time in the stomach will be higher prolong-
ing drug delivery and allowing drug diffusion through the
mucus barrier to the infection site [21,35].
The size and charge of chitosan particles will affect their
mucoadhesion and mucopenetration and thus their retention
time in the stomach. Microparticles have more difficulty to
penetrate through viscoelastic mucus layer than nanoparticles.
However, nanoparticles smaller than 200 nm could be internal-
ized by gastric epithelial cells [36]. Furthermore, for an efficient
mucoadhesion, particles must be positively charged, which is
usually obtained by increasing chitosan MW and DD [37].
Nevertheless, an elevated number of positive charges could
make the particles too mucoadhesive avoiding their penetration
through the mucus layer [21], making them more prone to be
washed out upon mucus turnover.
Several methods and approaches that have been proposed for
the preparation of chitosan particles are summarized in TABLE 1
and schematized in a review from Agnihotri et al. [38].
Drug loading into chitosan particles is commonly performed
by mixing it in the chitosan solution prior to particles forma-
tion and crosslinking [39], but incubation of previously formed
particles with the drug can also be performed [40]. Hejazi and
Amiji [40] demonstrated that the encapsulation of tetracycline
onto chitosan microspheres was higher (69% w/w) when drug
was incubated for up to 48 h with previously formed
microspheres than when mixed in chitosan solution (8% w/w).
Due to the high solubility of chitosan in acidic conditions,
uncrosslinked chitosan particles cannot maintain their three-
dimensional structure in gastric fluids [28,41]. The rapid dissolu-
tion of chitosan particles or an extensive swelling of the
particles induces a fast release of the drug, which might not be
desirable. In order to overcome this restriction, ionic crosslink-
ing of chitosan particles using tripolyphosphate (TPP) [42] or
covalent crosslinking using glutaraldehyde [43] or genipin [41]
can be performed. Genipin is a naturally occurring crosslinking
agent described as being 10000 times less toxic than glutaralde-
hyde [44].
It should be considered that crosslinking after drug loading
could induce chemical reactions with the active drug, which is
O O
O
NH2HO
O
CH2OH
HO
CH2OHNHCOCH3
O
nN-acetyl glucosamine Glucosamine
Figure 2. Chemical structure of chitosan.
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Table 1. Examples of methods for preparation of chitosan micro/nanoparticles.
Particle production method Particle size Advantages (+)/disadvantages (-)
Ionic gelation
Drop wise addition of chitosan solution (positively
charged) under constant stirring into a polyanionic
solution (negatively charged, generally TPP).
Complexation between oppositely charged species
results in chitosan to precipitate as spherical particles.
Nanoparticles (nm)
20–200 [37]
550–900 [32]
152–376 [42]
Microspheres (mm)
~170 [41]
100–400 [64]
+ Processing under mild conditions
+ Organic solvent free
+ Low-toxicity impact of reagents
+ No changes in drug chemistry
- Difficult entrapment of high molecular weight drugs
- Poor stability in acidic conditions
Precipitation/coacervation
• Addition of a solute (generally a salt) to chitosan
solution, forming micro/nanoparticles due to a
decrease in chitosan solubility
• Chitosan solution might also be blown into an alkali
solution using a compressed air nozzle to form
coacervate droplets
Nanoparticles (nm)
100–250 [65]
Microspheres (mm)
1.5–2.5 [66]
+ No complex apparatus needed
+ Few purification steps required
+ Organic solvent free
+ High loading capacity combined with a sustained
drug release
- Poor stability in acidic conditions
Spray drying
Preparation of chitosan solution where a suitable
crosslinking agent could be added (if desired). This
solution or dispersion is then atomized in a stream of
hot air. Atomization leads to the formation of small
droplets, from which solvent evaporates instantly
leading to the formation of free flowing particles.
Temperature and humidity might be regulated.
Microspheres (mm)
3–12 [67]
140–281 [68]
+ Simple, reproducible and easy to scale up
+ Low-cost process
+ Fast solvent removal
+ Good sphericity
+ Narrow size distribution
+ Low dependency of the solubility of the drug and
polymer
- High temperatures required
- Size influenced by several parameters
- Possible difficulty in spraying fluid of high viscosity
Supercritical antisolvent precipitation
Spraying of the chitosan solution into a precipitation
chamber with supercritical CO2 (antisolvent), causing
rapid contact between the two media. A higher
super-saturation ratio of the solution is generated,
resulting in fast nucleation and growth.
Microparticles (mm)
1.0–2.5 [47]
+ Processing under mild conditions
+ Complete antisolvent removal
+ Nontoxic reagents
+ Narrow size distribution
+ No changes in drug chemistry
Emulsion crosslinking
Chitosan aqueous solution is extruded into an oil
phase, generally liquid paraffin (under intensive
stirring), forming and water-in-oil (w/o) emulsion.
Aqueous droplets are stabilized by adding a surfactant.
The stable emulsion is crosslinked by using an
appropriate crosslinking agent such as glutaraldehyde.
Microspheres (mm)
60–100 [39]
100–330 [69]
350–690 [70]
+ Control of particle size
+ Good sphericity
- Slow process
- Chemical crosslinking agents used, possibly inducing
chemical reactions with the drug
- Difficult removal of the unreacted crosslinking agent
Solvent Evaporation
Aqueous chitosan solution is added to an organic
phase with vigorous stirring to form the primary water
in oil emulsion (w/o). The latter is then added to a
large volume of water containing a surfactant, forming
a multiple emulsion (w/o/w). The double emulsion is
then subjected to stirring until most of the organic
solvent evaporates, leaving solid microspheres.
Microspheres (mm)
100–200 [71]
+ Processing under mild conditions
+ Favorable for encapsulation of thermally sensitive
drugs
+ Indicated for delivery of small molecule drugs
+ Good sphericity
- Organic solvents usage
- Low drug encapsulation efficiency
Reverse micellar method
The surfactant is dissolved in an organic solvent
followed by the addition of chitosan, drug and
crosslinking agent, under constant vortexing overnight.
The organic solvent is evaporated, obtaining a
transparent dry mass. The latter is dispersed in water
and then a suitable salt is added to precipitate the
surfactant out.
Nanoparticles (nm)
~100 [72]
+ Narrow size distribution
- Organic solvent usage
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not desirable. Also, crosslinking is performed through chitosan
amine groups, reducing the number of free primary amines
able to be protonated. As such, increasing the crosslinking
decreases the mucoadhesion, size and swelling ability of chito-
san particles in acidic conditions [41,45], affecting drug release
profile. Zhu et al. [46] observed that chitosan microspheres ioni-
cally crosslinked with TPP present good mucoadhesive proper-
ties but allow a fast release of a hydrophilic drug (Berberine).
On the other hand, chemically crosslinked chitosan micro-
spheres enable a sustained drug release profile but show inferior
mucoadhesiveness. In order to solve this inconsistency between
mucoadhesiveness and release rate of chitosan microspheres,
they proposed an approach where Eudragit L100 cores are
encapsulated within the chitosan microsphere using an emulsifi-
cation/coagulation procedure (size: 380 mm; entrapment
efficiency: 71%), allowing ionic crosslinked microspheres with
low crosslinking density to be used for the controlled release of
hydrophilic antibiotics [46].
Regarding H. pylori treatment, amoxicillin-loaded chitosan
microspheres (50–100 mm) were produced by Patel and
Patel [39] using the emulsification crosslinking method. The
improved effect of encapsulating amoxicillin to treat H. pylori
was demonstrated in vivo using Wistar rats. In a single-dose
administration test, the inhibition was markedly observed when
dose was increased from 4 to 15 mg/kg. A similar in vivo study
was performed by Patel and Patil [47] using smaller amoxicillin-
chitosan microspheres (1.0–2.5 mm) produced using the
supercritical antisolvent precipitation method, revealing that
H. pylori inhibition was not influenced by particle size.
To improve H. pylori treatment, chitosan-based micro/
nanoparticles can be specifically directed to the infection site by
covalently binding, on the surface of the particles, ligands with
affinity toward gastric mucosa or bacteria.
Lectins can specifically bind to carbohydrate moieties of
glycoproteins located in gastric mucosa. Lectin can be coupled
to chitosan particles improving the absorption of drugs [21]
while presenting a good resistance to digestion within gastric
environment [20]. The conjugation of the lectin (Con-A) on
clarithromycin-loaded chitosan microspheres increased micro-
spheres adhesion to the stomach mucosa of albino rats from
12 to 85% [48]. Retention time was also enhanced from 3 h to
over 6 h in New Zealand albino rabbits for Con-A conjugated
microspheres.
Fucose can be used to target lectin-type receptors on the
surface of H. pylori. Fucose-conjugated nanoparticles containing
a triple therapy (amoxicillin/clarithromycin/omeprazole) were
produced by ionotropic gelation chitosan-glutamic acid conju-
gates and TPP as crosslinker [32]. These functionalized nanopar-
ticles demonstrated in vitro an H. pylori eradication rate of 97%
against 91% of nonconjugated chitosan nanoparticles and 81%
of plain triple therapy. In vivo studies using H. pylori-infected
Swiss albino mice demonstrated that fucose-conjugated nanopar-
ticles containing the triple therapy treatment (53.57 mg/kg
amoxicillin/17.8 mg/kg clarithromycin and 1.42 mg/kg omepra-
zole) were able to completely eradicate H. pylori infection.
Nonfunctionalized nanoparticles and plain triple therapy were
only able to eradicate 50 and 33% of the mice, respectively [32].
Chitosan-based pH-responsive micro/nanoparticles
Chitosan-based polyelectrolyte complexes can be prepared by
mixing protonated chitosan with anionic polymers from natural
(e.g., alginate [49,50], heparin [36], poly-y-glutamic acid [51,52],
etc.) (TABLE 2) or synthetic (e.g., poly(acrylic acid), etc.) origin
[53–55].
The advantage of using these systems for gastric applications is
that they can be pH-sensitive, that is, polyelectrolyte complexes
can be prepared in a way that electrostatic interactions between
polymers are strong enough at acidic pH, but unstable at physio-
logical pH to release the drug near H. pylori local of infection.
Furthermore, these strong but reversible interactions between
oppositely charged polyelectrolytes avoid the need of covalent
crosslinkers and their associated disadvantages. Chitosan-based
polyelectrolytes can be applied for drugs that, due to their hydro-
phobicity, negative charge or high MW, cannot be released from
chitosan crosslinked particles. The size, charge and stability of
the polyelectrolyte complexes depend on the individual proper-
ties of each polymer (charge, MW), the ratio between polymers,
the ionic strength and pH of the solution, the mixing order as
well as speed and diameter of the dispersing element [55].
Many different polyelectrolyte complexes, in the form of
micro- or nanoparticles, have been developed for encapsulation
of antibiotics for H. pylori treatment, and some examples are
briefly summarized in TABLE 3.
As previously described with chitosan micro/nanoparticles,
polyelectrolyte complexes can also be functionalized to target
H. pylori. Fucose-chitosan/heparin nanoparticles loaded with
amoxicillin are mentioned in TABLE 3.
Chitosan can also be used as coating for anionic particles. A
chitosan-coated pH-responsive liposome system containing
doxycycline (as a model antibiotic drug) for the treatment of
H. pylori infection was developed [56]. Liposomes are spherical
vesicles composed of one or more phospholipid bilayers that
have been studied as drug delivery systems for both hydrophilic
and hydrophobic compounds. Furthermore, liposomes also
mimic cell membranes, allowing an effective penetration of
encapsulated drug into intracellular spaces. However, the appli-
cations of liposomes, particularly those with sizes below
100 nm, are often limited due to their spontaneous fusion [56].
Chitosan-modified gold (AuCh) nanoparticles (size ~10 nm)
strongly bound to the surface of anionic phospholipid lipo-
somes (size ~75 nm) at acidic pH, inhibit liposome fusion and
detached from the liposomes at physiological pH, enable free
liposomes to fuse with target bacterial membrane and release
the therapeutic drug. Antimicrobial studies demonstrated
higher H. pylori antibacterial effect of the doxycycline-loaded
AuCh-liposome nanoparticles when compared with the same
concentration of doxycycline in solution.
Amoxicillin-loaded alginate/carboxymethyl cellulose microbe-
ads (size 745–889 mm/entrapment efficiency 52–92%) were
coated with chitosan to achieve a controlled release of the
The potential utility of chitosan micro/nanoparticles in the treatment of gastric infection Review
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antibiotic in stomach environment [57]. It was demonstrated
that chitosan coating induced mucoadhesive properties to the
microbeads and delayed amoxicillin delivery to up to 8 h,
releasing 41% of amoxicillin.
Chitosan as binding agent
The adhesion of H. pylori to chitosan in a pH range that simu-
lates gastric conditions (2.6, 4.0 and 6.0) was first demonstrated
using chitosan as thin films crosslinked with genipin [58].
Furthermore, the percentage of dead adherent bacteria ranged
from 76% at pH 6 to 93% at pH 2.6. As such, rather than being
used as a gastric drug delivery vehicle, chitosan microspheres
have been designed and applied as an H. pylori-binding sys-
tem [23,41]. It is expected that after oral administration, these
microspheres will adhere H. pylori in the stomach and remove
them through the gastrointestinal tract (upon gastric mucus turn-
over). Chitosan microspheres with approximately 170 mm were
produced by ionotropic gelation with TPP [41] followed by the
minimal genipin crosslinking necessary to avoid microspheres
dissolution in acidic pH without losing their mucoadhesiveness.
In vivo studies using C57BL/6 mice demonstrated that
these chitosan microspheres have a gastric retention of 2 h [41].
H. pylori adhesion to these microspheres was evaluated in a range
of acidic pHs, confirming that several H. pylori strains bind to
the microspheres (FIGURE 3). Furthermore, these microspheres are
not cytotoxic and revealed able to both partially remove and
prevent H. pylori adhesion to a gastric cell line [23].
This system was further improved by directing the micro-
spheres toward H. pylori. Immobilization of carbohydrates,
namely, Leb and sLex, that specifically bind to H. pylori adhe-
sins was first screened using model surfaces [59] and afterwards
transposed to chitosan microspheres [60]. It was found that
glycan-targeted materials were able to bind specifically to
H. pylori strains that express the corresponding adhesin,
meaning that Leb-modified materials adhere favorably to
BabA-positive strains and sLex-modified materials adhere
Table 2. Anionic polymers commonly used for preparation of chitosan-based polyelectrolyte complexes.
Polymer chemical structure Polymer characteristics
O
O
O
O
OH
–OOC
OH
HO
–OOCOH
OH
O
O
O
OHO
–OOC
–OOC
OH
O
n
M M
OH
G: guluronate M: mannuronate
G G
Alginate:
• Natural anionic and hydrophilic
polysaccharide typically obtained from
brown seaweed or bacteria
• Composed of alternating blocks of (1-4)
linked a-L-guluronic (G) and
b-D-mannuronic acid (M) monomers
• Widely explored for biomedical
applications, namely as matrix for the
entrapment and/or delivery of a variety of
proteins, peptides, drugs and cells, due
to its excellent biocompatibility, low
toxicity, biodegradability and mild
gelation conditions by addition of
divalent cations such as Ca2+
n
O
O O
OSO3–
COO–
O
O
CH2OSO3–
NHSO3–HO
HO
Heparin:
• Natural anionic and highly sulfated
glycosaminoglycan
• Composed of repeating disaccharide
units of D-glucosamine and uronic acid
linked by 1-4 interglycosidic bonds
• It is well known for its anticoagulant
properties, but also by its ability to bind
to cell receptors and accelerate gastric
ulcer healing, which is associated with
mucosal regeneration, proliferation and
angiogenesis
N
COOH
α β γ
O nH
Poly-g-glutamic acid (g-PGA):
• Natural, hydrophilic, nontoxic, poly-amino
acid, which is biodegradable and
relatively nonimmunogenic
• Can be used as carriers for active
substances and can be easily modulated
in order to control the delivery of drugs,
proteins, etc.
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preferentially to SabA-positive strains. This strategy is
extremely promising, particularly given the present shift of
focus onto a more personalized medicine. The immobiliza-
tion of other carbohydrates into microspheres for administra-
tion depending on the strain of H. pylori that is infecting the
patient, or the administration of cocktails of microspheres
with different carbohydrates are interesting possibilities for
future treatments.
Expert commentary & five-year view
The currently available antibiotic-based treatments for H. pylori
gastric infection have been unsuccessful in several patients, mostly
due to bacterial resistance and poor patient compliance. It
is expected that the amount of antibiotic-resistant H. pylori
will increase in a near future due to the bad use (abuse) of antibi-
otics, leading to an increased number of patients that need an
alternative treatment. Furthermore, multiple H. pylori infection
and even multiple-antibiotic-resistant H. pylori infection have
been observed, which also compromises the current therapeutic
efficacy.
Antibiotics encapsulation into gastric retentive polymers,
namely, chitosan, has improved their biological effects, by
protecting them from the acidic gastric fluids and increasing
their availability at the infection site. However, although this
strategy could improve patients’ compliance, it will not solve
the problem of antibiotic resistance.
A promising alternative to the conventional antibiotic ther-
apy is the use of antimicrobial compounds obtained from natu-
ral sources [18,59] that have different bacteria target/pathways
than most antibiotics (the ribosome–clarithromycin; the cell
wall synthesis–amoxicillin and bacterial DNA replication–
metronidazole [61]). Nevertheless, due to their low solubility,
sensitivity and instability in gastric conditions, most of
these natural-based compounds also need to be encapsulated
for their in situ delivery. As such, we predict that chitosan
micro/nanoparticles will continue to have a major role in
H. pylori therapies, mainly due to chitosan’s biocompatibility,
biodegradability, mucoadhesiveness, ease of handling and facil-
ity to be chemically modified.
In all the strategies previously described, it was demonstrated
that the incorporation of target molecules toward H. pylori
such as fucose or carbohydrates (namely, Leb or sLex) improved
the efficiency of the systems. It is our belief that targeted treat-
ments using chitosan micro/nanoparticles specific to H. pylori
are highly promising since they will avoid the destruction of
the normal gut microbiome of the patients [62]. This strategy
may include particles chemically modified with targeting
compounds that bind H. pylori urease, flagella, adhesins, etc.,
in order to inhibit, kill or remove the bacteria.
A recent investigation performed by our group takes advantage
of chitosan bioadhesive and antimicrobial properties, and uses
chitosan microspheres to bind and remove H. pylori from the
stomach of infected hosts, through the normal gastrointestinal
tract. Although this therapy may not be enough to remove all
bacteria that infect the patient, especially the ones that are in the
intercellular spaces or inside gastric cells, it is expected that they
can remove most of H. pylori and have a synergistic effect when
combined with other drugs. Since these chitosan particles will
not induce bacteria resistance and can be used without damage
to the patient, they can also be used to prevent reinfection.
Despite the great potential of using chitosan and chitosan
derivatives in pharmaceutical and biomedical applications, none
of the described chitosan systems are currently in the market.
Chitosan is only US FDA approved for use in wound
dressings. Nevertheless, chitosan was approved for dietary appli-
cations in Japan, Italy and Finland [63]. This difficulty in being
FDA approved is mainly related with the fact that its physico-
chemical characteristics can change drastically with its source,
MW and associated polydispersity index, DD, size and formu-
lation. Furthermore, since chitosan is a natural compound, it is
always difficult to maintain the reproducibility between batches.
Nevertheless, the current growing interest in using chitosan in
medical (pharmaceutical) applications improved the industrial
capacity to produce more pure, cost–effective and uniform
Figure 3. Confocal microscopy images of chitosan microspheres (in red) with adherent FITC-labeled Helicobacter pylori strain
J99 (in green) under pH 2.6, pH 4.0 and pH 6.0 (from left to right).
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chitosan, representing important progress for its pharmaceutical
industrialization in a near future.
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Key issues
• Helicobacter pylori (H. pylori) infects about half of the world’s population and its persistent infection is associated with a strong risk for
the development of gastric adenocarcinoma.
• The failure of the current available antibiotic-based therapy (~1 in each 5 patients) demonstrated the need of alternative treatments.
• Chitosan is a natural biocompatible polymer with great potential in H. pylori treatment, mainly due to its gastric retentive and
antimicrobial properties, but also because it can easily be chemically modified.
• Chitosan properties are mainly related with its primary amine groups that are directly related with its degree of deacetylation.
• In H. pylori infection treatment, chitosan is mostly used as gastric drug delivery system, whether as crosslinked particles, as
polyelectrolyte complexes with anionic polymers or as coatings. Nevertheless, it has recently been proposed as an H. pylori
binding system.
• In order to prevent premature release of the encapsulated drug, chitosan particles must be crosslinked to avoid its fast dissolution in
gastric acidic conditions.
• Polyelectrolyte complex-based chitosan particles can be pH-responsive, that is, particles are stable in acidic pH (drug preservation) and
unstable at physiological pH to release the drug near H. pylori infection site (near gastric epithelial cells).
• Chitosan microspheres crosslinked with genipin have great potential as H. pylori-binding systems for the clearance of this bacterium
from infected host through normal gastrointestinal tract since they can bind H. pylori, are noncytotoxic and are stable during all the
digestive process.
• In order to increase their residence time in the stomach, chitosan particles can be conjugated with lectins to target the gastric mucosa
through lectin-carbohydrate recognition.
• In order to be directed toward H. pylori, chitosan particles can be conjugated with fucose or glycans (Leb, sLex, …) to target H. pylori
adhesins.
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